prednisone has been researched along with melphalan in 1014 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 388 (38.26) | 18.7374 |
| 1990's | 222 (21.89) | 18.2507 |
| 2000's | 197 (19.43) | 29.6817 |
| 2010's | 177 (17.46) | 24.3611 |
| 2020's | 30 (2.96) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Finkel, HE; Schilling, A | 1 |
| Dawkins, RL; Zilko, PJ | 1 |
| Horácek, J; Kubát, R; Svehla, F | 1 |
| Kubanek, B; Schreml, W | 1 |
| Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Hahn, RG; Ingle, JN; O'Connell, MJ; O'Fallon, JR; Payne, WS; Rubin, J; Scanlon, PW | 1 |
| Stoll, BA | 1 |
| Bern, MM; Corkery, J; Tullis, JL | 1 |
| Brunner, KW; Wagner, HP | 1 |
| Gailani, S; Henderson, ES; Seon, BK | 2 |
| Kwan, YL; Phadke, KP; Young, SG | 1 |
| Cornell, CJ; Kochwa, S; McIntyre, OR; Pajak, TF; Weksler, BB | 1 |
| Konttinen, A; Lefvert, AK; Pirskanen, R; Somer, H; Wasastjerna, C | 1 |
| Buxbaum, JN; Chuba, J; Hurley, ME; Spiro, T | 1 |
| Ferraris, AM; Haupt, E; Ratti, M | 1 |
| Cardamone, JM | 1 |
| Livingston, RB | 1 |
| Sullivan, MP; Sutow, WW | 1 |
| Kaufman, BM | 1 |
| Carcassonne, Y; Foa, J | 1 |
| Band, P; Bauer, M; Carbone, PP; Tormey, D | 1 |
| Olsen, TS; von Eyben, F | 1 |
| Furno, F; Giovanelli, E; Locatelli, F; Neretto, G; Pellerito, R | 1 |
| Doll, DC; Weiss, RB | 1 |
| Basten, A; Bradstock, K; Clancy, R; Richards, J; Uther, J | 1 |
| Stavrides, A; Wechsler, HL | 1 |
| Hitzig, WH; Joller, P; Kruse, K; Lasson, U; Stein, H | 1 |
| Sieber, SM | 1 |
| Greipp, PR; Kyle, RA | 1 |
| Dickman, PS; Feldman, PS; Taetle, R | 1 |
| Glatstein, E; Hoppe, RT; Kaplan, HS; Portlock, CS; Rosenberg, SA | 1 |
| Buonanno, G; Cantore, N; Castaldo, C; Russolillo, S; Tortarolo, M | 1 |
| Wiltshaw, E | 1 |
| McIntyre, OR | 1 |
| Alexanian, R; Gonzalez, F; Trujillo, JM | 1 |
| Jänner, M; Lippert, HD; Stolzenbach, G | 1 |
| Buonanno, G; Castaldo, C; Gonnella, F; Russolillo, S; Tortarolo, M; Valente, A | 1 |
| Allegra, JC; Lippman, ME | 1 |
| Alexanian, R; Stegman, R | 1 |
| Coleman, M; Cooper, MR; Cuttner, J; Harley, JB; Kochwa, S; McIntyre, OR; Pajak, TF | 1 |
| Caballero, O; Martínez, J; Marty, ML; Mayans, J; Sanz, MA | 1 |
| Blom, J; Gailani, S; Holland, JF; Kyle, RA; McIntyre, OR; Pajak, TF; Seligman, BR | 1 |
| Bailey, AJ; Bergsagel, DE; Langley, GR; MacDonald, RN; Miller, AB; White, DF | 1 |
| Cohen, JR; Schrier, SL; Schwartz, RS | 1 |
| Miller, S; Perrotta, AL | 1 |
| Palva, I | 1 |
| Felder, M; Keiser, G; Wirth, W | 1 |
| Kraj, M; Mariańska, B; Rostkowska, J; Snigurowicz, J | 1 |
| Alexanian, R; Bonnet, J; Gehan, E; Haut, A; Salmon, S; Weick, J | 1 |
| Badia, L; Caballero, M; Calabuig, JR; Herranz, C; Marty, ML; Mayans, J; Redon, J; Sanz, MA; Soler, A | 1 |
| Case, DC; Clarkson, BD; Lee, DJ | 1 |
| Solomon, A | 1 |
| Crow, SE; Madewell, BR; Nickerson, TR | 1 |
| Kossard, S; Winkelmann, RK | 1 |
| Burnstein, SL; Calabro, JJ; Henderson, ES; Jordan, E | 1 |
| Alexanian, R; Gehan, E; Haut, A; Saiki, J; Weick, J | 1 |
| Sonntag, RW | 4 |
| Collina, A; Corvetta, A; Danieli, G; Leoni, P; Montillo, M | 1 |
| Cohen, HJ | 1 |
| Klahr, C; Presant, CA | 1 |
| Górska, B; Pawelski, S; Rechowicz, K; Sylwestrowicz, T; Zupańska, B | 1 |
| Mehta, AD | 1 |
| Amor, B; Belpomme, A; Belpomme, D; Delbarre, F; Delrieu, A; Depierre, R; Feuilhade de Chauvin, F; Fries, D; Le Mevel, B; Mathé, G; Menkes, C; Pouillart, P; Serrou, B; Simon, F | 1 |
| Ardouin, M; Eon, JY; Le Blay, R; Urvoy, M | 1 |
| Kohli, RK; Prezyna, AP; Vladutiu, AO | 1 |
| Bergsagel, DE | 7 |
| Salmon, SE | 2 |
| Bergsagel, DE; Pruzanski, W | 1 |
| Capra, JD; McLaughlin, CL; Solomon, A | 1 |
| Barré, JP; L'Hirondel, JL; Loyau, G; Maniéce, M; Preud'Homme, JL | 1 |
| Baele, G; Coutant, G; Hamers, J; Van Hove, W | 1 |
| Carbone, PP | 3 |
| Blaney, DJ; Denton, D; Franco, RS; Wright, RC | 1 |
| Prokipchuk, EJ; Pruzanski, W | 1 |
| Kane, RD; Paulson, DF; Stocks, LH | 1 |
| Newton, PA | 1 |
| Swan, GW; Vincent, TL | 1 |
| Cooperberg, AA; de Champlain, MB; Rosenberg, A; Schwartz, JP; Siminovitch, J | 1 |
| Levo, Y; Many, A; Ramot, B; Yalon, M | 1 |
| Albert, P; Zsuzsa, M | 1 |
| Kapadia, SB; Krause, JR | 1 |
| Djaldetti, M; Freidin, N; Klein, B; Lewinski, U; Shabtai, F | 1 |
| Holland, JF | 2 |
| Medina, D; Shepherd, F | 1 |
| Alexanian, R; Brown, BW; Drewinko, B; Hokanson, JA; Thompson, JR | 1 |
| Hansen, HH; Hansen, M; Mouridsen, H; Osterlind, K; Palshof, T | 1 |
| Blok, J; Cleton, FJ; de Waal, FC; Mulder, E; Smets, LA | 1 |
| Kane, RD; Mickey, DD; Paulson, DF | 1 |
| Rickel, L | 1 |
| Bayrd, ED; Kyle, RA; Pierre, RV | 1 |
| Adamson, RH; Sieber, SM | 1 |
| Rosen, BJ | 1 |
| Abdou, NI; Abdou, NL | 1 |
| Jowsey, J; Kelly, PJ; Kyle, RA; Taves, DR | 1 |
| Mitchell, MS | 1 |
| Conn, RB; Harbaugh, ME; Hill, EM | 1 |
| Burkholder, P; Cohen, HJ; Hallal, J; Lessin, LS | 1 |
| Dubovsky, D; Jacobs, P | 1 |
| Alexanian, R; Balcerzak, S; Bonnet, JD; Gehan, EA; Haut, A; Hewlett, JS; Monto, RW | 1 |
| Fernández Rañada, JM; López Pascual, J; Montero, J; Ribera, C; Salazar, DG; Talero, D | 1 |
| Cornwell, GG; Cuttner, J; Falkson, G; Glidewell, O; Harley, JB; Holland, JF; Kyle, RA; Martz, G; Silver, RT; Sonntag, RW; Spurr, C; Wasserman, LR; Wiernik, PM | 1 |
| Abraham, GN; Griner, PF; Ristow, SC; Shoulson, I | 1 |
| Brown, TC; Dotten, DA; Olin, J; Pruzanski, W | 1 |
| Beaumont, JL; Boyer-Neumann, C; Delfraissy, JF; Doukan, S; Tchernia, G; Toan, ND; Venencie, PY; Vieillefond, A | 1 |
| Wallack, EM | 1 |
| Carlton, E; Hartz, CE; Mroz, F; Rosen, C; Segal, H | 1 |
| Camba, L; Durie, BG | 1 |
| Blumenreich, M; Djulbegovic, B; Hadley, T; Joseph, G | 1 |
| Aboukrat, P; Marcelli, C; Simon, L | 1 |
| Celsing, F; Hansson, H; Hast, R; Pisa, P; Stenke, L | 1 |
| Artim, R; Davidson, H; Gandara, D; George, C; MacKenzie, MR; Meyers, F; Ray, G; Schiff, S; Shields, J; Wold, H | 1 |
| Bach, I; Hoster, M; Norpoth, K; Popp, W; Schmieding, W; Schürfeld, C; Vahrenholz, C | 1 |
| Hernando, JC; Pais, JR; Pascual, J; Pérez Vaquero, MA; Sureda, A | 1 |
| Avvisati, G; Cantonetti, M; Coppetelli, U; La Verde, G; Papa, G; Petrucci, T; Stasi, R; Tribalto, M | 1 |
| Alexanian, R; Barlogie, B; Delasalle, K; Dimopoulos, MA | 1 |
| Antinolfi, I; Cimino, R; Ferrara, F; Mele, G; Mettivier, V; Rametta, V | 1 |
| Grünwald, HW; Kalman, AC; Rosner, F | 1 |
| Attal, M; Fournie, B; Huguet, F; Laroche, M; Laurent, G; Mazieres, B; Payen, C; Pris, J; Schlaifer, D | 1 |
| Pelliniemi, TT; Tienhaara, A | 1 |
| Azais, I; Bernard, JF; Doyen, C; Grosbois, B; Laporte, JP; Le Loet, X; Menard, JF; Michaux, JL; Monconduit, M; Pollet, JP | 1 |
| Boccadoro, M; Pileri, A | 2 |
| Bonera, E; Calvi, A; Lombardi, C; Savio, A; Savio, E | 1 |
| Heilman, RL; Holley, KE; Kyle, RA; Offord, KP; Velosa, JA | 1 |
| Harada, M; Murakawa, M; Shibuya, T; Tsuda, Y | 1 |
| Ascari, E; Danova, M; Giordano, M; Invernizzi, R; Luoni, R; Rastaldi, MP; Riccardi, A; Ucci, G; Zambelli, ML | 1 |
| Caravelli, J; Chapman, D; Clarkson, BD; Gaynor, JJ; Merke, DP; Myers, J; Straus, DJ; Yahalom, J | 1 |
| Einhorn, S; Grandér, D; von Stedingk, LV; von Stedingk, M; Wasserman, J | 1 |
| Corrado, C; Pavlovsky, S | 1 |
| Bastion, Y; Coiffier, B; Tigaud, JD | 1 |
| Fishman, SJ; McBurney, EI; McCormick, CM | 1 |
| Amemiya, Y; Kobayashi, Y; Miura, Y; Mori, S; Ohsaka, A; Saito, K; Sakai, T; Sakamoto, S | 1 |
| Bucalossi, A; Cantore, M; Leoncini, L; Smerieri, F | 1 |
| Bello, JL; Feliu, J; García de Bustos, J; Losada, G; Manso, F; Quevedo, E | 1 |
| Cohen, AM; Eckhardt, S; Günczler, P; Huber, H; Jungi, WF; Ludwig, H; Nachbaur, D; Schüller, J; Seewann, HL; Senn, H | 1 |
| Cortelezzi, A; Hjorth, M; Rödjer, S; Turesson, I; Westin, J; Zador, G | 2 |
| Björkholm, M | 1 |
| Grabowska, S; Morelowska, M; Piotrowski, L | 1 |
| Matsuzaki, M; Ono, K; Sano, M; Shimamoto, Y; Yamaguchi, M | 1 |
| Brito Barroso, ML; González Brito, G; Hernández Nieto, L; Marsá Vila, L; Raya Sánchez, JM | 1 |
| Kraj, M; Maj, S; Mendek-Czajkowska, E; Pogłód, R; Rostkowska, J; Sabliński, J | 1 |
| Dmoszyńska, A; Kowalewski, J; Kraj, M; Kurowska, M; Maj, S; Mendek-Czajkowska, E; Pogłód, R; Rostkowska, J; Sokołowska, B; Sokołowska, U | 1 |
| Coldewey, R; Deicher, H; Peest, D | 1 |
| Casale, R; Colantonio, D; Collacciani, A; Natali, G; Pasqualetti, P | 1 |
| Golenkov, AK | 1 |
| Boyd, MA; Case, DC; Ervin, TJ; Redfield, DL | 1 |
| Cuttner, J | 1 |
| Spitzer, G | 1 |
| Baggio, G; Bolzonella, S; Casara, D; Chiarion-Sileni, V; De Besi, P; Favaretto, A; Frizzarin, M; Paccagnella, A; Salvagno, L; Soesan, M | 1 |
| Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Juliusson, G; Mellstedt, H; Osterborg, A | 1 |
| Barlogie, B; Beckord, J; Crowley, J; Pugh, RP; Salmon, SE | 1 |
| Westin, J | 1 |
| Goddard, IR; Jackson, R; Jones, JM | 1 |
| Gertz, MA; Greipp, PR; Kyle, RA | 1 |
| Andriani, A; Avvisati, G; Barbui, T; Boccadoro, M; Cantonetti, M; Carotenuto, M; Comotti, B; Dammacco, F; Marmont, F; Tribalto, M | 1 |
| Carpenter, JT; Levine, EG; Raczynski, JM | 1 |
| Petru, E; Schmähl, D | 1 |
| Cohen, AS; Jones, LA | 1 |
| Falda, M; Levis, A; Marmont, F; Resegotti, L | 1 |
| Baldini, L; Cesana, BM; Chiorboli, O; Cro, L; Fumagalli, S; Maiolo, AT; Polli, EE; Radaelli, F; Segala, M | 1 |
| Hirayama, C | 1 |
| Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM | 1 |
| Dorr, A | 1 |
| Brown, MP; Walls, RS | 1 |
| Fujii, H; Horishi, M; Kitagawa, Y; Kuzuyama, Y; Miyoshi, M; Suyama, Y; Taniwaki, M; Urata, Y; Yashige, H | 1 |
| Ando, R; Hamaguchi, H; Kanemitsu, H; Marumo, F; Matsuda, O; Miyake, S; Takemura, T; Uchida, S; Yokota, T | 1 |
| Bonnet, JD; Cheson, B; Coltman, CA; Crowley, J; Finley, P; Hutchins, LF; Milder, MS; Saeed, S; Salmon, SE; Tesh, D | 1 |
| Diagne, M; Gueye, M; Kone, S; Ndiaye, IP; Ndiaye, MM | 1 |
| Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J | 2 |
| Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM | 1 |
| Alcalá, A; Alonso, C; Besses, C; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, J; Sanz Sanz, MA; Zubizarreta, A | 1 |
| Factor, SM; Reed, LJ; van Hoeven, KH | 1 |
| Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Johansson, B; Osterborg, A | 1 |
| Alexanian, R; Barlogie, B; Cheson, B; Dicke, K; Dixon, DO; Jagannath, S; Lemaistre, FC; Pruitt, K; Smallwood, L; Zagars, G | 1 |
| De Blasio, A; De Laurenzi, A; De Rosa, L; Montuoro, A; Pacilli, L; Petti, N | 1 |
| Avvisati, G; Boccadoro, M; Cantonetti, M; Cavo-Comotti, BM; Frieri, R; Gallamini, A; Gallone, G; Lauta, VM; Liberati, M; Marmont, F | 1 |
| Avvisati, G; Petrucci, MT; Pulsoni, A; Tribalto, M | 1 |
| Ehrsson, H; Eksborg, S; Mellstedt, H; Osterborg, A; Wallin, I | 1 |
| Brandwein, JM; Callum, J; Keating, A; Scott, JG; Sutcliffe, SB | 1 |
| Bladé, J; López Guillermo, A; Montserrat, E; Rovira, M; Rozman, C; Rozman, M; Urbano, A | 1 |
| Freedman, J; Garvey, MB; Stewart, AK | 1 |
| Baumgartner, G; Fortelny, A; Pecherstorfer, M; Schmoranzer, F; Vesely, M | 1 |
| Jestrimski, KW; Lowenthal, RM | 1 |
| Kyle, RA | 4 |
| Cooper, MR; Welander, CE | 1 |
| Koziner, B; Zori Comba, A | 1 |
| Bisson, M; Massias, P; Paule, B; Quillard, J | 1 |
| Straus, DJ | 1 |
| Brière, J; Casassus, P; Desablens, B; Gandhour, C; Guilhot, F; Harousseau, JL; Ifrah, N; Le Prise, PY; Lemevel, A; Tourani, JM | 1 |
| Caravelli, J; Chapman, D; Clarkson, BD; Gaynor, J; Lee, BJ; Merke, D; Myers, J; Nisce, LZ; Straus, DJ | 1 |
| Avvisati, G; Giovangrossi, P; Mandelli, F; Petrucci, MT; Tribalto, M | 1 |
| Apple, JS; Baber, C; Paulson, DF; Putman, CE | 1 |
| Baldini, L; Cortelezzi, A; Fritz, E; Kriegisch, A; Kuehrer, I; Pirker, R; Polli, E; Preis, P; Scheithauer, W; Zielinski, C | 1 |
| Baldini, L; Cortelezzi, A; Fritz, E; Kührer, I; Ludwig, H; Polli, E; Scheithauer, W | 1 |
| Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Gyllenhammar, H; Järnmark, M; Johansson, B; Juliusson, G; Osterborg, A | 1 |
| Athens, J; Constanzi, JJ; Gad-el-Mawla, N; Glucksberg, H; Green, S; Hoogstraten, B; Maloney, T; Metch, B; Osborne, CK; Rivkin, SE | 1 |
| Imamura, Y | 1 |
| Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Johansson, B; Mellstedt, H; Osterborg, A | 1 |
| Blumsohn, A; Sinoff, CL | 1 |
| Barbui, T; Boccadoro, M; Comotti, B; Dammacco, F; Gallamini, A; Marmont, F; Neretto, G; Petrucci, MT; Pileri, A; Resegotti, L | 1 |
| Bastrup-Madsen, P; Bergmann, OJ; Boesen, AM; Ellegaard, J; Johnsen, HE; Pedersen, BB | 1 |
| Del Vecchio, L; Ferrara, F; Mele, G; Montuori, R; Rametta, V; Ronconi, F | 1 |
| García Laraña, J; Odriozola, J; Pérez de Oteyza, J; Sureda, A | 1 |
| Alexanian, R; Barlogie, B; Cabanillas, F; Velasquez, WS | 1 |
| Djukanović, R; Elezović, I; Rolović, Z | 1 |
| Bentwich, Z; Green, L; Hurwitz, N; Schattner, A; Varon, D | 1 |
| Dammacco, F; Miglietta, A; Perfetto, SC | 1 |
| Biosca, M; Bueno, J; Fernandez, JM; Garcia-Bragado, F; Parra, R | 1 |
| Coldewey, R; Deicher, H; Peest, D; Schedel, I; Schmoll, HJ | 1 |
| Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S | 1 |
| Dhingra, K | 1 |
| Boyd, M; Case, DC; Dorsk, BM; Hayes, DM | 1 |
| Alcalá, A; Alonso, C; Besalduch, J; García-Conde, J; Garijo, J; Gomis, F; Gutierrez, M; Guzmán, MC; Montserrat, E; Moraleda, JM | 1 |
| Blicharski, J; Piatkowska-Jakubas, B; Skotnicki, AB | 1 |
| Gola, A; Niewolna, M; Weryńska, B | 1 |
| Bang, YJ; Choi, DH; Heo, DS; Heo, M; Kim, BK; Kim, HJ; Kim, NK; Lee, M; Lee, SJ; Park, SY | 1 |
| Coleman, M; Cooper, MR; Eaton, W; Leone, L; McIntyre, OR; Propert, K; Tefft, M; Wolf, DJ; Zimmer, B | 1 |
| Antman, KH; Ryan, LM; Siegel, RD | 1 |
| Dengler, HJ; Engel, M; Hartlapp, JH; Hügl, E; Loos, U; Musch, E | 1 |
| Alexanian, R; Barlogie, B; Cabanillas, F; Cheson, B; Dicke, K; Dixon, D; Smallwood, L | 1 |
| Ishikawa, E; Kawakami, M; Kuraishi, Y; Meguro, S; Tanaka, H | 1 |
| Danova, M; Dörmer, P; Luoni, R; Riccardi, A; Ucci, G | 1 |
| Belch, A; Bergsagel, D; Klimo, P; Shelley, W; White, D; Willan, A; Wilson, K | 1 |
| Deicher, H; Peest, D | 1 |
| Cavagnaro, F; Corrado, C; de Tezanos Pinto, M; Huberman, A; Lein, JM; Palau, M; Pavlovsky, S; Santarelli, MT; Saslavsky, J | 1 |
| Bury, J; Fillet, G; Salmon, J | 1 |
| Costanzi, JJ; Pollard, RB | 1 |
| Bonadonna, G; Buzdar, A; Jones, SE; Montague, E; Moon, TE; Powles, T; Rivkin, S; Valagussa, P | 1 |
| Bennet, P; Bisson, M; Clerc, D; Massias, P; Medicis, P; Paule, B | 1 |
| Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S | 1 |
| Belch, A; Brox, L; Hanson, J; Palmer, M | 1 |
| Adler, G; Görg, C; Görg, K; Havemann, K; Pflüger, KH | 1 |
| Bosselmann, HP; Franke, A; Gaede, B; Lachhein, L | 1 |
| Prematilleke, MN | 1 |
| Cea, X; Cristoffanini, AP; Vidal, MA; Zapata, C | 1 |
| Gruber, A; Osby, E | 1 |
| Bartolucci, AA; Cohen, HJ; Forman, WB; Silberman, HR | 1 |
| Gazová, S; Hrubisko, M; Prümmerová, J; Sakalová, A; Steruská, M | 1 |
| Bonnet, J; Carter, S; Costanzi, JJ; Dabich, L; Dixon, DO; Durie, BG; Files, JC; Rivkin, S; Salmon, SE; Stephens, R | 1 |
| Boll, J; Deicher, H; Essers, U; Gamm, H; Glück, S; Görg, K; Gramatzki, M; Peest, D; Schedel, I; Schmoll, HJ | 1 |
| Costanzi, JJ; Green, S; McDivitt, RW; O'Bryan, R; Osborne, CK; Rivkin, SE; Stephens, RL | 1 |
| Cortelezzi, A; Fillet, G; Flener, R; Kuzmits, R; Ludwig, H; Peetermans, M; Polli, E; Scheithauer, W; Van Camp, BG | 1 |
| Bjark, P; Bondevik, A; Bull, O; Dehli, O; Kildahl-Andersen, O; Kvambe, V; Lamvik, J; Nordahl, E; Ytrehus, K | 1 |
| Berry, WR; Cox, EB; Graham, SD; Laszlo, J; Paulson, DF; Walker, A | 1 |
| Cohen, N; Golik, A; Marcus, EL; Modai, D; Sigler, E; Zaidenstein, R | 1 |
| Bayer, GK; Bowie, EJ; Camoriano, JK; Greipp, PR | 1 |
| Ahrenberg, P; Ala-Harja, K; Almqvist, A; Apajalahti, J; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Palva, IP | 1 |
| Gonnering, RS | 1 |
| Grebe, G; Lira, P; Walker, B | 1 |
| Del Potro, E; Diaz-Mediavilla, J; Krsnik, I; Peñalver, MA | 1 |
| Bickers, J; Case, DC; Cooper, MR; Fefer, A; Kempf, R; Neefe, J; Sacher, R; Scarffe, JH; Spiegel, RJ; Thompson, J | 1 |
| Brianzoni, MF; Centurioni, R; Leoni, P; Montillo, M; Olivieri, A; Salvi, A | 1 |
| Belch, A; Brox, L; Koch, M; Palmer, M; Pollock, E | 1 |
| Belch, A; Bergsagel, D; Brandes, L; Klimo, P; Shelley, W; White, D; Willan, A; Wilson, K | 1 |
| Chokas, W; Levin, M | 1 |
| Háber, J; Klener, P; Kolesková, E; Setková, O | 1 |
| Bickers, J; Case, DC; Cooper, MR; Fefer, A; Kempf, R; Neefe, J; Sacher, R; Scarffe, JH; Spiegel, R; Thompson, J | 1 |
| Benson, MD | 1 |
| Hurvitz, AI; Leifer, CE; MacEwen, EG; Matus, RE | 1 |
| Carter, C; Greaves, M; Preston, FE | 1 |
| Rosin, A; Sonnenblick, M; van Dijk, JM; Weissberg, N | 1 |
| Ho, AD; Hunstein, W; Keilholz, U; Theml, H; Wittkamp, S | 1 |
| Ascari, E; Cassano, E; Danova, M; Merlini, G; Montecucco, C; Riccardi, A; Ucci, G | 1 |
| Alexanian, R | 2 |
| Becherer, C; Busch, FW; Ostendorf, P; Steinke, B; Waller, HD | 1 |
| Blanco, L; Montalbán, C; Sabán, J; Serrano Ríos, M; Serrano, M; Sevilla, F; Zapatero, A | 1 |
| Constanzi, J; Foulkes, M; Gad-el-Mawla, N; Glucksberg, H; Osborne, CK; Rivkin, SE; Tranum, W | 1 |
| Binsack, T; Sauer, H; Wilmanns, W | 1 |
| Bove, L; Carroll, RJ; Case, DC; Dorsk, BM; Hayes, DM; Paul, SD; Sonneborn, HL | 1 |
| Cooper, RG | 1 |
| Aghai, E; Ben Ari, Y; David, M; Froom, P; Kohan, R; Quitt, M | 1 |
| Carter, SK | 3 |
| Henderson, IC | 1 |
| Fisher, B; Wolmark, N | 1 |
| Cusick, J; MacLennan, IC | 1 |
| Bartolucci, A; Cohen, HJ | 1 |
| Amadori, S; Boccadoro, M; Cantonetti, M; Centurioni, R; Dammacco, F; Franchi, A; Papa, G; Pileri, A; Tribalto, M; Vacca, A | 1 |
| Clausen, NA; Drivsholm, A; Hansen, OP; Laursen, B | 1 |
| Cortelezzi, A; Flener, R; Kuzmits, R; Ludwig, H; Polli, E; Scheithauer, W; Van Camp, BG | 1 |
| Come, SE; Gargan, TJ; Satwicz, PR | 1 |
| Chen, XW; Lin, TB; Lu, SF | 1 |
| Garton, JP; Gertz, MA; Greipp, PR; Kyle, RA | 1 |
| Joshua, DE; Kronenberg, H; Wearne, A | 1 |
| Monasch, E; Pegels, HG; van der Lelie, H; von dem Borne, AE | 1 |
| Garrett, TJ; Savage, D | 1 |
| Gertz, MA; Kyle, RA | 2 |
| Ascari, E; Merlini, G; Montecucco, C; Riccardi, A | 1 |
| Gebhardt, KP; Kövary, PM; Lukitsch, O | 1 |
| Calomeni, JA; Smith, JR | 1 |
| Boyd, NF; Campbell, JA; Elhakim, T; Heasman, KZ; Sutherland, HJ | 1 |
| Blanco, L; Escribano, L; Montalbán, C; Odriozola, J; Sevilla, F; Zapatero, A | 1 |
| Cornwell, GG; Kyle, RA; Leone, L; McIntyre, OR; Pajak, TF | 1 |
| Case, DC; Fanning, JP; Porensky, RS | 1 |
| Keane, WM; Khaleeli, M; Lee, GR | 1 |
| Casalino, C; Maroncelli, P | 1 |
| Fortuny, I; Kennedy, BJ; Kiang, DT; Theologides, A | 1 |
| Nordquist, RE; Shaw, MT; Twele, TW | 1 |
| Barandun, S; Bütler, R; Lopez, V; Pflugshaupt, R; Spengler, GA | 1 |
| Hudson, P; Stephens, PJ | 1 |
| Clément, F | 2 |
| Kjems, E; Mansa, B; Videbaek, A | 1 |
| Isobe, T; Osserman, EF | 1 |
| Jordon, RE; Muller, SA; Perry, HO; Rogers, RS; Schroeter, AL; Winkelmann, RK | 1 |
| Zubrod, CG | 1 |
| Hoogstraten, B | 1 |
| Jortay, A; Mendes da Costa, P; Noterman, J | 1 |
| Maier, C; Riedler, GF; Vorburger, E | 1 |
| Frei, E; Goldin, A; Schabel, FM | 1 |
| Parker, AC | 1 |
| Favre, E; Martz, G; Sonntag, R | 1 |
| Braun, HJ | 2 |
| Brunner, KW; Martz, G | 1 |
| Grünwald, H; Rosner, F | 1 |
| Harley, JB; Kim, I; Weksler, B | 1 |
| Alexanian, R; Finkelstein, JB; Rodriguez, LH; Shullenberger, CC | 1 |
| Bergsagel, DE; Cowan, DH; Hasselback, R | 1 |
| Brody, JI; Samitz, MH | 1 |
| Hansen, OP; Jessen, B; Videbaek, A | 2 |
| Ungaro, P | 1 |
| Dietze, F; Lisewski, G; Reitzig, P; Schulz, HJ | 1 |
| Clarkson, BD; Krakoff, IH; Lee, BJ; Sahakian, G | 1 |
| Bernard, DB; Bezwoda, WR; Bothwell, TH; Lynch, SR; Shulman, G; Stevens, K | 1 |
| Harris, RI; Kohn, J | 1 |
| Klener, P | 1 |
| Booth, LJ; Minielly, JA; Smith, EK | 1 |
| Fölsch, E | 1 |
| Ravina, A | 1 |
| Blank, N; Kountz, SL; Merigan, TC; Swenson, RS | 1 |
| Brunet, A; Dubost, C; Gandjbakhch, I; Gontard, F; Guilmet, D; Kaufmann, H; Legrain, M; Soyer, R | 1 |
| Dubois, M; Guilmet, D; Legrain, M; Rottembourg, J; Wajcner, G | 1 |
| Barrière, H; Bureau, B; Bureau, Y; Litoux, P; Senelar, R | 1 |
| Jean, G; Lambertenghi-Deliliers, G; Polli, E; Ranzi, T | 1 |
| Salmon, SE; Sullivan, PW | 1 |
| Alexanian, R; Bonnet, J; Gehan, E; Haut, A; Hewlett, J; Lane, M; Monto, R; Wilson, H | 1 |
| Beevers, DG | 1 |
| Estrada, PC; Scardino, PL | 1 |
| Drivsholm, A; Videbaek, A | 1 |
| Ladefoged, J; Nielsen, B; Pedersen, K | 1 |
| Athens, JW; Cartwright, GE; McArthur, JR; Wintrobe, MM | 1 |
| Grabstald, H; Huvos, AG; Sharma, TC | 1 |
| Bayrd, ED; Kyle, RA; Maldonado, JE | 1 |
| Korst, DR | 1 |
| Basch, CM; Rosenbaum, EH | 1 |
| Alexanian, R; Haut, A; Khan, AU; Lane, M; McKelvey, EM; Migliore, PJ; Stuckey, WJ; Wilson, HE | 1 |
| Menéndez-Corrada, R; Reyes, FM; Rivera, JV | 1 |
| Bernadou, CA; Montarcé, OJ | 1 |
| Caggiano, V; Cuttner, J; Solomon, A | 1 |
| Clarkson, BD; Koziner, B; Lee, BJ; Myers, J; Straus, DJ | 1 |
| Arlin, Z; Gee, T; Kempin, S; Koziner, B; Lee, BJ; McCormick, B; Mertelsmann, R; Myers, J; Nisce, LZ; Straus, DJ | 1 |
| Bierling, P; Brun, B; Cordonnier, C; Dreyfus, B; Farcet, JP; Feuilhade, F; Kuentz, M; Man, NG; Reyes, F; Rochant, H; Vernant, JP | 1 |
| Adams, DA; Adams, T; Cohen, AH; Gipstein, RM; Grabie, MT | 1 |
| Dyck, PJ; Kelly, JJ; Kyle, RA; Miles, JM | 1 |
| Albers, JW; Donofrio, PD; Greenberg, HS; Mitchell, BS | 1 |
| Ahre, A; Björkholm, M; Brenning, G; Engstedt, L; Gahrton, G; Hällen, J; Holm, G; Johansson, B; Johansson, SG; Karnström, L; Killander, A; Lerner, R; Lockner, D; Lönnqvist, B; Mellstedt, H; Simonsson, B; Stalfelt, AM; Ternstedt, B; Wadman, B | 1 |
| Didlake, R; Files, JC; Kirchner, KA; Krueger, RP; Raju, S | 1 |
| Alexanian, R; Dreicer, R | 1 |
| Cochi, S; De Laurenzi, A; Ferraro, P; Pacilli, L | 1 |
| Athens, JW; Costanzi, JJ; Foulkes, MA; Glucksberg, H; Knight, WA; O'Bryan, RM; Rivkin, SE; Stephens, RL | 1 |
| Boerner, D; Dziuba-Traber, H; Peter, HH | 1 |
| Curuchet, M; Dragosky, M; Garay, G; Huberman, AB; Lein, JM; Palmer, L; Pavlovsky, S; Quiroga-Micheo, E; Saslavsky, J; Tezanos Pinto, M | 1 |
| Gartenhaus, W; Jagathambal, K; Phillips, E; Rai, KR; Sawitsky, A | 1 |
| Abbrederis, K; Gastl, G; Gattringer, C; König, P | 1 |
| Ahre, A; Björkholm, M; Brenning, G; Engstedt, L; Gahrton, G; Gyllenhammar, H; Holm, G; Järnmark, M; Johansson, B; Mellstedt, H | 1 |
| Bunn, PA; Carney, DN; Cohen, MH; Eddy, JL; Ihde, DC; Minna, JD; Morstyn, G; Schechter, GP | 1 |
| Jones, SE; Moon, TE | 1 |
| Foulkes, M; Glucksberg, H; Rivkin, SE | 1 |
| Adelstein, DJ; Herzig, RH; Lazarus, HM; Smith, MC | 1 |
| McLeod, BC; Sassetti, RJ; Viernes, AL | 1 |
| Emmerich, B | 1 |
| Assaf, ME; Burucua, JE; De María, HE; Gasparini, S; Pizzolato, MA | 1 |
| Bartolucci, AA; Cohen, HJ; Silberman, HR; Tornyos, K | 1 |
| Grussendorf, M; Ritz, E; Seelig, HP; Waldherr, R | 1 |
| Davis, TE; Gilchrist, KW; Neville, AJ | 1 |
| Geniram, A; Guarino, P; Marini, U; Scio, P; Venturino, M | 1 |
| Anisimowicz, J; Mizan, K | 1 |
| Confalonieri, F; Foresti, V | 1 |
| Alexanian, R; Barlogie, B; Smith, L | 1 |
| Case, DC | 3 |
| Busch, FW; Ostendorf, P; Stapelfeld, S; Steinke, B; Waller, HD | 1 |
| Bauer, K; Bettelheim, P; Gössinger, H; Hinterberger, W; Korninger, K; Lechner, K; Neumann, E; Niessner, H; Pabinger-Fasching, I | 1 |
| Brynes, RK; Chan, WC; O'Neal, S; Soffer, T; Vogler, WR | 1 |
| Iwata, Y; Kageyama, S; Kamio, N; Karitani, Y; Kataoka, Y; Katayama, N; Kobayashi, T; Ohno, T; Ohota, C; Tanaka, I | 1 |
| Blanco, L; García Laraña, J; Montalbán, C; Odriozola, J; Sevilla, F; Zapatero, A | 1 |
| Harris, DC; Ibels, LS; Isbister, JP; Ravich, RB; Wells, JV | 1 |
| Błasińska-Morawiec, M; Krykowski, E; Mazurowa, A; Olszańska-Skorek, T; Polkowska-Kulesza, E; Płuzańska, A; Robak, T; Urbańska-Ryś, H | 1 |
| Bergsagel, D | 1 |
| Baccarani, M; Cavo, M; Gobbi, M; Lipizer, A; Tura, S | 1 |
| Halie, MR; Houwen, B; Marrink, J; Nieweg, HO; Ockhuizen, T; van Dobbenburgh, OA | 1 |
| Franchi, F; Monfardini, S; Santoro, A; Schieppati, G; Valagussa, P | 1 |
| Bolzonella, S; Cartei, G; Chiarion Sileni, V; Fiorentino, MV; Fosser, V; Paccagnella, A; Salvagno, L | 1 |
| Anger, G; Wutke, K | 1 |
| Dutcher, JP; Wiernik, PH | 1 |
| Halie, MR; Houwen, B; Marrink, J; Nieweg, HO; Ockhuizen, T; Piersma, H; Van Dobbenburgh, OA | 1 |
| Durham, JB; Farhangi, M; Thakur, VM | 1 |
| Erlandson, RA; Hurvitz, AI; Johnson, GF; Lieberman, PH; MacEwen, EG; Patnaik, AK | 1 |
| Deshayes, P; Grobois, B; Le Loët, X; Menard, JF; Monconduit, M; Piguet, H; Prevost, E; Tanguy, A | 1 |
| Al-Mondhiry, H; Arlin, Z; Clarkson, B; Dowling, M; Gee, T; Hecht, S; Kempin, S; Koziner, B; Lee, BJ; Little, C; Mayer, K; Phillips, E; Reich, L; Straus, D; Thaler, HT | 1 |
| Baccarani, M; Cavo, M; Gobbi, M; Savelli, G; Tura, S | 1 |
| Friedland, ML; Strother, SV | 1 |
| Cavo, M; Gobbi, M; Tura, S | 1 |
| Antonutto, G; Colle, R; Falconieri, G; Ruscio, M; Sala, P; Tonutti, E | 1 |
| Pihlstedt, P | 1 |
| Cereda, UG; De Micheli, N; Grisetti, GC; Invernizzi, F; Monti, G; Pessina, E | 1 |
| Boccafogli, A; Scolozzi, R | 1 |
| Bladé, J; Estapé, J; Feliú, E; Millá, A; Montserrat, E; Rozman, C | 1 |
| Alexanian, R; Bodey, GP; Yap, BS | 1 |
| Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A | 1 |
| Murphy, KE | 1 |
| Chanana, AD; Chandra, P; Chikkappa, G; Cronkite, EP; Thompson, KH | 1 |
| Becherini, JO; Cavagnaro, F; Jait, C; Lein, JM; Micheo, EQ; Musso, A; Pavlovsky, S; Pileggi, JE; Pizzolato, M; Suárez, A | 1 |
| Andrews, BS; Beacham, BE; Cooper, PH; Greer, KE | 1 |
| Cowan, K; Lippman, M | 1 |
| Dekker, A; Kapadia, SB; Macpherson, TA | 1 |
| Kilian, Z; Kołakowski, L; Kraj, M; Maj, S; Mariańska, B; Mendek, E; Rostkowska, J; Roszkowski, S; Snigurowicz, J | 1 |
| Arcese, W; Colombo, R; Franchii, A; Pastore, S; Tribalto, M | 1 |
| Caprini, JA; Cohen, E; Cunningham, MP; Knox, KL; Oviedo, MA; Robinson, B; Scanlon, EF | 1 |
| Abramson, N; Bennett, JM; Horton, J; Lurie, P; Mietlowski, WL; Schilling, A | 1 |
| Athens, J; Costanzi, J; Gad-el-Mawla, N; Glucksberg, H; Hoogstraten, B; Maloney, T; McCracken, J; Rasmussen, S; Rivkin, SE; Tranum, B; Vaughn, C | 1 |
| Ahmann, DL; Bisel, HF; Creagan, ET; Edmonson, JH; Frytak, S; Hahn, RG; Ingle, JN; O'Fallon, JR; Payne, WS; Rubin, J; Scanlon, PW | 1 |
| Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF | 1 |
| Holley, KE; Kyle, RA; Wagoner, RD | 1 |
| Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT | 1 |
| Coscia, GC; Discalzi, G; Racca, P; Ricci, C; Uberti, M | 1 |
| Houwen, B; Marrink, J; Nieweg, HO; Ockhuizen, T | 1 |
| Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L | 1 |
| Eichhorn, K; Kaltofen, G; Quietzsch, D | 1 |
| Bataille, R; Blotman, F; Bussière, JL; Ciurana, AJ; Lopitaux, R; Morlock, G; Rampon, S; Rosenberg, F; Sany, J; Serre, H; Simon, L | 1 |
| Faura, MV; García Zueco, JC; Giraldo, MP; Mur, P; Piñan, MA; Raichs, A; Rubio Felix, D; Ruíz-Marcuello, E | 1 |
| Goucher, G; Hawkins, J; Rowland, V | 1 |
| Alexanian, R; Barlogie, B; Boyer, H; Drewinko, B; Rubinow, SI | 1 |
| Gassel, WD; Sodomann, CP | 1 |
| Alonso, C; Badia, JM; Brunet, J; Delgado, E; Fuentes, J; Lacasta, A; Llanos, M; Mendoza, LA; Ojeda, B | 1 |
| Lishner, M; Slingerland, J; Sutcliffe, SB; Theresa, C | 1 |
| Alessandrino, EP; Astori, C; Bernasconi, P; Brusamolino, E; Canevari, A; Castelli, G; Lazzarino, M; Morra, E; Orlandi, E; Pagnucco, G | 1 |
| Capnist, G; Contu, A; Craviotto, L; Damasio, E; Fabris, P; Olmeo, N; Rizzoli, V; Spriano, M; Tedeschi, L; Vespignani, M | 1 |
| Belch, AR; Bergsagel, PL; Mant, MJ; Pilarski, LM; Smith, AM; Szczepek, A | 1 |
| Irjala, K; Laakso, M; Lahtinen, R; Mattila, K; Pelliniemi, TT; Pulkki, K; Rajamäki, A; Tienhaara, A | 1 |
| Chapman, CS; Ghosh, K; Murphy, P; Sivakumaran, M; Wood, JK | 1 |
| Pascali, E | 1 |
| Bosanquet, AG; Catovsky, D; Crotty, GM; McCann, SR; Mills, MJ | 1 |
| Hayama, T; Hirano, M; Horie, T; Kato, M; Kishigami, Y; Nakamura, N; Nakamura, O; Nishinarita, S; Sawada, U; Shimada, H | 1 |
| Fernández, P; García, MC; Gil, MT; Rivas, C; Roldán, V | 1 |
| Dreger, P; Haferlach, T; Klöss, M; Loeffler, M; Löffler, H; Petersen, B; Schmitz, N | 1 |
| Bastion, Y; Brice, P; Coiffier, B; Espinouse, D; Gisselbrecht, C; Haioun, C; Marolleau, JP; Reyes, F; Salles, G; Sonet, A | 1 |
| Anderbring, E; Einhorn, S; Grandér, D; Mellstedt, H; Ost, A; Osterborg, A; Sangfelt, O | 1 |
| Aghai, E; Attias, D; Brenner, B; Cohen, AM; Kaufman, S; Manor, Y; Many, A; Meytes, D; Shaklai, M; Shtalrid, M | 1 |
| Kedar, I; Segal, A | 1 |
| Fishback, NF; Koss, MN; Moran, CA; Suster, S | 1 |
| Feugier, P; Guerci, AP; Guerci, O; Guillemin, F; Péré, P; Pourel, J | 1 |
| Barr, R; Belch, A; Bergsagel, D; Browman, GP; O'Reilly, S; Rubin, S; Shustik, C; Sicheri, D; Walker, I; Wilson, KS | 1 |
| Cohen, AM; Eckhardt, S; Günczler, P; Huber, H; Ludwig, H; Morant, R; Nachbaur, D; Polliack, A; Seewann, HL; Senn, HJ | 1 |
| Behar, RA; Hoppe, RT; Horning, SJ | 1 |
| Chatterjee, R; Goldstone, AH; Katz, M; McGarrigle, HH; Mills, W | 1 |
| Leib, MS; Saunders, GK; Trevor, PB; Waldron, DR | 1 |
| Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D | 1 |
| Anderson, KC | 1 |
| Ahlström, H; Aström, G; Carlson, K; Nyman, R; Simonsson, B | 1 |
| Cohen, AM; Djaldetti, M; Lewinski, UH; Mittelman, M; Pick, AI; Weiss, H | 1 |
| Colović, MD; Janković, GM; Miletić, VD; Nikolov, VS; Suvajdzić, ND | 1 |
| Brice, P; Castaigne, S; Gisselbrecht, C; Marolleau, JP; Pautier, P | 1 |
| Betticher, DC; Cerny, T; Fey, MF | 1 |
| Barlogie, B; Crowley, JJ; Finley, P; Grogan, TM; Pugh, RP; Salmon, SE | 1 |
| Buswell, L; Coleman, CN; Kalish, LA; Shulman, LN | 1 |
| Kageyama, S; Kawai, T; Kawakami, S; Tsuzuki, M; Ueda, T; Yamauchi, T; Yonese, J | 1 |
| Acquaviva, PC; Bille, F; Henry, JF; Toussirot, E | 1 |
| Fedder, G; van Tol, KM | 1 |
| Gola, A; Kotlarek-Haus, S; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wołowiec, D | 1 |
| Enomoto, H; Fujioka, S; Inoue, Y; Nara, M; Saito, T; Suzuki, K | 1 |
| Alexanian, R; Dimopoulos, M | 1 |
| Holománová, D; Lipsic, T; Mikulecký, M; Mistrík, M; Sakalová, A; Steruská, M | 1 |
| Ashkenazi, Y; Gottschalk-Sabag, S; Hershko, C; Meerkin, D | 1 |
| Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J | 1 |
| Alexanian, R; Delasalle, KB; Dimopoulos, MA; Weber, D | 1 |
| Dolgos, J; Patakfalvi, A | 1 |
| Bernhardt, B; Canellos, G; Cooper, MR; Dear, K; Duggan, D; Ellerton, J; Faragher, D; McIntyre, OR; Ozer, H; Schiffer, C | 1 |
| Björeman, M; Björkholm, M; Brenning, G; Carlson, K; Celsing, F; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Osterborg, A | 1 |
| Furuyama, M; Hihara, J; Saku, M; Takeo, S | 1 |
| Hupp, JR; Lilly, GE; Vincent, SD | 1 |
| Alcalá, A; Alonso, C; Besalduch, J; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, JF; Sanz, MA; Zubizarreta, A | 1 |
| Togawa, A | 1 |
| Baczyński, S; Kuliszkiewicz-Janus, M | 1 |
| Hossfeld, DK; Junge, I; Seeger, D; Weh, HJ | 1 |
| Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; De Paoli, A; Di Stasi, M; Mora, O; Petrini, M; Piccinini, L; Piva, N; Riccardi, A; Rinaldi, E; Trotti, G; Ucci, G | 1 |
| Eika, S; Hippe, E; Hjorth, M; Holmberg, E; Kaasa, S; Palva, I; Westin, J; Wisløff, F | 1 |
| Crowley, J; Modiano, MR; Salmon, SE; Villar-Werstler, P | 1 |
| Ascari, E; Brugnatelli, S; Formisano, R; Gobbi, PG; Grignani, G; Pieresca, C; Riccardi, A; Ucci, G | 1 |
| Anderson, J; Cohen, AS; Falk, R; Jones, LA; Libbey, C; Simms, R; Skinner, M; Wang, M | 1 |
| Aul, C; Heyll, A | 1 |
| Frickhofen, N; Friedrich, JM; Hoffmeister, A; Mattfeldt, T; Merkle, E; Prümmer, O; Weber, CK | 1 |
| Attal, M; Bataille, R; Casassus, P; Facon, T; Fuzibet, JG; Harousseau, JL; Ifrah, N; Maisonneuve, H; Payen, C; Rossi, JF; Sotto, JJ; Stoppa, AM | 1 |
| Gripenberg, M | 1 |
| Handelsman, H | 1 |
| Borbujo, J; Casado, M; de Lucas, R; Manzano, R | 1 |
| Bottari, G; Martini, R; Santini, S | 1 |
| Alcalá, A; Bladé, J; Conde, E; Conzález-Brito, G; Escudero, ML; Estapé, J; Fontanillas, M; García-Conde, J; Maldonado, J; Montserrat, E; Moro, MJ; Pascual, A; Rozman, C; San Miguel, JF; Trujillo, J | 1 |
| Garćia, J; Grañena, A; Palou, J; Sarrá, J; Valls, A; Vivancos, P | 1 |
| Barlogie, B; Bracy, D; Desikan, KR; Jagannath, S; Siegel, D; Tricot, G; Vesole, DH | 1 |
| Hjorth, M; Kaasa, S; Westin, J; Wisløff, F | 1 |
| Bonini, A; Carotenuto, M; Cascavilla, N; D'Arena, G; Di Mauro, L; Greco, MM; Melillo, L; Minervini, MM; Musto, P; Sajeva, MR; Scalzulli, P | 1 |
| Haynes, AP; Iqbal, A; McQuaker, IG; Russell, NH | 1 |
| Gregory, SA; Greipp, PR; Kay, NE; Kyle, RA; O'Connell M, J; Oken, MM; Spiegel R, J; Tsiatis, A | 1 |
| Billadeau, D; Greipp, P; Kay, NE; Kyle, RA; Leong, T; Liu, P; Oken, MM; Quam, L; Van Ness, B | 1 |
| Bergethon, P; Comenzo, RL; Dubrey, S; Falk, RH; Faller, DV; Finn, K; Sarnacki, D; Simms, RW; Skinner, M; Vosburgh, E; Wright, DG | 1 |
| Chatziyianni, M; Maniatis, A; Mitsouli, C; Papanastasiou, K; Perifanis, V; Pouli, A; Zervas, K | 1 |
| Alcalá, A; Besses, C; Bladé, J; Estapé, J; Fontanillas, M; García-Conde, J; Maldonado, J; Montserrat, E; Moro, MJ; Muñoz, M; Rozman, C; San Miguel, J | 1 |
| Hirabayashi, N; Hotta, T; Ichikawa, A; Kamiya, O; Kato, R; Kato, Y; Kawashima, K; Kobayashi, M; Mizuno, H; Nagura, E; Naito, K; Nishiwaki, H; Nitta, M; Saito, H; Shibata, T; Shimizu, K; Takeyama, H; Tanaka, M; Utsumi, M | 1 |
| Argentino, C; Avvisati, G; Boccadoro, M; Comotti, B; Dominietto, A; Frieri, R; Lauta, VM; Liberati, M; Marmont, F; Musto, P; Palumbo, A; Pileri, A; Tribalto, M | 1 |
| Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R | 1 |
| Barbui, T; Bertini, M; Botto, B; Cinieri, S; Cortellazzo, S; Falda, M; Freilone, R; Grignani, F; Levis, A; Liberati, AM; Locatelli, F; Lovisone, E; Marmont, F; Pizzuti, M; Resegotti, L; Rossi, A; Viero, P; Vitolo, U | 1 |
| Attal, M; Harousseau, JL | 2 |
| Keimowitz, RM | 1 |
| Gertz, MA; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Therneau, TM; Witzig, TE | 1 |
| Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM | 1 |
| Avilés, A; Delgado, S; Díaz-Maqueo, JC; Fernández, A; Huerta-Guzmán, J | 1 |
| Hjorth, M; Wisløff, F | 1 |
| Antonijevic, N; Colovic, M; Jovanovic, V; Radosevic-Radojkovic, N; Rolovic, Z | 1 |
| Lila, AM; Mazurov, VI; Novik, AA | 1 |
| Anderson, L; Linch, DC; Vaughan Hudson, B; Vaughan Hudson, G | 1 |
| La Verde, G; Mandelli, F; Petrucci, MT; Pulsoni, A | 1 |
| Mizoguchi, H; Wada, M | 1 |
| Calasanz Abinzano, MJ; Cuesta Palomero, B; Panizo Santos, C; Rifón Roca, J; Rocha Hernando, E | 1 |
| Cassileth, P; Cooper, BW; Fernandez, H; Kutteh, L; Lazarus, HM; Miller, KB; Morelli, J; Pecora, AL; Roitman, D; Schenkein, DP; Stadtmauer, E | 1 |
| Barbui, T; Bellavita, P; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Abildgaard, N; Børset, M; Seidel, C; Sundan, A; Turesson, I; Waage, A | 1 |
| Belien, JA; Bloem, AC; de Leeuw, C; Dekker, AW; Izquierdo, MA; Lokhorst, HM; Raaijmakers, HG; Scheper, RJ; Sonneveld, P | 1 |
| Dmoszyńska, A; Sokołowska, B; Walter-Croneck, A; Wojtaszko, M | 1 |
| Ambrosone, L; Mansi, L; Marino, F; Orabona, P; Rambaldi, A; Rambaldi, M; Rambaldi, PF; Salvatore, T | 1 |
| Gertz, MA; Kyle, RA; Rajkumar, SV | 1 |
| Azaceta, G; Palomera, L; Soria, J; Varo, MJ | 1 |
| Bernat, S; García-Boyero, R; Gozalbo, T; Guinot, M | 1 |
| Di Leonardo, G; Di Simone, S; Furia, N; Pasqualoni, E; Quaglino, D | 1 |
| Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Schoch, R; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Arias, J; Besalduch, J; Bladé, J; Carnero, M; Escudero, ML; Estapé, J; Fontanillas, M; García-Conde, J; Gardella, S; Marti, JM; Montserrat, E; Rozman, C; San Miguel, JF | 1 |
| Bulabois, CE; Colombat, P; Dupas, B; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, A; Moreau, P; Rapp, MJ; Voillat, L | 1 |
| Cunningham, D; Popescu, RA; Wotherspoon, AC | 1 |
| Ackermann, J; DeSantis, M; Drach, J; Fiegl, M; Fritz, E; Gisslinger, H; Heinz, R; Huber, H; Krömer, E; Ludwig, H; Roka, S; Schuster, J; Schuster, R; Zojer, N | 1 |
| Usnarska-Zubkiewicz, L | 1 |
| Bragantini, G; Bresciani, P; Chuba, J; Ghiso, J; Pavlovsky, S; Pizzolato, M; Rostagno, A; Vidal, R | 1 |
| Browman, G; Cole, B; James, K; Johnston, D; Li, T; Pater, J; Sugano, D; Zee, B | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Rukavitsyn, OA | 1 |
| Belanger, C; Boccacio, C; Brouet, JC; Chevret, S; Divine, M; Dreyfus, F; Fermand, JP; Leblond, V; Macro, M; Mariette, X; Pertuiset, E; Ravaud, P | 1 |
| Bernasconi, M; Bettini, R; Tonolini, M | 1 |
| Azais, I; Bernard, JF; De Gramont, A; Doyen, C; Euller-Ziegler, L; Grosbois, B; Laporte, JP; Le Loët, X; Ménard, JF; Michaux, JL; Mineur, P; Monconduit, M; Peny, AM; Pollet, JP; Wetterwald, M | 1 |
| Bladé, J; Fernández-Calvo, J; García-Sanz, R; González, M; Miguel, JF; Moro, MJ; Orfão, A; Pérez-Simón, JA; Rasillo, A; Sanz, MA; Tabernero, MD | 1 |
| Colović, MD; Colović, RB; Janković, GM; Martinović-Cemerikić, VM | 1 |
| Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Kyle, RA; Lacy, MQ; Litzow, MR; Lust, JA; Pineda, AA; Tefferi, A; Witzig, TE | 1 |
| Benike, CJ; Blume, KG; Engleman, EG; Levy, R; Liso, A; Okada, CY; Reichardt, VL; Stockerl-Goldstein, KE | 1 |
| Bladé Creixenti, J; García-Sanz, R; San Miguel, JF | 1 |
| Hjorth, M; Nord, E; Westin, J; Wisløff, F | 1 |
| Bladé, J | 1 |
| Ampil, FL | 1 |
| Hjorth, M; Holmberg, E; Rödjer, S; Turesson, I; Westin, J; Wislöff, F | 1 |
| Dispenzieri, A; Gertz, MA; Lacy, MQ | 1 |
| Nartowicz, E; Polak, G; Tomczak-Watras, W | 1 |
| Hirabayashi, N; Ichikawa, A; Kamiya, O; Kawashima, K; Kobayashi, M; Mizuno, H; Nagura, E; Nitta, M; Saito, H; Sao, H; Shibata, T; Shimizu, K; Takeyama, H | 1 |
| Ataga, KI; Braeuning, P; Evans, HN; Graham, ML; Orringer, EP | 1 |
| del Potro Gómez, E; Morales Sanz, D | 1 |
| Bourantas, KL; Christou, L; Hatzimichael, EC; Siamopoulos, K; Sotsiou-Candila, F | 1 |
| Gertz, MA; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Witzig, TE | 1 |
| Biriukova, LS; Fetisova, EV; Margolin, OV; Pivnik, AV; Volodiaeva, EB | 1 |
| Greipp, PR; Kay, NE; Keimowitz, RM; Kyle, RA; Lenhard, RE; Leong, T; Oken, MM; Van Ness, B | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Grabensee, B; Heering, P; Hetzel, GR | 1 |
| Dunkley, S; Gibson, J; Iland, H; Joshua, D; Li, C | 1 |
| Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E | 1 |
| Abildgaard, N; Borset, M; Dahl, IM; Hjorth, M; Seidel, C; Sundan, A; Turesson, I; Waage, A | 1 |
| Ahmed, I; Cronk, JS; Crutchfield, CE; Dahl, MV | 1 |
| Chanalet, S; Chatel, M; Frenay, M; Lebrun, C | 1 |
| Buijt, I; Huijgens, PC; Ossenkoppele, GJ; Uyl-de Groot, CA | 1 |
| Araki, K; Fukuda, H; Hanada, S; Hirano, M; Ichimaru, M; Inaba, S; Konishi, H; Mikuni, C; Miura, A; Niimi, M; Ohno, Y; Sai, T; Shimamoto, Y; Shimoyama, M; Shirakawa, S; Tajima, K; Takenaka, T; Toki, H | 1 |
| Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; De Paoli, A; Delfini, C; Di Stasi, M; Giordano, M; Mora, O; Nicoletti, G; Piccinini, L; Riccardi, A; Rinaldi, E; Spanedda, R; Tinelli, C; Valentini, D | 1 |
| Hong, DS; Kim, YM; Lee, DW; Lee, KK; Oh, HS; Park, HS; Park, JS; Park, SK; Won, JH | 1 |
| Fradin, Z; Mittelman, M; Sender, BZ; Yarmolovsky, A; Zeidman, A | 1 |
| Ben Ayed, M; Bouaziz, M; Elloumi, M; Frikha, M; Makni, F; Masmoudi, H; Mseddi, S; Souissi, T | 1 |
| Krajewska, M; Krajewski, S; Lichtenstein, A; Reed, JC; Renner, S; Weisz, J | 1 |
| Himmelstein, SB; Kneipp, S | 1 |
| Angrilli, F; Ascari, E; Bertè, R; Broglia, C; Cavanna, L; Di Renzo, N; Ghirardelli, ML; Gobbi, PG; Iannitto, E; Molica, S; Petrilli, MP | 1 |
| Egerer, G; Goldschmidt, H; Ho, AD | 1 |
| Grabensee, B; Heering, P; Hetzel, GR; Heyll, A; Mondry, A; Schneider, P | 1 |
| Eucker, J; Jakob, C; Langelotz, C; Niemöller, K; Possinger, K; Sezer, O | 1 |
| Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O | 1 |
| Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S | 1 |
| Kovacsovics, T | 1 |
| Gulbrandsen, N; Wisløff, F | 1 |
| Benboubker, L; Colombat, P; Dugay, J; Gauvain, JB; Goupille, P; Linassier, C; Lucas, V; Luthier, F; Maigre, M; Rodon, P | 1 |
| Anagnostopoulos, N; Barbarousi, D; Bourantas, K; Dimopoulos, MA; Gregoraki, B; Maniatis, A; Pouli, A; Tzilianos, M; Venetis, E; Vyniou, N; Zervas, K | 1 |
| Gulbrandsen, N; Hjorth, M; Lenhoff, S; Nord, E; Westin, J; Wisløff, F | 1 |
| Alietti, A; Baldini, L; Colombi, M; Guffanti, A; Latargia, ML; Maiolo, AT; Vener, C | 1 |
| Moreau, P | 1 |
| Bohn, S; Ebnöther, M | 1 |
| Alexanian, R; Crowley, J; Jacobson, J | 1 |
| Bock, PR; Chabronová, I; Dedík, L; Gazová, S; Hanisch, J; Holomanova, D; Hrubisko, M; Mistrík, M; Sakalová, A; Schiess, W | 1 |
| Bokemeyer, C; Genvresse, I; Späth-Schwalbe, E; Wedding, U | 1 |
| Brinch, L; Dahl, IM; Ernst, P; Gruber, FX; Hammerstrøm, J; Nesthus, I; Tangen, JM; Waage, A; Wisløff, F | 1 |
| Ansén, S; Bischoff, S; Bohlen, H; Diehl, V; Dietlein, M; Re, D; Scheidhauer, K; Schicha, H; Tesch, H; Weihrauch, MR; Wolf, J | 1 |
| De Quiros, JF; del Río, JS; Iglesias, JR; Osuna, CG; Santos-Juanes, J | 1 |
| Bélanger, D; Bélanger, R; Boileau, J; Busque, L; Fish, D; Hébert, J; Kassis, J; Lavallée, R; Le Blanc, R; Letendre, F; Montminy-Métivier, S; Perreault, C; Roy, DC; Roy, J; Sauvageau, G | 1 |
| Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K | 1 |
| Bucci, P; Lo Muzio, L; Pannone, G | 1 |
| Arigliano, V; Artusi, T; Bonacorsi, G; Piccinini, L | 1 |
| Ariatti, C; Bertini, M; Boccomini, C; Botto, B; Calvi, R; Capello, D; Carbone, A; Freilone, R; Gaidano, G; Gallo, E; Gloghini, A; Milan, I; Novero, D; Orsucci, L; Palestro, G; Parvis, G; Pregno, P; Saglio, G; Vitolo, U; Vivenza, D; Zagonel, V | 1 |
| Mann, KP; Medeiros, LJ; Sen, F | 1 |
| Dreger, P; Glass, B; Haas, R; Kneba, M; Kröger, N; Kuse, R; Martin, S; Parwaresch, R; Schmitz, N; Sonnen, R | 1 |
| Barbui, T; Bassan, R; Carter, M; Casula, P; Di Bona, E; Fabris, P; Lambertenghi-Deliliers, G; Lerede, T; Lister, TA; Morandi, S; Pogliani, E; Rambaldi, A; Rohatiner, AZ; Rossi, G | 1 |
| Alcalá, A; Besalduch, J; Besses, C; Bladé, J; Brunet, S; Carbonell, F; Carnero, M; Conde, E; Escudero, ML; Estapé, J; Esteve, J; Fernández-Calvo, J; Font, L; Fontanillas, M; García-Conde, J; Gardella, S; Hernández-Martín, J; Maldonado, J; Martí, JM; Montserrat, E; Moro, MJ; Ortega, F; Ribera, JM; Rozman, C; San Miguel, JF; Trujillo, J | 1 |
| Okuda, T; Shindo, T; Yoshida, M; Yumoto, Y | 1 |
| Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D | 1 |
| Huijgens, PC; Zweegman, S | 1 |
| Ichikawa, A; Kamiya, O; Kawashima, K; Kobayashi, M; Mizuno, H; Nagura, E; Nitta, M; Saito, H; Shimizu, K; Takeyama, H; Wakita, A; Yamao, H | 1 |
| Comenzo, RL | 1 |
| Gertz, MA; Rajkumar, SV | 1 |
| Criado, PR; Lopes, LF; Pegas, JR; Ramos, CF; Tebcherani, AJ; Valente, NY; Vasconcellos, C | 1 |
| Clemente González, C; García Parés, D; García-Bragado Dalmau, F; Guardia Sánchez, R; Pérez Ayuso, MJ; Porcar Ramells, C | 1 |
| Elonen, E; Franssila, K; Itälä, M; Jantunen, E; Kuittinen, O; Lehtinen, T; Oinonen, R; Wiklund, T | 1 |
| Niederwieser, D; Pönisch, W | 1 |
| Bataille, R; Harousseau, JL; Mahé, B; Milpied, N; Misbahi, R; Moreau, P; Morineau, N; Rapp, MJ; Vigier, M | 1 |
| Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E | 1 |
| Arend, LJ; D'Agati, VD; Lauring, BP; Lobritto, SJ; Markowitz, GS; Nasr, SH | 1 |
| Albó, C; Arranz, R; Caballero, MD; Cabrera, R; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García Ruíz, JC; García-Conde, J; García-Laraña, J; Grande, C; Iriondo, A; Lahuerta, JJ; Marín, J; Moraleda, JM; Pérez-Equiza, C; Pérez-Simón, JA; Rifón, J; Rubio, V; San Miguel, JF; Sierra, J; Sureda, A; Varela, R; Vidal, MJ; Zuazu, J | 1 |
| Athens, JW; Costanzi, JJ; Green, SJ; Lew, D; Martino, S; Osborne, CK; Rivkin, SE; Vaughn, CB | 1 |
| Cavalieri, E; Falcucci, P; La Verde, G; Mandelli, F; Matera, R; Petrucci, MT; Pulsoni, A; Tosti, ME; Villivà, N | 1 |
| Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; Cavanna, L; Danova, M; De Paoli, A; Delfini, C; Giordano, M; Grasso, D; Mora, O; Nicoletti, G; Piccinini, L; Porta, C; Riccardi, A; Rinaldi, E; Spanedda, R; Tinelli, C; Tolcà, B | 1 |
| Afanas'ev, BV; Alekseeva, IuA; Medvedeva, NV; Mikhaĭlova, NB; Zaritskiĭ, AIu; Zubarovskaia, LS | 2 |
| Kajiguchi, T; Kojima, Y; Saito, M; Shimokawa, T; Takeyama, H | 1 |
| Messori, A; Santarlasci, B; Trippoli, S | 1 |
| Kaklamanis, P; Konstantopoulos, K; Mantzourani, M; Vaiopoulos, G | 1 |
| Benger, A; Foley, R; Garner, J; Haines, P; Henderson-O'Connor, N; Ingram, C; Kouroukis, CT; Marcellus, D; Meyer, R; O'Brien, BJ | 1 |
| Bory Ros, F; Coll Estrada, S; Galeras Sadurni, JA; Seoane Urgorri, A; Solà Lamoglia, R | 1 |
| Bastard, JP; Capeau, J; Diop, ME; Fellahi, S; Francois, T; Maachi, M | 1 |
| Davidson, MG; Dunston, SM; Gilger, BC; Michau, TM; Olivry, T; Proulx, DR; Rushton, SD | 1 |
| Merta, M; Rysavá, R; Spicka, I; Tesar, V | 1 |
| Dai, MS; Hou, TY; Kao, WY | 1 |
| Avvisati, G; De Fabritiis, P; De Felice, L; La Verde, G; Mandelli, F; Meloni, G; Palumbo, G; Petrucci, MT; Ribersani, M; Rusignuolo, A; Simone, F | 1 |
| De Muro, M; Levi, A; Mandelli, F; Martini, V; Petrucci, MT; Tirindelli, MC | 1 |
| Anagnostopoulos, N; Bourantas, K; Dimopoulos, MA; Economopoulos, T; Gika, D; Hamilos, G; Karmiris, T; Kouvatseas, G; Matsis, K; Mitsouli, C; Roussou, P; Symeonidis, A; Vervessou, E; Xilouri, I; Zervas, K; Zomas, A | 1 |
| Goring, RL; Lautzenhiser, SJ; Walker, MC | 1 |
| DENNY, WF; HAUT, A | 1 |
| SAMPEY, JR | 1 |
| DRIVSHOLM, A | 1 |
| GALTON, DA | 1 |
| Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M | 1 |
| Anderson, JJ; Berk, JL; Comenzo, RL; Dember, LM; Falk, RH; Finn, KT; Quillen, K; Sanchorawala, V; Seldin, DC; Skinner, M; Wright, DG | 1 |
| Alexandrakis, MG; Kyriakou, DS; Liapi, D; Moschandrea, J; Pappa, C; Passam, FH; Petreli, E; Roussou, P; Sfiridaki, K | 1 |
| Araki, A; Chuganji, Y; Kawahara, Y; Momoi, M; Nakanishi, H; Sazaki, N; Uraushihara, K; Yamamoto, T | 1 |
| Cotten, A; Duquesnoy, B; Flipo, RM; Gaxatte, C; Guillerm, G; Leroy, X; Mulleman, D | 1 |
| Gulbrandsen, N; Hjermstad, MJ; Wisløff, F | 1 |
| Chou, T; Deura, K; Hirano, M; Hotta, T; Itoh, K; Kawano, K; Konda, S; Matsuda, S; Mikuni, C; Mizorogi, F; Nagoshi, H; Ohno, T; Sai, T; Sano, M; Shimoyama, M; Suzuki, T; Takenaka, T; Tomonaga, M; Tsushita, K; Utsunomiya, A; Yamada, T | 1 |
| Chehal, A; Elhajj, I; Mourad, YA; Shamseddine, A; Taher, A | 1 |
| Berthou, C; Colombat, P; Deconinck, E; Delwail, V; Foussard, C; Gaillard, F; Gressin, R; Harousseau, JL; Lucas, V; Milpied, N | 1 |
| Alvino, S; Del Monte, G; Greco, C; Lopez, M; Venturo, I | 1 |
| Franck, PF; Kluin-Nelemans, JC; le Cessie, S; Schaar, CG; te Marvelde, MC; Wijermans, PW | 1 |
| Angelopoulou, MK; Dimopoulou, MN; Gribabis, DA; Kokoris, SI; Kyrtsonis, MC; Pangalis, GA; Siakantaris, MP; Vassilakopoulos, TP | 1 |
| Elira Dokekias, A; Malanda, F; Moutschen, M; Moyikoua, A; Purhuence, MF | 1 |
| Cannon, JD; Pullen, RL; Rushing, JD | 1 |
| Bertola, A; Boccadoro, M; Bringhen, S; Cavallo, F; Falco, P; Palumbo, A | 1 |
| Basous, L; Berrebi, A; Haran, MZ | 1 |
| Bladé, J; Carbonell, F; Fernandez-Calvo, J; García-Sanz, R; Gardella, S; Golvano, E; Hernández, JM; Mateo, G; San Miguel, JF; Soler, JA; Trujillo, J | 1 |
| Mohri, H | 1 |
| Annibali, O; Avvisati, G; Del Bianco, P; Foa, R; Fossati, C; Levi, A; Mandelli, F; Martini, V; Petrucci, MT; Tirindelli, MC | 1 |
| Gallego, E; Gómez Roldán, C; Llamas, F; López Montes, A; López Rubio, E; Massó, P; Pérez Martínez, J; Poblet, E | 1 |
| Carlson, K; Hjorth, M; Knudsen, LM | 1 |
| Haraguchi, N; Imagawa, S; Kaneko, Y; Satoh, H; Sekizawa, K | 1 |
| Basi, S; Fogo, AB; Schulman, G | 1 |
| Chan, RH; Cheung, W; Chim, CS; Loong, F; Ma, ES; Ooi, GC | 1 |
| Hyodo, H; Imagawa, J; Katayama, Y; Kimura, A; Kuroda, Y; Munemasa, S; Ohtaki, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y | 1 |
| Anderson, KC; Palumbo, A | 1 |
| Angelucci, E; Baldini, L; Boccomini, C; Brugiatelli, M; Cabras, MG; Calvi, R; Ciccone, G; Deliliers, GL; Federico, M; Gallo, E; Genua, A; Levis, A; Liberati, AM; Parvis, G; Pavone, E; Salvi, F; Sborgia, M; Vitolo, U | 1 |
| Barez, A; Bladé, J; Callís, M; Carbonell, F; Díaz-Mediavilla, J; Fernández-Calvo, J; Font, L; Fontanillas, M; García-Laraña, J; Gardella, S; Giraldo, P; Martí, JM; Mateos, MV; Moro, MJ; Palomera, L; Ribera, JM; Rosiñol, L; San Miguel, J; Soler, A; Sureda, A; Trujillo, J | 1 |
| Dingli, D; Grande, JP; Kyle, RA; Larson, DR; Plevak, MF | 1 |
| Bertola, A; Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Falco, P; Grasso, M; Musto, P; Nunzi, M; Palumbo, A | 1 |
| Bauchmüller, K; Engelhardt, M; Schmitt-Gräff, A; Strobel, ES | 1 |
| Angelucci, E; Baldini, L; Bordonaro, R; Broglia, C; Cavanna, L; Chisesi, T; Deliliers, GL; Federico, M; Gobbi, PG; Levis, A; Liberati, M; Merli, F; Pavone, V; Santini, G; Stelitano, C; Vitolo, U | 1 |
| Anglaret, B; Attal, M; Azaïs, I; Bataille, R; Blanc, M; Casassus, P; Collet, P; Dorvaux, V; Doyen, C; Eghbali, H; Eschard, JP; Facon, T; Ferrant, A; Grosbois, B; Harousseau, JL; Hulin, C; Jaubert, J; Lepeu, G; Maisonneuve, H; Maloisel, F; Mary, JY; Monconduit, M; Orfeuvre, H; Pégourie, B; Renaud, M; Rossi, JF; Sadoun, A; Thielemans, B; Thyss, A; Troncy, J; Vekemans, MC; Voillat, L; Wetterwald, M; Yakoub-Agha, I | 1 |
| Kyle, RA; Rajkumar, SV | 1 |
| Adam, Z; Drach, J; Gisslinger, H; Greil, R; Hinke, A; Klener, P; Kuhn, I; Linkesch, W; Ludwig, H; Maniatis, A; Morant, R; Schuster, J; Spicka, I; Tarkovács, G | 1 |
| Alberta, L; Bostom, A; Burnside, NJ; Robinson-Bostom, L | 1 |
| Beheshti, R; Chen, CI; Nanji, S; Prabhu, A; Stewart, AK; Sutton, D; Yi, QL | 1 |
| Arnulf, B; Belanger, C; Brouet, JC; Chevret, S; Divine, M; Dreyfus, F; Fermand, JP; Janvier, M; Katsahian, S; Leblond, V; Macro, M; Mariette, X; Pertuiset, E; Ravaud, P; Royer, B | 1 |
| Ferber, J; Loos, U; Musch, E; Schulte-Vennburg, M | 1 |
| Gruszka, A; Hrycek, A | 1 |
| Barbui, AM; Barbui, T; Belfiglio, M; Crippa, C; Delaini, F; Galli, M; Giussani, U; Nicolucci, A; Rambaldi, A; Valentini, M | 1 |
| Stammler, F | 1 |
| Carreiro, M; Cazalet, C; Grateau, G; Hachulla, E; Paccalin, M; Roblot, P; Rubi, M; Tricot, L | 1 |
| Assmann, M; Bittrich, A; Dachselt, K; Freund, M; Friedrich, T; Grobe, N; Harksel, B; Helbig, W; Herold, M; Merkle, K; Mitrou, PS; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Stelzer, E; Subert, R; Wilhelm, G | 1 |
| Anderson, KC; Barlogie, B; Chapman, RA; Cromer, JN; Crowley, JC; Dakhil, SR; Durie, B; Greipp, PR; Hurd, DD; Kyle, RA; Lanier, KS; Lazarus, HM; McCoy, J; Moore, DF; Salmon, SE | 1 |
| Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K | 1 |
| Bemelmans, RH; Schaar, CG; van Leeuwen, L; van Toorn, DW | 1 |
| Kunihiko, M; Mariko, Y; Shinichiro, O; Yasuo, I; Yusuke, T; Yutaka, H | 1 |
| Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Capparella, V; Caravita, T; Catalano, L; Ceccarelli, M; Ciccone, G; De Stefano, V; Falco, P; Galli, M; Grasso, M; Liberati, AM; Merla, E; Musto, P; Palumbo, A; Petrucci, MT; Rossini, F; Zamagni, E | 1 |
| Greipp, PR; Kay, NE; Kyle, RA; Leong, T; Li, S; Oken, MM; Van Ness, B | 1 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| Burton, A | 1 |
| Alcalá, A; Alegre, A; Besalduch, J; Bladé, J; Carrera, D; Casado, LF; de Arriba, F; de la Rubia, J; Fernández, P; García Boyero, R; García, PR; García-Laraña, J; Hernández, MT; Lahuerta, JJ; Martínez, R; Palomera Bernal, L; Pérez-Calvo, J; Ribera, JM; San Miguel, J; Sureda, A | 1 |
| Belkacémi, Y; Bolla, M; Castelain, B; Knobel, D; Landmann, C; Oner, FD; Ozsahin, M; Poortmans, P; Tsang, RW; Zouhair, A | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Handa, H; Irisawa, H; Komatsumoto, S; Matsushima, T; Murakami, H; Nojima, Y; Tsukamoto, N | 1 |
| Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB | 1 |
| Aldouri, M; Devereux, S; Milojković, D; Mufti, GJ; Pagliuca, A | 1 |
| Alegre, A; Bárez, A; García-Laraña, J; García-Sanz, R; Hernández, JM; Mateos, MV; Prósper, F; San Miguel, JF; Sureda, A | 1 |
| Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M | 1 |
| Facon, T | 2 |
| Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P | 1 |
| Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M | 1 |
| Merlini, G; Palladini, G; Perfetti, V | 1 |
| Fujimoto, Y; Ishihara, S; Izumi, H; Kaneko, K; Kato, M; Kuraishi, Y; Nagase, D; Natori, K; Umeda, M | 1 |
| Barr, R; Belch, A; Ding, K; Djurfeldt, M; Dolan, SP; Gill, K; Grewal, KS; Kovacs, MJ; Meyer, RM; Robinson, S; Rubin, SH; Rudinskas, L; Shepherd, LE; Shustik, C; Sicheri, DA; Vickars, L; Walde, D; Wilson, J; Wilson, K | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| De Miguel, J; Marabé, G; Mesa Latorre, J; Otero, S; Rebollar Merino, A | 1 |
| Attarbaschi, A; Fritsch, G; Gadner, H; Lawitschka, A; Lion, T; Matthes-Martin, S; Minkov, M; Mittheisz, E; Steiner, M; Zoubek, A | 1 |
| Jacobs, P; Mansvelt, E; Moodley, D; Ruff, P; Wood, L | 1 |
| Ishizawa, K | 1 |
| Ludwig, H; Schreder, M; Strasser-Weippl, K; Zojer, N | 1 |
| Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y | 1 |
| Fassas, AB; Tricot, G | 1 |
| Al-Ali, HK; Niederwieser, D; Wittekind, C | 1 |
| Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Boccadoro, M; Palumbo, A | 1 |
| Anglaret, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Grosbois, B; Guillerm, G; Harousseau, JL; Hulin, C; Jardel, H; Jaubert, J; Kolb, B; Maisonneuve, H; Martin, C; Mary, JY; Mathiot, C; Monconduit, M; Pegourie, B; Renaud, M; Troncy, J; Voillat, L; Yakoub-Agha, I | 1 |
| Ganser, A; Peest, D | 1 |
| Faiman, B | 1 |
| Baz, R; Fanning, S; Gaballa, S; Hussein, M; Karam, MA; Kelly, M; Kunkel, L; Reed, J | 1 |
| Darre, S; Facon, T | 1 |
| Albo, C; Alonso, N; Arranz, R; Caballero, D; Conde, E; Fernández-Rañada, JM; Gandarillas, M; García Vela, JA; Garzón, S; Grande, C; Hernández, MT; Lahuerta, JJ; Mateos, MV; Rodríguez, J | 1 |
| Gillmore, JD; Hawkins, PN; Wechalekar, AD | 1 |
| Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV | 1 |
| Briones, J; Camós, M; Colomo, L; Escoda, L; Espinosa, I; Estany, C; Gutiérrez-García, G; López-Guillermo, A; Martínez, S; Martino, R; Mercadal, S; Montserrat, E; Pedro, C; Ribera, JM; Xicoy, B | 1 |
| Fayers, PM; King, MT | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Capaldi, A; Caravita, T; Cavallo, F; Cavo, M; Ciccone, G; Derudas, D; Dore, F; Falco, P; Falcone, A; Gay, F; Liberati, AM; Montanaro, M; Musto, P; Palumbo, A; Ria, R; Zambello, R | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| Diehl, V; Evens, AM; Hutchings, M | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Durie, BG | 1 |
| Almy, F; Chary, P; Northrup, N; Webb, J | 1 |
| Junaid, A; Khan, KA; Siddiqui, NS; Siddiqui, S | 1 |
| Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A | 1 |
| Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S | 1 |
| Bladé, J; Rosiñol, L | 1 |
| Audard, V; Belhadj, K; Grimbert, P; Haioun, C; Hillon, ML; Lang, P; Matignon, M; Pardon, A; Remy, P; Sahali, D; Salomon, L; Vermes, E; Weiss, L | 1 |
| Ambrus, JL; Islam, A | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Alarcón, S; Barnés, C; Sánchez-Dalmau, BF; Vela, D | 1 |
| Kami, M; Komatsu, T; Tsubokura, M | 1 |
| Avvisati, G | 1 |
| García-Bustínduy, M; Martín-Herrera, A; Noda-Cabrera, A; Rodríguez-Martín, M; Sáez-Rodríguez, M | 1 |
| Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC | 1 |
| Friedenberg, WR; Greipp, PR; Jacobus, S; Kyle, RA; Rajkumar, SV; Slabber, CF | 1 |
| Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A | 1 |
| Berenson, JR | 1 |
| Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Azaïs, I; Benboubker, L; Casassus, P; Decaux, O; Dib, M; Doyen, C; Eschard, JP; Facon, T; Fontan, J; Garderet, L; Guillerm, G; Hulin, C; Lafon, I; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Rodon, P; Salles, B; Virion, JM | 1 |
| Barlogie, B; Bolejack, V; Crowley, JJ; Durie, BG; Hussein, MA; Jakubowiak, AJ; Zonder, JA | 1 |
| Bahlis, N; Mansoor, A; Stewart, DA | 1 |
| Deschler, B; Engelhardt, M; Ihorst, G; Jakob, C; Kleber, M; Koch, B; Liebisch, P; Sezer, O | 1 |
| Merlini, G; Palladini, G | 1 |
| Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H | 1 |
| Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM | 1 |
| Hägglund, H; Klimkowska, M; Lerner, R; Machaczka, M | 1 |
| Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Kuruvilla, J | 1 |
| Ameratunga, R; Chiu, W; Oei, P; Pullon, H; The, R; Woon, ST | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Durie, BG; Engelhardt, M; Frydrychowicz, A; Kleber, M; Pache, G; Schmitt-Gräff, A; Wäsch, R | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C | 1 |
| Gielerak, G; Hałka, J; Krzesiński, P; Matysiak, O; Smurzyński, P; Wierzbowski, R | 1 |
| Qiao, W; Wang, C; Wang, T; Xing, Y; Zhao, J | 1 |
| Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S | 1 |
| Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G | 1 |
| Bagratuni, T; Boyd, K; Davenport, EL; Davies, FE; Dickens, NJ; Gonzalez de Castro, D; Gregory, W; Johnson, DC; Morgan, GJ; Walker, BA; Wu, P | 1 |
| Stiefelhagen, P | 1 |
| Abildgaard, N; Ahlberg, L; Björkstrand, B; Carlson, K; Dahl, IM; Fayers, P; Forsberg, K; Gimsing, P; Gulbrandsen, N; Haukås, E; Hjertner, O; Hjorth, M; Juliusson, G; Karlsson, T; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Rolke, J; Strandberg, M; Sørbø, JH; Turesson, I; Waage, A; Wisløff, F | 1 |
| Boccadoro, M; Dispenzieri, A; Falco, P; Gay, F; Gertz, MA; Keith Stewart, A; Kumar, S; Palumbo, A; Petrucci, MT; Vincent Rajkumar, S | 1 |
| Alesiani, F; Blasi, N; Boccadoro, M; Bringhen, S; Brunori, M; Catarini, M; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Larocca, A; Leoni, P; Mele, A; Offidani, M; Oliva, S; Palumbo, A; Polloni, C; Visani, G | 1 |
| Fadjari, TH; Oehadian, A; Prasetya, D | 1 |
| Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S | 1 |
| Lonial, S | 1 |
| Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H | 1 |
| Boegsted, M; Christiansen, I; Gedde-Dahl, T; Gimsing, P; Johnsen, HE; Klausen, TW; Lenhoff, S; Lindås, R; Mellqvist, UH | 1 |
| Chao, TC; Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hsu, HC; Liu, JH; Teng, CJ; Teng, HW; Wang, WS; Yang, MH; Yang, YH; Yen, CC | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB | 1 |
| Rajkumar, SV | 2 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D | 1 |
| Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D | 1 |
| Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L | 1 |
| Palumbo, A | 1 |
| Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K | 1 |
| Harousseau, JL | 2 |
| Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M | 1 |
| Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V | 1 |
| Avcu, F; Baran, Y; Beyzadeoglu, M; Dirican, B; Gündüz, U; Mutlu, P; Ural, AU | 1 |
| Ando, K; Asakawa, T; Chou, T; Fukuda, H; Hotta, T; Iida, S; Mizoroki, F; Saito, I; Tobinai, K; Tsukasaki, K; Ueda, R; Uike, N | 1 |
| Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Schots, R | 1 |
| Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H | 1 |
| Ammerlaan, AH; Lokhorst, HM; Schaafsma, MR; Sinnige, HA; Sonneveld, P; Termorshuizen, F; Uyl-de Groot, CA; van der Griend, R; van Marwijk Kooy, M; Verelst, SG; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A | 1 |
| Beksaç, M; Benboubker, L; Bringhen, S; Caravita, T; Facon, T; Fayers, PM; Gimsing, P; Haznedar, R; Hulin, C; Mary, JY; Moreau, P; Musto, P; Palumbo, A; Schaafsma, M; Sonneveld, P; Termorshuizen, F; Turesson, I; Waage, A; Wijermans, P | 1 |
| Bisi, MC; Dias, FS; do Prado, AD; Piovesan, DM; Schmoeller, D; Staub, HL | 1 |
| Bartlett, NL; Cashen, AF; Foyil, KV; Grove, LE; Kennedy, DA | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I | 1 |
| D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O | 1 |
| Min, CK | 1 |
| Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS | 1 |
| Abumiya, M; Kameoka, Y; Miura, M; Sawada, K; Takahashi, N | 1 |
| Aziz, A; Baqui, MN; Begum, M; Debnath, RC; Dipta, TF; Habib, MA; Kabir, AL; Rahman, F; Rahman, MJ | 1 |
| Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S | 1 |
| Bila, J; Gotić, M; Mihaljević, B | 1 |
| Almagro, P; Garcia Pascual, L; Martí, JM; Rodriguez-Carballeira, M | 1 |
| Gündüz, U; Mutlu, P; Ural, AU | 1 |
| Cakana, A; Delforge, M; Dhawan, R; Esseltine, DL; Meunier, J; Regnault, A; Richardson, PG; Robinson, D; San Miguel, JF; van de Velde, H | 1 |
| Ma, X; Ren, C; Sheng, Z; Wang, B; Xia, B; Zhang, W | 1 |
| Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M | 1 |
| Badros, AZ | 1 |
| Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P | 1 |
| Chocholska, S; Dmoszynska, A; Grzasko, N; Hajek, R; Hus, M; Jurczyszyn, A; Morawska, M; Pluta, A; Walter-Croneck, A | 1 |
| Chigira, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shirane, S; Sugimoto, K; Wakabayashi, M | 1 |
| Charliński, G; Jedrzejczak, WW; Wiater, E | 1 |
| Brice, P; Brousse, N; Casasnovas, O; Delarue, R; Delmer, A; Haioun, C; Hermine, O; Lefrere, F; Ribrag, V; Salles, G; Tilly, H; Van Hoof, A | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Beuthien-Baumann, B; Bornhäuser, M; Ehninger, G; Kroschinsky, F; Middeke, JM; Ordemann, R; Platzbecker, U; Platzek, I; Stöhlmacher, J; van den Hoff, J; Zietz, C | 1 |
| Bertolini, F | 1 |
| Cherry, BM; Korde, N; Kwok, M; Landgren, O; Roschewski, M | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Carella, AM; Cavallo, F; De Paoli, L; Falco, P; Freilone, R; Gaidano, G; Gay, F; Grasso, M; Guglielmelli, T; Larocca, A; Mina, R; Molica, S; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Rocci, A; Rossi, D; Siez, ML | 1 |
| Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A | 1 |
| Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Advani, RH; Balise, R; Greenberg, PL; Hoppe, RT; Horning, SJ; Koontz, MZ; Rosenberg, SA | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| Lonial, S; Miguel, JF | 1 |
| Mina, R; Palumbo, A | 1 |
| Berraondo, J; de Casimiro, E; Lloret, T; Lluch, R; Novella, L; Sanz, F | 1 |
| Collet, P; Marotte, H; Nizeica, V | 1 |
| Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Goldschmidt, H; Nitschmann, S | 1 |
| Chevret, S; Facon, T; Mary, JY; Moatti, M; Moreau, P; Zohar, S | 1 |
| Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M | 1 |
| Back, AR; Lee, J; Phillips, JC; Schleis, SE; Smith, AN; Smrkovski, OA | 1 |
| Abajo del Álamo, C; del Olmo Revuelto, MA; Santos Pérez, MI | 1 |
| Drach, J; Drach-Schauer, B; Eder, S; Lamm, W | 1 |
| Ciampichini, R; Cocito, F; Corso, A; Ferretti, VV; Mangiacavalli, S; Mantovani, LG; Pascutto, C; Pochintesta, L; Pompa, A | 1 |
| Alici, E; Aschan, J; Gahrton, G; Holmberg, E; Liwing, J; Lund, J; Nahi, H; Uttervall, K | 1 |
| Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Amías-Lamana, V; Cabiró-Badimón, I; Hoyos-Chacón, J; Mesa-Gutiérrez, JC; Porta-Monnet, J; Rouras-López, A | 1 |
| Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S | 1 |
| Ambrosetti, A; Attolico, I; Barzan, A; Benedetti, F; Bergui, L; Billio, A; Carlo-Stella, C; Chiarenza, A; Devizzi, L; Di Nicola, M; Di Raimondo, F; Gianni, AM; Gueli, A; Guidetti, A; Intermesoli, T; Magni, M; Matteucci, P; Montanari, M; Mulè, A; Olivieri, A; Parvis, G; Patti, C; Rambaldi, A; Scimè, R; Tarella, C; Trentin, L; Valagussa, P; Viero, P; Viviani, S | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Daw, S; Hayward, J; Hewitt, M; Kirkwood, A; McCarthy, K; Morland, B; Shankar, A | 1 |
| Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A | 1 |
| Arranz, R; Bargay, J; Bello, JL; Caballero, MD; Conde, E; Coronado, M; González-Barca, E; Grande, C; Hernández, MT; Marín-Niebla, A; Martín, A; Montes-Moreno, S; Panizo, C; Pardal, E; Pérez-Ceballos, E | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI | 1 |
| Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J | 1 |
| Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK | 1 |
| Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E | 1 |
| Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ | 1 |
| Nagai, H | 1 |
| Tsurumi, H | 1 |
| Abenhardt, W; Aldaoud, A; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Münz, M; Nusch, A | 1 |
| Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H | 1 |
| Arnulf, B; Bahlis, NJ; Canepa, L; Delforge, M; Eisenmann, JC; Ervin-Haynes, A; Escoffre-Barbe, M; Ezaydi, Y; Facon, T; Fragasso, A; Giraldo-Castellano, P; Guo, S; Houck, V; Langer, C; Lemieux, B; Leyvraz, S; Minuk, L; Monzini, MS; Song, K; Vogl, DT; Yoon, SS; Zarnitsky, C | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chaleteix, C; Chiffoleau, A; Facon, T; Fortin, J; Hulin, C; Kolb, B; Leleu, X; Mary, JY; Moreau, P; Planche, L; Roussel, M; Tiab, M; Touzeau, C | 1 |
| Allred, J; Bergsagel, PL; Buadi, FK; Dispenzieri, A; Fonseca, R; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, AK | 1 |
| Beksac, M; Bringhen, S; Fıratlı-Tuğlular, T; Gimsing, P; Juliusson, G; Kristinsson, SY; Lupparelli, G; Palumbo, A; Sucak, GT; Turesson, I; Waage, A | 1 |
| Ishida, T | 1 |
| Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK | 1 |
| Cejalvo, MJ; de la Rubia, J | 1 |
| Schols, SE; Tick, LL | 1 |
| McCormack, PL | 1 |
| Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W | 1 |
| Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M | 1 |
| Abildgaard, N; Andersen, MN; Andersen, NF; Hokland, M; Møller, HJ; Rødgaard-Hansen, S | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S | 1 |
| Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z | 1 |
| Dou, J; Gu, N; Li, M; Luo, S; Ming, J; Shi, F; Wu, S; Xiong, F; Xue, J; Yang, C; Zhan, X; Zhang, T; Zhang, Y | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI | 1 |
| Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W | 1 |
| Alexandrakis, MG; Antonakis, A; Devetzoglou, M; Kokonozaki, M; Kyriakaki, S; Pappa, CA; Tsirakis, G; Tzardi, M; Vyzoukaki, R | 1 |
| Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A | 1 |
| Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R | 1 |
| Hellmich, M; Kuhr, K; Lehmacher, W; Srivastava, K; Wirth, D | 1 |
| Angrilli, F; Baldini, L; Cascavilla, N; Federico, M; Ferrari, A; Galimberti, S; Gobbi, PG; Ilariucci, F; Luminari, S; Mammi, C; Marcheselli, L; Merli, F; Musso, M; Polimeno, G; Scalzulli, PR; Stelitano, C | 1 |
| An, Z; Li, F; Song, P; Wang, L; Wang, X; Yu, Y; Zhai, Y; Zhao, Q; Zhou, X | 1 |
| Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB | 1 |
| Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| Ding, ZX; Li, BY; Lyu, WW; Song, DH; Wei, CM; Zhang, JJ; Zhao, QC | 1 |
| Aghemo, E; Benevolo, G; Boccadoro, M; Bringhen, S; Caravita, T; Carella, AM; Conticello, C; De Paoli, L; De Rosa, L; Derudas, D; Falcone, AP; Genuardi, M; Guglielmelli, T; Larocca, A; Liberati, AM; Montefusco, V; Morabito, F; Musolino, C; Nozzoli, C; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Petrucci, MT; Ponticelli, E; Sonneveld, P; Spada, S; Villani, O; Vincelli, ID | 1 |
| Ise, M; Kumagai, K; Matsubayashi, K; Tsujimura, H | 1 |
| Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB | 1 |
| Akashi, K; Hiyamuta, H; Kitazono, T; Masutani, K; Matsukuma, Y; Muta, T; Nakano, T; Taniguchi, M; Tsuchimoto, A; Tsuruya, K; Yamada, S; Yoshimoto, G | 1 |
| Clayton, E; Kozielski, F; Rath, O; Talapatra, SK; Tomasi, S | 1 |
| Azais, I; Belch, A; Chen, G; Dakhil, S; Dimopoulos, MA; Doyen, C; Dührsen, U; Eek, R; Ervin-Haynes, A; Facon, T; Garderet, L; Gisslinger, H; Goncalves, C; Houck, V; Hulin, C; Hunter, H; LeBlanc, R; Leleu, X; Leupin, N; Lu, J; Macro, M; Offner, F; Pégourié, B; Petrucci, MT; Rodon, P; Romeril, K; Royer, B; Shustik, C; Song, K | 1 |
| Bahlis, NJ; Chen, BE; Chen, C; Djurfeldt, M; Han, M; Hay, AE; Howsen-Jan, K; Meyer, RM; Murugesan, A; Reece, D; Reiman, T; Seftel, MD; Shepherd, L; Song, K; Stewart, K; White, D; Xie, Y; Zhu, L | 1 |
| Liu, HB; Wang, W | 1 |
| Contreras, I; Gómez-Sanz, F; González-Martin-Moro, J; Pilo-de-la-Fuente, B | 1 |
| Guo, C; He, P; Sun, C; Wang, X; Zhang, M | 1 |
| Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E | 1 |
| Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS | 1 |
| Butcher, B; Chong, G; Cull, G; Fay, K; Filshie, R; Gandhi, MK; Gill, D; Grigg, A; Hahn, U; Hertzberg, M; Hicks, RJ; Ho, SJ; Hofman, MS; Johnston, A; Kannourakis, G; Lewis, ID; Milliken, S; Renwick, W; Seymour, JF; Taper, J; Trotman, J; Warburton, P; Watson, AM; Wirth, A | 1 |
| Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM | 1 |
| Boccadoro, M; Bringhen, S; Grammatico, S; Petrucci, MT; Siniscalchi, A; Vozella, F | 1 |
| Bae, SB; Bae, SH; Cho, DY; Choi, CW; Do, YR; Hyun, MS; Jeong, SH; Jo, DY; Joo, YD; Kim, BS; Kim, H; Kim, HG; Kim, HJ; Kim, JA; Kim, JS; Kim, K; Kim, KH; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, YS; Kwak, JY; Lee, HS; Lee, JH; Lee, JJ; Lee, JO; Lee, MH; Lee, SM; Lee, WS; Lim, SN; Min, CK; Moon, JH; Mun, YC; Nam, SH; Park, JS; Park, KW; Park, MR; Park, SK; Shin, HJ; Song, MK; Yi, HG; Yoon, SS | 1 |
| Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS | 1 |
| Boostrom, BO; DeRegis, CJ; Freeman, K; Moore, AS; Robat, C; Thamm, DH | 1 |
| Ballanti, S; Bringhen, S; Corvatta, L; Liberati, AM; Offidani, M; Pulini, S | 1 |
| Peña, C; Quilodrán, JA; Valladares, X | 1 |
| Dieng, F; Diouf, C; Djiba, B; Fall, S; Ndao, AC; Ndiaye, FSD | 1 |
| Braziel, RM; Chansky, K; Chen, AI; Dunlap, JB; Fan, G; Gay, ND; Leonard, JT; Maziarz, RT; Okada, CY; Raess, PW; Stentz, A | 1 |
| Ludwig, H; Zojer, N | 1 |
| Campbell, P; Carson, R; Cavo, M; Chiu, C; Cook, M; Crepaldi, A; Crist, W; Deraedt, W; Dimopoulos, MA; Doyen, C; Fujisaki, T; Garg, M; Grosicki, S; Iosava, G; Jakubowiak, A; Kaplan, P; Knop, S; Liberati, AM; Lucio, P; Mateos, MV; Nagy, Z; Nguyen, H; Pour, L; Qi, M; San-Miguel, J; Shelekhova, T; Suzuki, K; Wang, J; Yoon, SS | 1 |
| Stirrups, R | 1 |
| Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S | 1 |
| Ando, K; Fukuhara, N; Gomyo, H; Hanamura, I; Hotta, T; Kobayashi, H; Kobayashi, N; Kumagai, K; Kurosawa, M; Maruyama, D; Matsuno, Y; Miyazaki, K; Morishima, Y; Nagai, H; Nakamura, S; Nosaka, K; Ogura, M; Ohmachi, K; Ohnishi, K; Ohyashiki, K; Sawada, K; Shimoyama, T; Takayama, N; Taniwaki, M; Tobinai, K; Tsukamoto, N; Tsukasaki, K; Uike, N; Usuki, K; Utsumi, T; Wakabayashi, M; Yakushijin, Y; Yamamoto, K | 1 |
| Choi, CW; Choi, H; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES | 1 |
| Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S | 1 |
| Syed, YY | 1 |
| Cho, SH; Jung, KS; Kim, Y; Shin, HJ | 1 |
| Amico, V; Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Cangiolosi, C; De Paoli, L; Evangelista, A; Falcone, AP; Fraticelli, V; Giuliani, N; Hájek, R; Innao, V; Larocca, A; Ledda, A; Liberati, AM; Mina, R; Montefusco, V; Musto, P; Oddolo, D; Offidani, M; Palumbo, A; Paris, L; Patriarca, F; Romano, A; Spada, S; Zambello, R | 1 |
| Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E | 1 |
| Hashim, M; Heeg, B; Ouwens, M; Postma, M; Soikkeli, F | 1 |
| Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| Aquino, S; Baldini, L; Ballanti, S; Boccadoro, M; Bringhen, S; Cellini, C; D'Agostino, M; De Rosa, L; Falco, P; Gazzera, G; Gentile, M; Grasso, M; Hájek, R; Larocca, A; Marasca, R; Palumbo, A; Paris, L; Pavone, V; Pescosta, N; Petrucci, MT; Pezzatti, S; Poggiu, M; Rota-Scalabrini, D; Santoro, A; Spada, S; Tosi, P | 1 |
| Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S | 1 |
| Deraedt, W; Dimopoulos, MA; Goldschmidt, H; Hashim, M; He, J; Heeg, B; Hu, P; Lam, A; Mateos, MV; San-Miguel, J; Sonneveld, P | 1 |
| Bhutani, M; Usmani, SZ | 1 |
| Killock, D | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R | 1 |
| Gertz, M; Vaxman, I | 1 |
| Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM | 1 |
| Charifa, A; Ko, CJ; Lee, A; Levy, L; McNiff, JM; Paulson, N; Perincheri, S | 1 |
| Cavo, M; Deraedt, W; Dimopoulos, MA; He, J; Jakubowiak, A; Kampfenkel, T; Lam, A; Mateos, MV; Qi, M; San-Miguel, J | 1 |
| Hollingworth, S; Loke, C; McPherson, I; Mollee, P; Mutsando, H; Tomlinson, R; Walpole, E; Weston, H; Wong, P; Yue, M | 1 |
| Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D | 1 |
| Cavo, M; Dimopoulos, MA; Fernandez, M; Garcia, A; He, J; Heeg, B; Hungria, V; Lam, A; Machnicki, G; Martínez-Baños, DM; Mateos, MV | 1 |
| Abonour, R; Agarwal, A; Ailawadhi, S; Durie, BGM; Gasparetto, C; Hardin, JW; Jagannath, S; Kitali, A; Lee, HC; Narang, M; Omel, JL; Rifkin, RM; Srinivasan, S; Terebelo, HR; Toomey, K; Wagner, L | 1 |
| Carson, R; Chari, A; Delioukina, M; Hulin, C; Hungria, V; Iida, S; Karlin, L; Kosh, M; Magen, H; Maisnar, V; Masterson, T; McCarthy, H; Parasrampuria, DA; Perrot, A; Pour, L; Qi, M; Rodriguez-Otero, P; Sureda Balari, A; Suzuki, K; Touzeau, C; Yang, S | 1 |
| Li, S; Liu, Q; Luo, X; Peng, L; Peng, Y; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Abella, E; Alcalá, M; Bustamante, G; Cejalvo, MJ; de la Rubia, J; Duro, R; García, A; García, R; Garzón, S; González, E; González, MS; González, Y; Jarque, I; López, R; Lostaunau, G; Martí, JM; Motlló, C; Pérez-Persona, E; Ramírez-Payer, Á; Sampol, A; Sarrà, J; Sastre, JL; Vázquez-Álvarez, J | 1 |
| Campbell, P; Cavo, M; Cook, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fastenau, J; Fujisaki, T; Garg, M; Gries, KS; Grosicki, S; Jakubowiak, A; Knop, S; Kudva, A; Liberati, AM; Losava, G; Lucio, P; Mateos, MV; Nagy, Z; Pour, L; San-Miguel, J; Shelekhova, T; Suzuki, K; Usenko, G; Wang, J; Wroblewski, S; Yoon, SS | 1 |
| Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M | 1 |
| Bladé, J; Campbell, P; Cavo, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fujisaki, T; Garg, M; Grosicki, S; Iida, S; Iosava, G; Knop, S; Kudva, A; Liberati, AM; Lucio, P; Mateos, MV; Nagy, Z; Pei, H; Pour, L; Qi, M; San-Miguel, J; Suzuki, K; Ukropec, J; Van Rampelbergh, R; Yoon, SS | 1 |
| Cuevas-Palomares, L; de Miguel-Sánchez, C; Díez-Angulo, R; Gabilondo-Jalón, M; Guinea de Castro, JM; Herraez, S; Menchaca, C; Mendizabal-Abad, A; Oiartzabal-Ormategui, I; Pérez-Persona, E; Pisón-Herrero, C; Robles-Castro, D; Salcedo-Cuesta, L; Santamaría-López, A; Unamunzaga-Cilaurren, A; Vega González-Viñaspre, A | 1 |
| Egea Valenzuela, J; Leal Rubio, JD; Mesa López, MJ; Muñoz Tornero, M; Salazar Nicolás, A | 1 |
| Aouba, A; Audemard-Verger, A; Battistella, M; Bigot, A; Brihaye, B; Cook, AR; Deriaz, S; Diot, E; El Karoui, K; Ferreira-Maldent, N; Hankard, A; Henique, H; Ingen-Housz-Oro, S; Jobard, S; Lioger, B; Magnant, J; Maillot, F; Paule, R | 1 |
| Fukushima, N; Iida, S; Imaizumi, Y; Kagami, Y; Kameoka, Y; Kataoka, T; Katsuya, H; Kobayashi, M; Kobayashi, T; Kubota, N; Kurosawa, M; Machida, R; Maruta, M; Maruyama, D; Morimoto, H; Nagai, H; Ohba, R; Omachi, K; Sunami, K; Suzuki, T; Tabayashi, T; Takayama, N; Tokunaga, M; Yamamoto, K; Yoshida, I | 1 |
| Balcerczak, E; Jeleń, A; Michalska, K; Pietrzak, J; Saed, L; Żebrowska-Nawrocka, M | 1 |
| Jeon, YW; Lee, JY; Min, CK; Park, SS; Shin, SH; Yahng, SA | 1 |
129 review(s) available for prednisone and melphalan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Child; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunotherapy; Leucovorin; Male; Melphalan; Methotrexate; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Prednisone; Rhabdomyosarcoma; Testicular Neoplasms; Thiotepa; Vinblastine; Vincristine | 1976 |
[Treatment of Kahler's disease].
Topics: Bone Neoplasms; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Procarbazine; Urethane; Vincristine | 1976 |
The action of antitumor agents: a double-edged sword?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azathioprine; Burkitt Lymphoma; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Female; Hodgkin Disease; Humans; Immunosuppressive Agents; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Mechlorethamine; Melphalan; Mercaptopurine; Methotrexate; Mice; Multiple Myeloma; Neoplasms; Prednisone; Pregnancy; Procarbazine; Time Factors; Vincristine | 1977 |
Pulmonary histopathologic changes associated with melphalan therapy.
Topics: Aged; Drug Therapy, Combination; Epithelium; Humans; Lung; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pulmonary Fibrosis | 1978 |
[Recent progress in chemotherapy of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine | 1978 |
Current concepts in cancer. Multiple myeloma.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulins; Lomustine; Melphalan; Multiple Myeloma; Neoplasm Staging; Plasmapheresis; Prednisone; Risk; Sodium Fluoride; Uremia | 1979 |
The treatment of plasma cell myeloma.
Topics: Animals; Carmustine; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Fluorouracil; Humans; Melphalan; Methotrexate; Mice; Mice, Inbred BALB C; Multiple Myeloma; Myeloma Proteins; Prednisone; Procarbazine; Remission, Spontaneous | 1976 |
The role of chemotherapy in the treatment of cancer of the breast.
Topics: Breast Neoplasms; Castration; Cyclophosphamide; Drug Resistance; Estrogens; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Prednisone; Thiotepa | 1975 |
Multiple myeloma. New treatment options.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Diphosphonates; Drug Resistance; Erythropoietin; Humans; Interferon-alpha; Interleukins; Melphalan; Multiple Myeloma; Prednisolone; Prednisone | 1992 |
Meta-analysis of chemotherapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisone; Survival Analysis; Treatment Outcome | 1992 |
[Recent biological and therapeutic advances in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Humans; Interferon-alpha; Karyotyping; Melphalan; Multiple Myeloma; Phenotype; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic | 1992 |
Ten-year survival in multiple myeloma: report of two cases and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate | 1992 |
Myeloma, melphalan, and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisone; Survival Rate | 1992 |
Standard chemotherapy for myelomatosis: an area of great controversy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis | 1992 |
[Multiple myeloma. Biological, prognostic, and therapeutic aspects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Myeloma Proteins; Pain; Palliative Care; Plasmacytoma; Prednisone; Prognosis | 1990 |
[Treatment of relapses and failures in disseminated Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Mechlorethamine; Melphalan; Methotrexate; Mitoguazone; Prednisone; Procarbazine; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine | 1991 |
[Chemotherapy of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Evaluation; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1991 |
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Humans; Melphalan; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Prednisone; Prognosis; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 1991 |
Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hodgkin Disease; Humans; Leukemia; Mechlorethamine; Melphalan; Neoplasms, Multiple Primary; Ovarian Neoplasms; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Retrospective Studies; Vincristine | 1991 |
Amyloidosis.
Topics: Amyloid; Amyloidosis; Colchicine; Humans; Melphalan; Prednisone; Prognosis | 1991 |
[Current management of amyloidosis].
Topics: Amyloidosis; Colchicine; Dimethyl Sulfoxide; Female; Humans; Melphalan; Middle Aged; Prednisone | 1991 |
Adjuvant therapy in breast cancer.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Prednisone; Tamoxifen; Vincristine | 1990 |
[Solitary intra and extracranial plasmocytoma. Apropos of a case and review of the literature].
Topics: Combined Modality Therapy; Humans; Male; Melphalan; Middle Aged; Occipital Bone; Parietal Bone; Plasmacytoma; Prednisone; Radiography; Skull Neoplasms | 1990 |
[Therapy of multiple myeloma and its complications].
Topics: Acute Kidney Injury; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Humans; Hypercalcemia; Interferon Type I; Kidney Failure, Chronic; Melphalan; Multiple Myeloma; Prednisone; Recurrence | 1990 |
Corticosteroid drugs: their role in oncological practice.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Dyspnea; Fluorouracil; Hodgkin Disease; Humans; Hypercalcemia; Leukemia; Leukemia, Lymphoid; Lymphoma; Mechlorethamine; Melphalan; Methotrexate; Multiple Myeloma; Palliative Care; Prednisone; Procarbazine; Receptors, Glucocorticoid; Vinblastine; Vincristine; Vomiting | 1986 |
Diagnosis and management of multiple myeloma and related disorders.
Topics: Alkylating Agents; Amyloidosis; Anemia; Anemia, Refractory; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Blood Transfusion; Bone and Bones; Bone Marrow Examination; Bone Marrow Transplantation; Bone Neoplasms; Calcium; Combined Modality Therapy; Diagnosis, Differential; Heavy Chain Disease; Humans; Immunoglobulin D; Immunotherapy; Interferons; Kidney Failure, Chronic; Leukemia; Melphalan; Mice; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Myeloma Proteins; Osteolysis; Osteosclerosis; Paraproteinemias; Plasma Cells; Plasmacytoma; Prednisone; Radionuclide Imaging; Waldenstrom Macroglobulinemia | 1986 |
Interferons in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Humans; Interferon Type I; Interferons; Melphalan; Multiple Myeloma; Prednisone; Radiography; Recombinant Proteins | 1986 |
[Rescue treatment in Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Lomustine; Mechlorethamine; Melphalan; Prednisone; Procarbazine; Vinblastine; Vincristine; Vindesine | 1987 |
Treatment of advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia; Lomustine; Lymphoma; Male; Mechlorethamine; Melphalan; Middle Aged; Neoplasms, Multiple Primary; Prednisone; Procarbazine; Remission Induction; Vinblastine; Vincristine; Vindesine | 1989 |
Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis | 1989 |
[Recent progress in the treatment of hematological malignancies. V. Therapy of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Dexamethasone; Doxorubicin; Humans; Interferon Type I; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1989 |
Melphalan/prednisone versus drug combinations for plasma cell myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic | 1989 |
[Possibility of using interferon in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Interferon Type I; Melphalan; Multiple Myeloma; Prednisone; Recombinant Proteins; Vincristine | 1988 |
[Value of protocols of alternating chemotherapy versus melphalan-prednisone during the induction phase of stage III myelomas. Critical review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prospective Studies; Random Allocation | 1987 |
Adjuvant therapy in primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Hospitalization; Humans; Lymph Nodes; Melphalan; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Random Allocation; Tamoxifen; Time Factors; United States; Vincristine | 1985 |
Multiple myeloma: current therapy and a glimpse of the future.
Topics: Acute Kidney Injury; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Diseases; Bone Marrow Transplantation; Drug Resistance; Humans; Hypercalcemia; Kidney Failure, Chronic; Melphalan; Multiple Myeloma; Prednisone; Spinal Cord Compression; Time Factors | 1985 |
Breast cancer chemotherapy: perioperative considerations in breast reconstruction.
Topics: Adult; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Methotrexate; Middle Aged; Prednisone; Surgery, Plastic; Tamoxifen; Thiotepa; Vincristine | 1985 |
The chemical therapy of breast cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Nitrogen Mustard Compounds; Prednisone; Thiotepa; Vinblastine; Vincristine | 1974 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclophosphamide; Cytarabine; Female; Fluorouracil; Humans; Leukemia L1210; Leukemia, Lymphoid; Lymphoma; Melphalan; Mercaptopurine; Methotrexate; Mice; Multiple Myeloma; Neoplasms; Nitrogen Mustard Compounds; Prednisone; Pregnancy; Time Factors; Trophoblastic Neoplasms; Vinblastine | 1971 |
Steroid therapy of multiple myeloma and macroglobulinemia.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic, Autoimmune; Blood Urea Nitrogen; Glucocorticoids; Humans; Hypercalcemia; Immunoglobulins; Leukemia; Lymphoma; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Waldenstrom Macroglobulinemia | 1973 |
Plasma cell myeloma. An interpretive review.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Carmustine; Cell Division; Cyclophosphamide; Drug Resistance; Humans; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Procarbazine; Prognosis; Remission, Spontaneous | 1972 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Hodgkin Disease; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Melanoma; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Vincristine | 1973 |
Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Drug Therapy, Combination; Female; Hematocrit; Hemoglobins; Humans; Immunoglobulins; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission, Spontaneous; Syndrome | 1974 |
[Therapy of paraproteinemic diseases].
Topics: Allopurinol; Androstanes; Antineoplastic Agents; Blood Proteins; Cyclophosphamide; Follow-Up Studies; Glucocorticoids; Humans; Melphalan; Plasmacytoma; Prednisone; Proteinuria | 1968 |
[Burkitt's lymphoma and acute leukemias].
Topics: Acute Disease; Animals; Asparaginase; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Fluorouracil; Humans; Leukemia; Melphalan; Mercaptopurine; Methotrexate; Mice; Oncogenic Viruses; Prednisolone; Prednisone; Vincristine | 1969 |
Chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Chromosomes, Human, 6-12 and X; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; T-Lymphocytes; Trisomy; Vincristine | 1984 |
Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Femur Head Necrosis; Humans; Hypercalcemia; Leukemia, Lymphoid; Male; Melphalan; Neoplasms, Multiple Primary; Paresthesia; Prednisone; Prognosis; Thrombocytopenia; Vincristine | 1982 |
Recent progress in breast cancer management. Combined modality (adjuvant) therapy.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mammary Neoplasms, Experimental; Melphalan; Methotrexate; Middle Aged; Prednisone; Vincristine | 1981 |
Thyroid-gland plasma cell neoplasm (plasmacytoma).
Topics: Adult; Aged; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Immunoenzyme Techniques; Immunoglobulin G; Male; Melphalan; Middle Aged; Plasmacytoma; Prednisone; Thyroid Neoplasms; Thyroidectomy; Thyroiditis | 1981 |
[Chemotherapy of multiple myeloma. Review of the recent trials].
Topics: Antineoplastic Agents; Azathioprine; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Procarbazine; Vincristine | 1981 |
Diagnosis and treatment of primary amyloidosis.
Topics: Acute-Phase Reaction; Adult; Aged; Amyloid; Amyloidosis; B-Lymphocytes; Biopsy; Child; Contraindications; Female; Heart Transplantation; Humans; Immunoglobulins; Immunohistochemistry; Joints; Male; Melphalan; Middle Aged; Nervous System; Paraproteinemias; Prednisone; Prognosis; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Skin; Staining and Labeling; Viscera | 1995 |
Interferon in multiple myeloma--does it pay?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1995 |
[Diagnosis and therapy of multiple myeloma: current aspects].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Diagnosis, Differential; Drug Therapy, Combination; Erythropoietin; Humans; Interferon-alpha; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prednisone; Prognosis | 1995 |
The treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1994 |
Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraproteinemias; Prednisone; Primary Myelofibrosis; Splenomegaly; Vincristine | 1994 |
[A case of solitary plasmacytoma that originated in a rib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Melphalan; Middle Aged; Plasmacytoma; Prednisone; Ribs | 1993 |
Haematopoietic stem-cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Survival Rate | 1996 |
Hematopoietic stem cell transplants for multiple myeloma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Pancytopenia; Plasma Cells; Prednisone; Prognosis; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Whole-Body Irradiation | 1996 |
Diagnosis, prognosis, and standard treatment of multiple myeloma.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1997 |
[Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Male; Melphalan; Multiple Myeloma; Paraproteins; Prednisolone; Prednisone; Risk Factors; Vincristine | 1997 |
[Therapy of multiple myeloma].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Time Factors | 1997 |
[Progress in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1997 |
Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations. Part IV: Multiple myeloma and Waldenström's macroglobulinemia.
Topics: Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Diagnosis, Differential; Drug Therapy, Combination; Hematologic Diseases; Humans; Melphalan; Multiple Myeloma; Prednisone; Waldenstrom Macroglobulinemia | 1998 |
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Treatment of multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Contraindications; Diphosphonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Infection Control; Interferon-alpha; Kidney Failure, Chronic; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Osteolysis; Prednisone; Prognosis; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 1999 |
Therapeutic strategies and controversies in the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Interferons; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1999 |
Breast metastasis from multiple myeloma: report of a case and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatal Outcome; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Palliative Care; Prednisone; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Tomography, X-Ray Computed; Treatment Outcome | 1998 |
[Multiple myeloma and other plasma cell dyscrasias].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Diagnosis, Differential; Heavy Chain Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 1999 |
Myeloma-associated systemic amyloidosis presenting as chronic paronychia and palmodigital erythematous swelling and induration of the hands.
Topics: Amyloidosis; Antineoplastic Agents, Alkylating; Chronic Disease; Drug Therapy, Combination; Erythema; Glucocorticoids; Hand Dermatoses; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Paronychia; Prednisone; Recurrence; Time Factors | 2000 |
Nephrotic syndrome secondary to amyloidosis.
Topics: Adult; Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Male; Medical History Taking; Melphalan; Nephrotic Syndrome; Physical Examination; Prednisone; Referral and Consultation | 2000 |
Autologous and allogeneic stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
Novel approaches to the treatment of primary amyloidosis.
Topics: Amyloidosis; Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Prednisone; Vincristine | 2000 |
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Morbidity; Prednisone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Multiple myeloma in elderly patients: presenting features and outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Comorbidity; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; France; Humans; Interferon-alpha; Life Tables; Lomustine; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasm Staging; Paraneoplastic Syndromes; Prednimustine; Prednisone; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Prednisone; Retrospective Studies; Survival Analysis; Vincristine | 2001 |
[Treatment of multiple myeloma in elderly patients: consensus of the Geriatric Oncology Working Group of the German Society of Hematologic Oncology and the German Society of Geriatrics].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Diphosphonates; Geriatric Assessment; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis | 2001 |
Management of patients with multiple myeloma: emphasizing the role of high-dose therapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Disease Progression; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk Factors; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2001 |
Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Life Tables; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vincristine | 2001 |
Multiple myeloma in association with sarcoidosis.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow Cells; Drug Therapy, Combination; Female; Granuloma; Humans; Immunoenzyme Techniques; Immunoglobulin kappa-Chains; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Sarcoidosis; Treatment Outcome | 2002 |
Treatment of myeloma: recent developments.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Humans; Interferons; Melphalan; Multiple Myeloma; Neoplasm Staging; Netherlands; Prednisone; Stem Cell Transplantation; Thalidomide | 2002 |
Primary systemic amyloidosis.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Heart Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Palliative Care; Prednisone; Prognosis; Survival Rate | 2000 |
Primary systemic amyloidosis.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Heart Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Prednisone; Prognosis; Survival Rate | 2002 |
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Echocardiography, Transesophageal; Etoposide; Heart Failure; Heart Neoplasms; Heart Septum; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Immunocompetence; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Middle Aged; Pleural Effusion; Prednisone; Remission Induction; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2002 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Finland; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Pharmacotherapy of multiple myeloma: an economic perspective.
Topics: Aged; Cost-Benefit Analysis; Drug Therapy; Economics, Pharmaceutical; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thalidomide | 2003 |
NEW AND OLD DRUGS IN THE MANAGEMENT OF HODGKIN'S DISEASE.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Bacterial Agents; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Dexamethasone; Folic Acid Antagonists; Hodgkin Disease; Humans; Isoniazid; Mannomustine; Melphalan; Methotrexate; Mitomycin; Mitomycins; Nitrogen Mustard Compounds; Phenylbutazone; Prednisolone; Prednisone; Thiotepa | 1964 |
[An autopsy case of the hepatocellular carcinoma associated with multiple myeloma which developed fatal massive hemolysis due to the Clostridium perfringens septicemia following TAE].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clostridium Infections; Clostridium perfringens; Embolization, Therapeutic; Fatal Outcome; Hemolysis; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Prednisone; Sepsis | 2003 |
Managing the patient with amyloidosis.
Topics: Amyloidosis; Anti-Inflammatory Agents; Causality; Diagnosis, Differential; Disease Progression; Humans; Incidence; Information Services; Internet; Mass Screening; Melphalan; Nurse's Role; Nursing Assessment; Patient Education as Topic; Prednisone | 2004 |
Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.
Topics: Aged; Amyloidosis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Combined Modality Therapy; Comorbidity; Cytokines; Databases, Factual; Dexamethasone; Female; Glomerulosclerosis, Focal Segmental; Humans; Immunoglobulin Light Chains; Kidney; Male; Melphalan; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Myeloma Proteins; Paraneoplastic Syndromes; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Prevalence; Proteinuria; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Vasculitis | 2005 |
Multiple myeloma: diagnosis and treatment.
Topics: Algorithms; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Retreatment; Stem Cell Transplantation; Thalidomide; Translocation, Genetic | 2005 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Therapy and management of systemic AL (primary) amyloidosis.
Topics: Amyloidosis; Dexamethasone; Glucocorticoids; Humans; Immunosuppressive Agents; Melphalan; Myeloablative Agonists; Prednisone; Stem Cell Transplantation; Thalidomide | 2006 |
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Thalidomide | 2007 |
Perspectives in treatment of AL amyloidosis.
Topics: Amyloidosis; Humans; Immunosuppressive Agents; Melphalan; Organ Transplantation; Prednisone; Stem Cell Transplantation | 2008 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
Treatment of Hodgkin lymphoma: the past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lomustine; Mechlorethamine; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Vinblastine; Vincristine; Vindesine | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
Standard therapy of advanced Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Mechlorethamine; Melphalan; Methylprednisolone; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2009 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2011 |
Multiple myeloma in the elderly: when to treat, when to go to transplant.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Transplantation, Autologous | 2010 |
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome].
Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Drug Therapy, Combination; Early Diagnosis; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin lambda-Chains; Melphalan; Paraproteinemias; Peripheral Nerves; POEMS Syndrome; Prednisone; Salivary Glands, Minor; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplants; Treatment Outcome | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide | 2011 |
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Boronic Acids; Bortezomib; Fatal Outcome; Humans; Leukemia, Plasma Cell; Male; Melphalan; Pleural Effusion, Malignant; Prednisone; Pyrazines; Treatment Failure | 2012 |
Evolving therapeutic paradigms for multiple myeloma: back to the future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Glucocorticoids; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Transplantation, Autologous | 2013 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
[Treatment strategy of Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunoconjugates; Mechlorethamine; Melphalan; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Rituximab; Vinblastine; Vincristine | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide | 2015 |
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2015 |
Maintenance therapy for multiple myeloma in the era of novel agents.
Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematology; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Germany; Humans; Melphalan; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Thalidomide | 2016 |
Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Thalidomide | 2016 |
Fixed duration vs continuous therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Disease-Free Survival; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Rate; Thalidomide; Time Factors | 2017 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome | 2019 |
Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Membrane Glycoproteins; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Transplantation Conditioning | 2019 |
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2020 |
301 trial(s) available for prednisone and melphalan
| Article | Year |
|---|---|
Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer.
Topics: Adult; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prednisone; Remission, Spontaneous; Time Factors | 1978 |
Chemotherapy of disseminated breast cancer. Current status and prospects.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Fluorouracil; Humans; Melphalan; Methotrexate; Neoplasm Metastasis; Prednisone; Vincristine | 1977 |
Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
Topics: Alkaline Phosphatase; Amyloidosis; Blood Coagulation; Clinical Trials as Topic; Creatinine; Double-Blind Method; Drug Therapy, Combination; Humans; Immunoelectrophoresis; Melphalan; Placebos; Prednisone; Proteinuria | 1978 |
Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission, Spontaneous; Vinblastine; Vincristine | 1979 |
Chemotherapy in the management of extramedullary plasmacytoma.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Neoplasm Metastasis; Plasmacytoma; Prednisone; Radiography | 1978 |
Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
Topics: Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukopenia; Melphalan; Multiple Myeloma; Prednisone; Prognosis | 1979 |
Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Topics: Carmustine; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone | 1979 |
The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulins; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Risk | 1979 |
Combination therapy for multiple myeloma.
Topics: Antineoplastic Agents; Azathioprine; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Remission, Spontaneous; Time Factors; Vincristine | 1977 |
Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo.
Topics: Bone and Bones; Bone Diseases; Calcium Carbonate; Clinical Trials as Topic; Fluorides; Humans; Melphalan; Multiple Myeloma; Osteosclerosis; Prednisone; Prospective Studies | 1975 |
Remission maintenance therapy for multiple myeloma.
Topics: Bone Neoplasms; Carmustine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Recurrence; Remission, Spontaneous; Time Factors; Vincristine | 1975 |
Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine.
Topics: Azathioprine; Blood Urea Nitrogen; Bone Neoplasms; Chlorambucil; Drug Therapy, Combination; Fluoxymesterone; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission, Spontaneous; Risk; Time Factors | 1975 |
Sequential therapy compared with combination therapy in multiple myeloma.
Topics: Autoradiography; Bence Jones Protein; Bone Neoplasms; Cell Count; Drug Therapy, Combination; Humans; Immunoglobulins; Kinetics; Melphalan; Methotrexate; Mitosis; Multiple Myeloma; Plasma Cells; Prednisone; Risk; Thymidine; Time Factors; Tritium; Vincristine | 1975 |
Prognostic factors in multiple myeloma.
Topics: Aged; Anemia; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Immunoglobulins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Plasma Cells; Prednisone; Prognosis; Remission, Spontaneous; Serum Albumin; Time Factors; Uremia | 1975 |
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Remission, Spontaneous; Risk; Uremia | 1975 |
Recombinant interferon-alpha 2A as maintenance treatment for patients with advanced stage chronic lymphocytic leukemia responding to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Incidence; Injections, Intramuscular; Interferon alpha-2; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Peptichemio; Prednisone; Recombinant Proteins; Vincristine | 1992 |
Intensive combined therapy for previously untreated aggressive myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Recurrence; Salvage Therapy; Transplantation, Autologous; Vincristine; Whole-Body Irradiation | 1992 |
VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Vincristine | 1992 |
Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Female; Hematocrit; Hodgkin Disease; Humans; Lomustine; Lymphatic Metastasis; Male; Mechlorethamine; Melphalan; Middle Aged; Models, Biological; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Analysis; Vinblastine; Vincristine; Vindesine | 1990 |
Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Remission Induction; Vincristine | 1991 |
Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins | 1991 |
Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies | 1991 |
[Therapeutic plasmapheresis in patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasmapheresis; Prednisone; Vincristine | 1991 |
[Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Interferon-alpha; Levamisole; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Thymus Extracts; Vincristine | 1991 |
Waldenström's macroglobulinemia: long-term results with the M-2 protocol.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Administration Schedule; Humans; Leukopenia; Melphalan; Nausea; Prednisone; Vincristine; Vomiting; Waldenstrom Macroglobulinemia | 1991 |
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Child; Combined Modality Therapy; Cyclophosphamide; Humans; Melphalan; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Prednisone; Prognosis; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1991 |
Treatment of multiple myeloma with interferon alpha: the Scandinavian experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone | 1991 |
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1991 |
Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Recombinant Proteins; Sweden | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Vincristine | 1991 |
No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Calcium; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Vincristine | 1991 |
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Humans; Interferon Type I; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Recombinant Proteins; Vincristine | 1990 |
Adjuvant therapy in breast cancer.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Prednisone; Tamoxifen; Vincristine | 1990 |
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Vincristine | 1990 |
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Prednisone; Vincristine | 1990 |
A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
Topics: Actuarial Analysis; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Injections, Intravenous; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Sweden | 1990 |
Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Remission Induction; Time Factors | 1990 |
Oral melphalan pharmacokinetics: influence of interferon-induced fever.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Drug Interactions; Female; Fever; Half-Life; Humans; Interferon Type I; Male; Melphalan; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Prednisone | 1990 |
Interferons in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Humans; Interferon Type I; Interferons; Melphalan; Multiple Myeloma; Prednisone; Radiography; Recombinant Proteins | 1986 |
Treatment of advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia; Lomustine; Lymphoma; Male; Mechlorethamine; Melphalan; Middle Aged; Neoplasms, Multiple Primary; Prednisone; Procarbazine; Remission Induction; Vinblastine; Vincristine; Vindesine | 1989 |
Results and prognostic factors following optimal treatment of advanced Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Lomustine; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Vinblastine; Vincristine; Vindesine | 1989 |
VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Random Allocation; Recombinant Proteins; Vincristine | 1989 |
Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Interferon Type I; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Random Allocation; Recombinant Proteins; Vincristine | 1989 |
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Random Allocation; Sweden; Vincristine | 1989 |
Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Radical; Melphalan; Methotrexate; Prednisone; Vincristine | 1989 |
Melphalan/prednisone versus drug combinations for plasma cell myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic | 1989 |
Induction treatment with alpha-interferon in multiple myeloma: an interim report from MGCS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon Type I; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic | 1989 |
Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Cycle; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Drug Evaluation; Humans; Melphalan; Multiple Myeloma; Paraproteinemias; Plasma Cells; Prednisone; Prognosis; Random Allocation; Vincristine | 1989 |
Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Random Allocation; Vincristine | 1988 |
Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Lomustine; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Random Allocation; Vincristine | 1988 |
Treatment of multiple myeloma: an Argentine Group for the Treatment of Acute Leukemia Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Random Allocation; Semustine; Vincristine | 1988 |
A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; Random Allocation; Spain | 1988 |
[Possibility of using interferon in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Interferon Type I; Melphalan; Multiple Myeloma; Prednisone; Recombinant Proteins; Vincristine | 1988 |
[Results of the combined treatment of advanced multiple myeloma by the M-2 protocol: cyclophosphamide, vincristine, melphalan, nitrosourea and prednisone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Prednisone; Vincristine | 1987 |
Multiple myeloma in Korea--clinical analysis and treatment results in 61 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1987 |
Melphalan and prednisone plus total bone marrow irradiation as initial treatment for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1988 |
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Random Allocation; Remission Induction; Time Factors | 1988 |
[Induction and maintenance therapy in multiple myeloma. Results of a multicenter study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Evaluation; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Vincristine | 1988 |
An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Random Allocation | 1988 |
The use of interferon in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Humans; Immunotherapy; Interferon Type I; Melphalan; Multiple Myeloma; Prednisone; Recombinant Proteins | 1987 |
Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Information Systems; Lymphatic Metastasis; Medical Records; Melphalan; Methotrexate; Middle Aged; Postoperative Care; Prednisone; Random Allocation; Time Factors; Vincristine | 1987 |
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Multiple Myeloma; Prednisone; Random Allocation; Risk; Time Factors; Vincristine | 1986 |
Results and further perspectives of plasmocytoma chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1986 |
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Hematologic Diseases; Humans; Levamisole; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Random Allocation; Vincristine | 1986 |
Current results of a multicenter trial in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Random Allocation; Vincristine | 1986 |
Adjuvant therapy of breast cancer: Southwest Oncology Group studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Melphalan; Methotrexate; Middle Aged; Prednisone; Vincristine | 1986 |
Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Interferon Type I; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prospective Studies; Random Allocation; Recombinant Proteins; Vincristine | 1986 |
Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Random Allocation; Vincristine | 1986 |
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Humans; Male; Melphalan; Methotrexate; Prednisone; Prostatic Neoplasms; Random Allocation; Vincristine | 1986 |
Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunoglobulins; Lomustine; Male; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1987 |
Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peptichemio; Prednisone; Vincristine | 1986 |
Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Nodes; Melphalan; Methotrexate; Prednisone; Vincristine | 1985 |
Adjuvant chemotherapy for breast cancer. Implications of clinical trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Melphalan; Menopause; Methotrexate; Neoplasm Metastasis; Prednisone; Random Allocation; Vincristine | 1985 |
Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Menopause; Methotrexate; Prednisone; Prognosis; Tamoxifen; Vincristine | 1985 |
Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Random Allocation; Vincristine | 1985 |
Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1985 |
Treatment of multiple myeloma: a randomized study of three different regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunoglobulin A; Immunoglobulin D; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Peptichemio; Prednisone; Prognosis; Random Allocation; Vincristine | 1985 |
Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1985 |
[Interferon in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Humans; Interferon Type I; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Random Allocation; Recombinant Proteins; Vincristine | 1985 |
Breast cancer chemotherapy: perioperative considerations in breast reconstruction.
Topics: Adult; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Melphalan; Methotrexate; Middle Aged; Prednisone; Surgery, Plastic; Tamoxifen; Thiotepa; Vincristine | 1985 |
Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.
Topics: Amyloidosis; Colchicine; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Random Allocation; Risk | 1985 |
Response rate and survival in myeloma patients receiving prednisone alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Random Allocation; Recurrence | 1985 |
Hormone therapy for malignant myeloma.
Topics: Androgens; Cyclophosphamide; Hemoglobinometry; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Prednisone | 1973 |
[Therapeutic experiences in multiple myeloma].
Topics: Aniline Compounds; Antineoplastic Agents; Blood Sedimentation; Carmustine; Clinical Trials as Topic; Drug Synergism; Hemoglobinometry; Humans; Melphalan; Multiple Myeloma; Mustard Compounds; Prednisone; Procarbazine; Prognosis; Remission, Spontaneous | 1972 |
[Intermittent tosstherapy of plasmacytoma with melphalan and predniso(lo)ne].
Topics: Clinical Trials as Topic; Humans; Immunoglobulins; Melphalan; Plasmacytoma; Prednisolone; Prednisone; Time Factors | 1973 |
[Study of the metastasizing carcinoma of the breast (author's transl)].
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Melphalan; Methotrexate; Neoplasm Metastasis; Prednisone; Vincristine | 1973 |
Combination chemotherapy for multiple myeloma.
Topics: Antineoplastic Agents; Benzoates; Drug Combinations; Evaluation Studies as Topic; Humans; Immunoglobulin G; Melphalan; Multiple Myeloma; Prednisone; Procarbazine; Remission, Spontaneous | 1972 |
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Blood Proteins; Humans; Immunoelectrophoresis; Melphalan; Multiple Myeloma; Prednisone; Urea | 1969 |
Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Vinblastine; Vincristine; Vindesine | 1984 |
Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
Topics: Adult; Age Factors; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prospective Studies | 1983 |
Chemotherapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Humans; Levamisole; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Random Allocation; Vincristine | 1984 |
Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Menopause; Methotrexate; Prednisone; Vincristine | 1983 |
Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Menopause; Methotrexate; Prednisone; Tamoxifen | 1983 |
The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
Topics: Adjuvants, Immunologic; Aziridines; Azirines; Clinical Trials as Topic; Cyclophosphamide; Double-Blind Method; Humans; Killer Cells, Natural; Leukocyte Count; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1984 |
A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunoglobulins; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasm Staging; Prednisone; Random Allocation; Semustine; Time Factors; Vincristine | 1984 |
Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Humans; Immunoglobulins; Interferon Type I; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Random Allocation | 1984 |
Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Staging; Prednisone; Vincristine | 1984 |
The use of a natural history data base to compare outcome among several trials of adjuvant chemotherapy for stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Methotrexate; Neoplasm Staging; Prednisone; Prognosis; Vincristine | 1984 |
Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Menopause; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Vincristine | 1984 |
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium Gluconate; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Fluoxymesterone; Humans; Long-Term Care; Melphalan; Multiple Myeloma; Prednisone; Radiography; Sodium Fluoride; United States; Vitamin D | 1984 |
[Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1984 |
Peptichemio in multiple myeloma. (Preliminary results).
Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peptichemio; Prednisone | 1981 |
Chemotherapy of plasma-cell myeloma.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1980 |
Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Semustine; Time Factors | 1980 |
Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.
Topics: Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Hemoglobinometry; Humans; Immunoglobulin M; Kidney Diseases; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proteinuria; Urea | 1980 |
Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
Topics: Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lomustine; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Uremia | 1980 |
Recent progress in breast cancer management. Combined modality (adjuvant) therapy.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mammary Neoplasms, Experimental; Melphalan; Methotrexate; Middle Aged; Prednisone; Vincristine | 1981 |
Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1981 |
Follow-up adjuvant chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Melphalan; Neoplasm Recurrence, Local; Prednisone; Prognosis; Prospective Studies | 1982 |
Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Random Allocation | 1982 |
Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Melphalan; Menopause; Methotrexate; Prednisone; Vincristine | 1982 |
A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukocyte Count; Leukopenia; Mastectomy; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prognosis; Random Allocation; Thrombocytopenia | 1982 |
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Random Allocation; Thrombocytopenia | 1982 |
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Random Allocation; Thrombocytopenia; Vincristine | 1982 |
Chemotherapy and radiotherapy in locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carmustine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Melphalan; Middle Aged; Prednisone; Survival Rate; Uterine Cervical Neoplasms | 1995 |
Impact of interferon at induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferons; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1994 |
Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Topics: Acute-Phase Proteins; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium; Clodronic Acid; Creatinine; Female; Hemoglobins; Humans; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prednisone; Prognosis; Regression Analysis; Risk Factors; Serum Albumin; Survival Rate; Uric Acid | 1995 |
Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fatal Outcome; Female; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pilot Projects; Prednisolone; Prednisone; Remission Induction; Staining and Labeling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vidarabine; Vinca Alkaloids; Vincristine | 1995 |
Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Neoplasm Proteins; Prednisone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 1995 |
Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Israel; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Survival Analysis; Vincristine | 1995 |
Development of a criterion for response to therapy at 6 months in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Vincristine | 1995 |
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Chi-Square Distribution; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proportional Hazards Models; Recombinant Proteins; Remission Induction; Survival Rate | 1995 |
Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Europe; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Remission Induction; Survival Rate; Vincristine | 1995 |
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Vincristine | 1995 |
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Combined Modality Therapy; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Rate; Time Factors | 1995 |
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glucocorticoids; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Survival Analysis; Vincristine | 1994 |
Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etanidazole; Humans; Infusions, Intravenous; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone | 1994 |
Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis.
Topics: Adult; Aged; Amyloidosis; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Prednisone; Recombinant Proteins; Survival Rate | 1993 |
No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Melphalan; Middle Aged; Platelet Aggregation; Prednisone; Survival Rate | 1993 |
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Analysis | 1993 |
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1993 |
Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon-alpha; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate; Vincristine | 1993 |
Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Rate | 1996 |
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloproliferative Disorders; Peptichemio; Prednisone; Recombinant Proteins; Vincristine | 1996 |
Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Recombinant Proteins; Sensitivity and Specificity; Surveys and Questionnaires | 1996 |
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Carmustine; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Survival Analysis; Vincristine; White People | 1996 |
A prognostic index for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin Isotypes; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Peptichemio; Plasma Cells; Prednisone; Probability; Prognosis; Prospective Studies; Risk Assessment; Survival Rate; Time Factors; Vincristine | 1996 |
Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
Topics: Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cause of Death; Colchicine; Drug Therapy, Combination; Female; Gout Suppressants; Humans; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Treatment Outcome | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prospective Studies; Salvage Therapy; Survival Analysis; Vincristine | 1996 |
Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Transplantation, Autologous; Vincristine | 1996 |
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Feeding and Eating Disorders; Fever; Humans; Interferon alpha-2; Interferon-alpha; Melphalan; Multiple Myeloma; Nausea; Pain; Prednisone; Quality of Life; Recombinant Proteins; Social Behavior; Vomiting | 1996 |
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Myocardial Infarction; Neutropenia; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine | 1996 |
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Clone Cells; Codon; Combined Modality Therapy; Cyclophosphamide; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Female; Genes, ras; Humans; Immunologic Factors; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Restriction Fragment Length; Prednisone; Prognosis; Survival Analysis; Vincristine | 1996 |
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
Topics: Adult; Amyloidosis; Cardiomyopathies; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Karnofsky Performance Status; Male; Melphalan; Middle Aged; Nephrotic Syndrome; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Remission Induction; Treatment Outcome | 1996 |
Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunologic Factors; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Rate; Vincristine | 1996 |
Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclophosphamide; Doxorubicin; Female; Geriatric Assessment; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Survival Rate; Vincristine | 1996 |
A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Melphalan; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Procarbazine; Vincristine | 1997 |
Standard therapy versus autologous transplantation in multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Vincristine | 1997 |
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Cardiomyopathies; Colchicine; Drug Therapy, Combination; Humans; Kidney Diseases; Melphalan; Middle Aged; Prednisone; Prospective Studies; Survival Analysis; Treatment Outcome | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Over Studies; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 1997 |
Improved outcome in solitary bone plasmacytomata with combined therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Plasmacytoma; Prednisone; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Forecasting; Health Status; Humans; Interferon alpha-2; Interferon-alpha; Melphalan; Multiple Myeloma; Multivariate Analysis; Pain; Prednisone; Prospective Studies; Quality of Life; Recombinant Proteins; Risk Factors; Survival Analysis; Treatment Outcome | 1997 |
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Prednisone; Salvage Therapy; Treatment Outcome; Vincristine | 1997 |
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Filgrastim; Follow-Up Studies; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Leucovorin; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Recombinant Proteins; Treatment Outcome; Vincristine | 1997 |
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methotrexate; Methylprednisolone; Middle Aged; Mitomycins; Prednisone; Prospective Studies; Treatment Outcome; Vincristine | 1998 |
Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Remission Induction; Therapeutics; Vincristine | 1998 |
[Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease Progression; Female; Humans; Interleukin-6; Kidney Failure, Chronic; Male; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Prednisone; Receptors, Interleukin; Receptors, Interleukin-6; Recombinant Fusion Proteins; Survival Rate; Tumor Necrosis Factor-alpha; Vincristine | 1998 |
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer Vaccines; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Dexamethasone; Doxorubicin; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hemocyanins; Humans; Immunocompetence; Immunoglobulin Idiotypes; Immunotherapy, Active; Lymphocyte Activation; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Remission Induction; T-Lymphocytes, Cytotoxic; Transplantation, Autologous; Treatment Outcome; Vaccination; Vincristine | 1999 |
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
Topics: Aged; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Quality of Life | 1997 |
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG).
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Interferons; Male; Melphalan; Middle Aged; Multiple Myeloma; Norway; Prednisone; Probability; Retrospective Studies; Survival Analysis; Sweden; Time Factors | 1999 |
Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Amyloidosis; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Survival Rate; Vincristine | 1999 |
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Carmustine; Cyclophosphamide; Hematologic Diseases; Humans; Infections; Interferon Type I; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Analysis; Vincristine | 1999 |
Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
Topics: Biomarkers; Disease-Free Survival; Humans; Interferon-alpha; Melphalan; Membrane Glycoproteins; Multiple Myeloma; Prednisone; Prognosis; Proteoglycans; Reference Values; Regression Analysis; Survival Analysis; Syndecan-1; Syndecans; Time Factors | 2000 |
Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate; Vincristine | 1999 |
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Survival Analysis; Time Factors; Treatment Outcome | 2000 |
Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Prospective Studies; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2000 |
Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Health Status; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Patient Satisfaction; Prednisone; Quality of Life | 2000 |
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Greece; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
Topics: Cost-Benefit Analysis; Female; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Surveys and Questionnaires; Survival Rate; Transplantation, Autologous | 2001 |
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Humans; Lomustine; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2000 |
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2000 |
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Survival Analysis; Survival Rate; Vincristine | 2001 |
Bendamustine in the treatment of multiple myeloma: results and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Prospective Studies; Remission Induction; Survival Rate | 2002 |
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Radical; Melphalan; Menopause; Methotrexate; Middle Aged; Prednisone; Survival Rate; Vincristine | 2003 |
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Drug Evaluation; Female; Humans; Male; Melphalan; Multiple Myeloma; Peptichemio; Prednisone; Prospective Studies; Software Design; Survival Analysis; Vincristine | 2003 |
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cost-Benefit Analysis; Female; Financing, Organized; Health Expenditures; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Models, Statistical; Multiple Myeloma; Prednisone; Survival Analysis | 2003 |
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
Topics: Amyloidosis; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Leukapheresis; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2004 |
Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Japan; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Treatment Outcome; Vincristine | 2004 |
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Female; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine; Vindesine | 2004 |
Early response to therapy and survival in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Regression Analysis; Survival Rate | 2004 |
Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Survival Rate | 2005 |
The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Aged; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Male; Melphalan; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Phenotype; Prednisone; Prognosis; Stem Cell Transplantation; Treatment Outcome; Vincristine | 2005 |
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Transplantation, Autologous; Vincristine | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Spain; Survival Analysis; Treatment Outcome; Vincristine | 2005 |
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2005 |
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Infections; Interferon-alpha; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Patient Selection; Prednisone; Survival Analysis; Treatment Outcome | 2006 |
Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Glucocorticoids; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prednisone; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vincristine | 2005 |
Sequential, cycling maintenance therapy for post transplant multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Interferon-alpha; Male; Melphalan; Multiple Myeloma; Pilot Projects; Prednisone; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Germany, East; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Quality of Life; Remission Induction; Survival Analysis; Time Factors; Treatment Failure | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Clinical Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Radiotherapy, Adjuvant; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome; United States; Vincristine; Whole-Body Irradiation | 2006 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2006 |
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2006 |
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 2006 |
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
Topics: Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2006 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease-Free Survival; Humans; Immunophenotyping; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2006 |
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Female; Humans; Infections; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Polyethylene Glycols; Prednisone; Survival Rate; Treatment Outcome | 2006 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide | 2007 |
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Glucocorticoids; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide | 2007 |
A new standard of care for elderly patients with myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Delivery of Health Care; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Survival Rate; Thalidomide | 2007 |
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Survival Rate; Thalidomide | 2007 |
Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Rituximab | 2007 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2008 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis | 2008 |
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Follow-Up Studies; Humans; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Update on recent developments for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Female; Humans; Interferon Type I; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Rate; Vincristine | 2009 |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Thrombocytopenia | 2009 |
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Probability; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
Topics: Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide; Time Factors; Transplantation, Autologous | 2009 |
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome | 2010 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome | 2009 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Melphalan; Multiple Myeloma; Polydeoxyribonucleotides; Prednisone; Salvage Therapy; Thalidomide; Treatment Outcome | 2010 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Predictive Value of Tests; Prednisolone; Prednisone; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Teniposide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2010 |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Dexamethasone; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proportional Hazards Models; Regulatory Factor X Transcription Factors; Thalidomide; Transcription Factors; Vincristine; X-Box Binding Protein 1 | 2010 |
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Melphalan; Multiple Myeloma; Placebos; Prednisone; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neutropenia; Pain; Prednisone; Quality of Life; Regression Analysis; Thalidomide; Treatment Outcome | 2010 |
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Denmark; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Male; Melphalan; Middle Aged; Multiple Myeloma; Norway; Prednisone; Prognosis; Proportional Hazards Models; Selection Bias; Sweden; Transplantation, Autologous | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors | 2011 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Female; Humans; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Opportunistic Infections; Prednisone; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Doxorubicin; Feasibility Studies; Female; Humans; Interferons; Japan; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Vincristine | 2011 |
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant | 2011 |
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Models, Statistical; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome | 2011 |
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neutropenia; Panobinostat; Prednisone; Recurrence; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Quality of Life; Treatment Outcome | 2012 |
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide | 2012 |
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Kidney Diseases; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Thalidomide | 2013 |
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence | 2013 |
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neoplasms, Second Primary; Odds Ratio; Prednisone; Proportional Hazards Models; Pyrazines; Risk; Spain; Treatment Outcome | 2013 |
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Surveys and Questionnaires; Thalidomide | 2013 |
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bayes Theorem; Drug Therapy, Combination; Expert Testimony; Humans; Melphalan; Models, Statistical; Multiple Myeloma; Myeloablative Agonists; Prednisone; Stem Cell Transplantation; Surveys and Questionnaires; Survival Analysis; Thalidomide | 2013 |
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2014 |
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease-Free Survival; Economics, Pharmaceutical; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prednisone; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Autologous transplantation and maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis | 2015 |
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Female; Health Status; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide | 2015 |
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Monitoring; Female; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Prednisone; Treatment Outcome | 2015 |
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2015 |
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Quality of Life; Thalidomide | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2016 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosphamide; Czech Republic; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Risk Factors; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2015 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Italy; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide | 2016 |
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome; Withholding Treatment | 2016 |
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Survival Rate | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Dexamethasone; Drug Monitoring; Female; Humans; Immunity; Lenalidomide; Male; Melphalan; Monitoring, Physiologic; Multiple Myeloma; Neoplasm, Residual; Prednisone; Prognosis; Survival Analysis; Thalidomide; Vincristine | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Thalidomide | 2016 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Positron-Emission Tomography; Prednisone; Retreatment; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2017 |
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2017 |
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Survival Analysis; Treatment Outcome | 2017 |
Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone | 2017 |
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prednisone; Prognosis; Survival Rate; Thalidomide | 2018 |
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infections; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate | 2018 |
Daratumumab for untreated multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Confidence Intervals; Disease-Free Survival; Female; Hospitals, University; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Proportional Hazards Models; Spain; Survival Analysis | 2018 |
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Prednisone; Rituximab; Transplantation, Autologous; Vincristine; Young Adult | 2018 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2020 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Frail Elderly; Frailty; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Thalidomide | 2020 |
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Progression-Free Survival; Treatment Outcome | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult | 2020 |
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Propensity Score; Treatment Outcome | 2020 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Disease Progression; Drug Administration Schedule; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Thalidomide; Time Factors; United States | 2020 |
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Latin America; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Propensity Score; Retrospective Studies; Standard of Care | 2020 |
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Patient Reported Outcome Measures; Prednisone; Quality of Life; Treatment Outcome | 2021 |
592 other study(ies) available for prednisone and melphalan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Ancillary measures in treatment of myeloma. Use of immune serum globulin, fluoride, or androgen.
Topics: Androgens; Bone Neoplasms; Drug Therapy, Combination; Evaluation Studies as Topic; Fluorides; Fluoxymesterone; gamma-Globulins; Humans; Immunotherapy; Melphalan; Multiple Myeloma; Prednisone; Testosterone | 1975 |
Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy.
Topics: Agammaglobulinemia; Amyloidosis; Bence Jones Protein; Dermatomyositis; gamma-Globulins; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Sepsis; Skin Tests | 1975 |
[A case of IgD plasmacytoma with unusual neurological symptoms].
Topics: Encephalomyelitis; Female; Humans; Hypertension; Immunoglobulin D; Melphalan; Middle Aged; Neurologic Manifestations; Paralysis; Plasmacytoma; Polyradiculopathy; Prednisone | 1977 |
[Therapy of malignant tumors through the internist].
Topics: Bleomycin; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Melphalan; Methotrexate; Osteosarcoma; Plasmacytoma; Prednisone; Sarcoma, Ewing; Vincristine | 1977 |
Ovarian function and adjuvant chemotherapy for breast cancer.
Topics: Adult; Age Factors; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Melphalan; Middle Aged; Ovary; Prednisone; Recurrence | 1978 |
Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy.
Topics: Amyloidosis; Drug Therapy, Combination; Female; Humans; Melphalan; Middle Aged; Oxymetholone; Paraproteinemias; Penicillamine; Prednisone | 1978 |
Treatment of primary amyloidosis.
Topics: Amyloidosis; Drug Therapy, Combination; Fluoxymesterone; Humans; Melphalan; Penicillamine; Prednisone | 1978 |
[Chemotherapy of malignant skeletal tumors (author's transl)].
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Humans; Lymphoma; Melphalan; Multiple Myeloma; Neoplasm Metastasis; Palliative Care; Prednisone; Vincristine | 1979 |
Kappa light chain--myeloma associated with adult Fanconi syndrome: response of the nephropathy to treatment of myeloma.
Topics: Adult; Bence Jones Protein; beta 2-Microglobulin; Bone Neoplasms; Fanconi Syndrome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Lumbar Vertebrae; Melphalan; Neoplasm Metastasis; Plasmacytoma; Prednisone; Radiotherapy Dosage; Spinal Neoplasms; Vincristine | 1978 |
Sideroblastic anaemia and leukaemia in multiple myeloma.
Topics: Anemia, Sideroblastic; Female; Humans; Immunoglobulin A; Immunoglobulin kappa-Chains; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Preleukemia | 1978 |
Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience.
Topics: Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Remission, Spontaneous; Testosterone | 1979 |
Myasthenia gravis and monoclonal IgG gammopathy.
Topics: Acetylcholine; Antibodies, Anti-Idiotypic; Blood Protein Electrophoresis; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin G; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Melphalan; Middle Aged; Myasthenia Gravis; Prednisone; Pyridostigmine Bromide; Receptors, Cholinergic | 1979 |
Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone.
Topics: Alkylating Agents; Amyloidosis; Cyclophosphamide; Humans; Immunoglobulin A; Immunoglobulin D; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Immunoglobulin M; Male; Melphalan; Middle Aged; Prednisone | 1979 |
Multiple myeloma without detectable Ig synthesis.
Topics: Bone Marrow; Drug Therapy, Combination; Female; Humans; Immunoglobulins; Melphalan; Middle Aged; Multiple Myeloma; Osteolysis; Plasma Cells; Prednisone; Radiography; Skull | 1979 |
Four months with a dull pain in the back.
Topics: Back Pain; Blood Protein Electrophoresis; Bone Marrow Examination; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1977 |
Childhood cancer: the improving prognosis.
Topics: Asparaginase; Child; Cyclophosphamide; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Hodgkin Disease; Humans; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Melphalan; Mercaptopurine; Methotrexate; Neoplasms; Nitrogen Mustard Compounds; Osteosarcoma; Prednisone; Procarbazine; Prognosis; Remission, Spontaneous; Rhabdomyosarcoma; Teniposide; Thioguanine; Vincristine; Wilms Tumor | 1976 |
Primary amyloidosis, paraproteinaemia and neuropathy.
Topics: Amyloidosis; Female; Humans; Melphalan; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prednisone | 1976 |
Cytomegalovirus pneumonia after treatment with melphalan and prednisone. Report of a case.
Topics: Cytomegalovirus Infections; Humans; Lung; Male; Melphalan; Middle Aged; Multiple Myeloma; Pneumonia, Viral; Prednisone | 1978 |
[Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
Topics: Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Vincristine | 1979 |
Multiple myeloma management.
Topics: Drug Therapy, Combination; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1977 |
Plasma cell leukemia: response to conventional myeloma therapy.
Topics: Aged; Humans; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone | 1977 |
The successful treatment of primary amyloidosis with intermittent chemotherapy.
Topics: Adult; Amyloidosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Melphalan; Prednisone | 1978 |
Immunoblastic lymphadenopathy with purpura and cryoglobulinemia.
Topics: Allopurinol; Anemia; B-Lymphocytes; Cryoglobulins; Female; Humans; Leukopenia; Lymphatic Diseases; Melphalan; Middle Aged; Paraproteinemias; Prednisone; Purpura, Hyperglobulinemic | 1977 |
Lymph node plasmacytoma in a child: clinical and immunological findings with special reference to S-Ig and complement receptor subtypes.
Topics: B-Lymphocytes; Biopsy; Child; Clone Cells; Complement C3; Female; Humans; Immunity, Cellular; Immunoglobulin A; Lymph Nodes; Melphalan; Plasmacytoma; Prednisone; T-Lymphocytes | 1978 |
Acute leukemia in multiple myeloma.
Topics: Aged; Chromosomes; Diploidy; Female; Humans; Leukemia, Myeloid, Acute; Long-Term Care; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission, Spontaneous | 1977 |
[Follicular mucinosis with generalized para-amyloidosis as a cutaneous paraneoplastic syndrome in myeloma (IgD and light chain plasmacytoma). A demonstration of the course using melphalan-prednisone therapy with a 3 years remission].
Topics: Amyloidosis; Drug Therapy, Combination; Humans; Immunoglobulin D; Immunoglobulin Light Chains; Male; Melphalan; Multiple Myeloma; Nails; Prednisone; Remission, Spontaneous; Sebaceous Glands; Skin Diseases | 1977 |
Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
Topics: Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1978 |
Chemotherapy for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Middle Aged; Neoplasm Metastasis; Prednisone; Vincristine | 1979 |
Solid tumors in multiple myeloma.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Prednisone | 1979 |
[Extraskeletal manifestations of unusual localization in a case of myeloma (author's transl)].
Topics: Female; Humans; Immunoglobulin G; Lymphatic Metastasis; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Prednisone | 1979 |
Therapy of primary amyloidosis with melphalan and prednisone.
Topics: Amyloidosis; Colchicine; Drug Therapy, Combination; Female; Hepatomegaly; Humans; Melphalan; Middle Aged; Nephrotic Syndrome; Prednisone; Splenomegaly | 1979 |
Multiple myeloma: results with the M-2 protocol in a community hospital.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Hospitals, Community; Humans; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1979 |
[Current treatment of myeloma].
Topics: Humans; Melphalan; Multiple Myeloma; Prednisone | 1979 |
[2 cases of multiple myeloma with osteosclerosis].
Topics: Aged; Cyclophosphamide; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Multiple Myeloma; Osteolysis; Osteosclerosis; Prednisone | 1979 |
[Analysis of the results of treatment of multiple myeloma].
Topics: Adult; Aged; Antibodies, Neoplasm; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Time Factors; Vincristine | 1979 |
[Multiple myeloma transforming into acute leukaemia (author's transl)].
Topics: Cell Transformation, Neoplastic; Humans; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Time Factors | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission, Spontaneous; Time Factors; Vincristine | 1977 |
Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein.
Topics: Adult; Aged; Bence Jones Protein; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1978 |
Infectious peritonitis in a cat that subsequently developed a myeloproliferative disorder.
Topics: Ampicillin; Animals; Cat Diseases; Cats; Male; Melphalan; Myeloproliferative Disorders; Peritonitis; Prednisone; Virus Diseases | 1978 |
Response of generalized granuloma annulare to alkylating agents.
Topics: Aged; Alkylating Agents; Chlorambucil; Female; Granuloma; Humans; Male; Melphalan; Middle Aged; Prednisone; Skin Diseases | 1978 |
Multiple myeloma complicating the course of seronegative systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Systemic; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Skin | 1978 |
Unmaintained remissions in multiple myeloma.
Topics: Cell Transformation, Neoplastic; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Myeloma Proteins; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Time Factors | 1978 |
[Prognosis and therapy of multiple myeloma].
Topics: Blood Transfusion; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Orthopedic Equipment; Pain; Plasmapheresis; Prednisone; Prognosis; Remission, Spontaneous | 1978 |
[Treatment of plasmacytoma].
Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Plasmacytoma; Prednisone | 1978 |
Combination chemotherapy for primary amyloidosis reconsidered.
Topics: Amyloidosis; Drug Therapy, Combination; Female; Fluoxymesterone; Follow-Up Studies; Humans; Melphalan; Penicillamine; Prednisone | 1978 |
Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Remission, Spontaneous; Time Factors | 1978 |
[Results of treatment of autoimmune hemolytic anemias].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Alkylating Agents; Anemia, Hemolytic, Autoimmune; Azathioprine; Chlorambucil; Cyclophosphamide; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Prednisone; Splenectomy | 1978 |
Regression of amyloidosis in multiple myeloma.
Topics: Amyloidosis; Drug Therapy, Combination; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1978 |
Prognostic factors and treatment of multiple myeloma: interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone.
Topics: Adult; Aged; Creatinine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulins; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1978 |
[Ophthalmoplegia revealing Kahler's disease].
Topics: Aged; Bone Neoplasms; Female; Humans; Melphalan; Multiple Myeloma; Ophthalmoplegia; Prednisone | 1978 |
Monoclonal IgE with renal failure.
Topics: Acute Kidney Injury; Fluorescent Antibody Technique; Humans; Hypergammaglobulinemia; Hypertension; Immunoglobulin E; Kidney; Male; Melphalan; Middle Aged; Prednisone | 1976 |
Expansion of the growth fraction in multiple myeloma with alkylating agents.
Topics: Adult; Bone Marrow; Cell Count; DNA Replication; Humans; Kinetics; Male; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1975 |
Treatment of plasma cell myeloma with cytotoxic agents.
Topics: Acute Disease; Alkylating Agents; Bence Jones Protein; Bone Neoplasms; Carmustine; Cell Count; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Mechlorethamine; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Remission, Spontaneous; Time Factors | 1975 |
Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.
Topics: Amino Acid Sequence; Antineoplastic Agents; Bence Jones Protein; Bone Marrow; Bone Marrow Cells; Carmustine; Cyclophosphamide; Electrophoresis; Electrophoresis, Starch Gel; Female; Humans; Immunodiffusion; Immunoelectrophoresis; Immunoglobulin Fragments; Melphalan; Middle Aged; Molecular Weight; Multiple Myeloma; Prednisone; Proteinuria | 1975 |
[Gamma heavy chain disease. A new case].
Topics: Arthritis; Cyclophosphamide; Female; Heavy Chain Disease; Humans; Immunoglobulin A; Immunoglobulin Heavy Chains; Immunoglobulin M; Melphalan; Middle Aged; Molecular Weight; Prednisone; Sarcoma; Uterine Neoplasms | 1975 |
Simultaneous occurrence of hypocholesterolemia, hypocalcemia and hypofibrinogenemia in a case of multiple myeloma.
Topics: Afibrinogenemia; Blood Proteins; Cholesterol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypocalcemia; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1975 |
Scleromyxedema.
Topics: Dermabrasion; Humans; Male; Melphalan; Middle Aged; Mucopolysaccharidoses; Myxedema; Paraproteinemias; Prednisone; Psoriasis; Recurrence; Skin Diseases | 1976 |
Malabsorption syndrome with IgG(lambda) M component: response to chemotherapy.
Topics: Celiac Disease; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Intestine, Small; Malabsorption Syndromes; Male; Melphalan; Middle Aged; Prednisone | 1976 |
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Estrogens; Fluorouracil; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melphalan; Methotrexate; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Vincristine | 1977 |
Multiple myeloma: uncommon or uncommonly diagnosed?
Topics: Adult; Anemia; Blood Sedimentation; Bone Diseases; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pain; Prednisone | 1977 |
Optimal control analysis in the chemotherapy of IgG multiple myeloma.
Topics: Bone Neoplasms; Cell Division; Cell Survival; Cyclophosphamide; Drug Administration Schedule; Humans; Immunoglobulin G; Melphalan; Models, Biological; Multiple Myeloma; Prednisone | 1977 |
Immunoblastic lymphadenopathy: case report and literature review.
Topics: Aged; Bone Marrow; Cell Nucleus; Cyclophosphamide; Endoplasmic Reticulum; Female; Humans; Immune System Diseases; Lymph Nodes; Lymphatic Diseases; Melphalan; Mitochondria; Plasma Cells; Prednisone | 1977 |
[Intermittent low dose melphalan and prednisone in multiple myeloma].
Topics: Humans; Melphalan; Multiple Myeloma; Prednisone | 1977 |
[Combined cytostatic therapy of plasmacytoma].
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone | 1977 |
Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma.
Topics: Aged; Alkylating Agents; Humans; Male; Melphalan; Multiple Myeloma; Neoplasms, Multiple Primary; Prednisone; Sarcoma, Kaposi | 1977 |
Transmission and scanning electron microscopy study on plasma cell leukemia.
Topics: Acute Disease; Cell Nucleolus; Cell Nucleus; Endoplasmic Reticulum; Humans; Leukemia, Plasma Cell; Male; Melphalan; Microscopy, Electron; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Plasma Cells; Prednisone; Remission, Spontaneous | 1977 |
Therapy of primary breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Humans; Lymphatic Metastasis; Melphalan; Menopause; Methotrexate; Postoperative Care; Prednisone; Vincristine | 1977 |
[Therapy of myeloma].
Topics: Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone | 1977 |
Enhancement and inhibition of mammary tumor formation and growth by cytostatic drugs.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Female; Fluorouracil; Mammary Neoplasms, Experimental; Melphalan; Methotrexate; Mice; Mice, Inbred BALB C; Precancerous Conditions; Prednisone; Vincristine | 1977 |
Tumor growth patterns in multiple myeloma.
Topics: Cell Division; Female; Humans; Kinetics; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Prednisone; Remission, Spontaneous | 1977 |
Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Lomustine; Melphalan; Methotrexate; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Prednisone | 1977 |
Grand rounds: Multiple myeloma.
Topics: Diagnosis, Differential; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1976 |
Early responses to chemotherapy detected by pulse cytophotometry.
Topics: Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Bone Marrow Cells; Cell Division; Child; Cytarabine; DNA, Neoplasm; Doxorubicin; Fluorometry; Humans; Leukemia; Lymphoma, Non-Hodgkin; Melphalan; Prednisone; Vincristine | 1976 |
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil; Humans; Male; Melphalan; Methotrexate; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Vincristine | 1976 |
Emotional support for the multiple myeloma patient.
Topics: Fear; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nurse-Patient Relations; Prednisone | 1976 |
Multiple myeloma and acute leukemia associated with alkylating agents.
Topics: Acute Disease; Aged; Bone Marrow; Bone Marrow Cells; Bone Marrow Examination; Bone Neoplasms; Hemoglobins; Humans; Leukemia, Myeloid; Leukemia, Plasma Cell; Leukocyte Count; Male; Melphalan; Microscopy, Electron; Middle Aged; Multiple Myeloma; Plasma Cells; Prednisone; Testosterone; Time Factors | 1975 |
Letter: Maintenance therapy in myeloma: risk versus benefit.
Topics: Carmustine; Humans; Leukemia, Myeloid, Acute; Melphalan; Multiple Myeloma; Prednisone | 1975 |
Multiple myeloma. A clinical review.
Topics: Alkylating Agents; Amyloidosis; Antibodies, Anti-Idiotypic; Bence Jones Protein; Blood Cell Count; Blood Proteins; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Drug Therapy, Combination; Heavy Chain Disease; Humans; Immunoelectrophoresis; Immunoglobulins; Kidney Diseases; Melphalan; Multiple Myeloma; Prednisone; Proteinuria | 1975 |
The monoclonal nature of lymphocytes in multiple myeloma. Effects of therapy.
Topics: Animals; B-Lymphocytes; Binding Sites, Antibody; Cell Division; Cells, Cultured; Clone Cells; Fluorescent Antibody Technique; Humans; Immune Sera; Immunoelectrophoresis; Immunoglobulin A; Immunoglobulin G; Leukocyte Count; Melphalan; Multiple Myeloma; Prednisone; Rabbits; Receptors, Antigen, B-Cell; Trypsin | 1975 |
Chemotherapy of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Neoplasm Metastasis; Prednisone; Prognosis; Vincristine | 1975 |
Antithrombin and antithromboplastin activity accompanying IgG myeloma. Report of a case with a severe bleeding tendency.
Topics: Antithrombins; Blood Coagulation Tests; Ear Diseases; Factor IX; Factor V; Factor VIII; Hemagglutination Inhibition Tests; Hematoma; Hemorrhage; Hot Temperature; Humans; Immunoelectrophoresis; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Plasmapheresis; Prednisone; Prothrombin Time; Thromboplastin | 1975 |
Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.
Topics: Adult; Amyloidosis; Biopsy; Bone Marrow; Bone Marrow Cells; Female; Fluoxymesterone; Humans; Kidney Glomerulus; Melphalan; Microscopy, Electron; Nephrotic Syndrome; Penicillamine; Phagocytosis; Prednisone; Remission, Spontaneous | 1975 |
Letter: Treatment of myeloma.
Topics: Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Procarbazine; Vincristine | 1975 |
Chemotherapy in the treatment strategy of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone | 1975 |
[Plasma cell leukaemia. Haematological features and response to treatment (author's transl)].
Topics: Aged; Drug Therapy, Combination; Female; Humans; Immunoglobulin A; Immunoglobulin G; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Paraproteins; Prednisone | 1975 |
Editorial: Major advance in breast-cancer therapy.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphatic Metastasis; Melphalan; Methotrexate; Neoplasm Metastasis; Prednisone; Time Factors; Vincristine | 1976 |
Reversal of systemic manifestations of cryoglobulinemia. Treatment with melphalan and prednisone.
Topics: Cryoglobulins; Female; Humans; Immunoglobulin G; Immunoglobulin M; Melphalan; Middle Aged; Neurologic Manifestations; Paraproteinemias; Prednisone; Remission, Spontaneous; Skin Manifestations | 1976 |
Cryocrystalglobulinemia.
Topics: Adult; Cryoglobulins; Crystallization; Cyclophosphamide; Female; Hematologic Diseases; Humans; Melphalan; Prednisone | 1976 |
[Necrobiotic xanthogranuloma with paraproteinemia].
Topics: Aged; Female; Granuloma; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Melphalan; Necrobiotic Disorders; Paraproteinemias; Prednisone; Xanthomatosis | 1992 |
Plasmapheresis in chronic demyelinating polyneuropathy.
Topics: Adult; Female; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Plasmapheresis; Prednisone | 1992 |
Primary hyperparathyroidism in an elderly patient with multiple myeloma.
Topics: Aged; Aged, 80 and over; Calcium; Cyclic AMP; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyroidism; Immunoglobulin G; Immunoradiometric Assay; Male; Melphalan; Multiple Myeloma; Parathyroid Hormone; Phosphorus; Prednisone; Ultrasonography | 1992 |
[Value of C-reactive protein assay for the monitoring of the course of treated multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisolone; Prednisone; Time Factors | 1992 |
Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution?
Topics: Cytokines; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Prednisone | 1992 |
Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Radiotherapy; Remission Induction; Survival Analysis; Vincristine | 1992 |
Investigations of the frequency of DNA strand breakage and cross-linking and of sister chromatid exchange frequency in the lymphocytes of patients with multiple myeloma undergoing cytostatic therapy with melphalan and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Linking Reagents; DNA; Female; Humans; Lymphocytes; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Sister Chromatid Exchange | 1992 |
Non-secretory multiple myeloma presenting as primary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Leukemia, Plasma Cell; Melphalan; Multiple Myeloma; Prednisone; Vincristine | 1992 |
Primary dexamethasone treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1992 |
Flow cytometric DNA analysis and clinical correlations in multiple myeloma.
Topics: Adult; Aged; Aneuploidy; DNA; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prednisone; Survival Analysis | 1992 |
Bilateral breast involvement in a 71-year-old white man with lambda light chain disease. Regression after a new chemotherapy combination. A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Humans; Immunoglobulin lambda-Chains; Male; Melphalan; Multiple Myeloma; Peptichemio; Podophyllotoxin; Prednisone; Remission Induction; Time Factors | 1992 |
Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease.
Topics: Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypergammaglobulinemia; Immunoglobulin Light Chains; Kidney Diseases; Male; Melphalan; Middle Aged; Prednisone; Retrospective Studies; Survival Analysis; Time Factors | 1992 |
Successful treatment of primary amyloidosis with dimethylsulfoxide and cytoreductive chemotherapy.
Topics: Adult; Amyloidosis; Dimethyl Sulfoxide; Drug Therapy, Combination; Heart Failure; Hepatomegaly; Humans; Male; Melphalan; Prednisone | 1992 |
[p170 in multiple myeloma and acute leukemia].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Colonic Neoplasms; Cytarabine; Daunorubicin; Drug Resistance; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Male; Melphalan; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Peptichemio; Plasma Cells; Prednisone; Remission Induction; Survival Rate; Tumor Cells, Cultured; Vincristine | 1991 |
Influence of interferon on antibody production and viability of malignant cells from patients with multiple myeloma.
Topics: Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Cell Survival; Humans; Immunoglobulins; Interferons; Melphalan; Multiple Myeloma; Prednisone | 1991 |
Pulsed high-dose corticosteroids and melphalan as an alternative therapy for refractory cutaneous T-cell lymphoma.
Topics: Dexamethasone; Drug Therapy, Combination; Humans; Lymphoma, T-Cell, Cutaneous; Male; Melphalan; Middle Aged; Prednisone; Skin Neoplasms | 1992 |
Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions.
Topics: Aged; Antibodies, Viral; Antigens, CD; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Human T-lymphotropic virus 1; Humans; Immunoblastic Lymphadenopathy; Immunophenotyping; Lymph Nodes; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Remission Induction; Survival Rate; Vincristine | 1992 |
[Extraskeletal diffusion of multiple myeloma. A clinico-pathological description of 4 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Laryngeal Neoplasms; Male; Melphalan; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Prednisone; Prognosis; Stomach Neoplasms; Testicular Neoplasms; Vincristine | 1991 |
[Plasma cell leukemia: our experience in 4 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisolone; Prednisone; Remission Induction; Teniposide | 1991 |
[Solitary plasmacytoma of the maxillary sinus].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Lomustine; Male; Maxillary Sinus Neoplasms; Melphalan; Plasmacytoma; Prednisone | 1991 |
Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Remission Induction; Vincristine | 1991 |
[Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Male; Melphalan; Methotrexate; Multiple Myeloma; Prednisone; Risk; Vincristine | 1991 |
Overall vs. tumor-related survival in multiple myeloma. German Myeloma Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Humans; Melphalan; Methotrexate; Multiple Myeloma; Prednisone; Vincristine | 1991 |
Diurnal variations of serum beta 2-microglobulin in multiple myeloma.
Topics: beta 2-Microglobulin; Circadian Rhythm; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Premedication; Radioimmunoassay | 1991 |
Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Prednisone; Vincristine; Waldenstrom Macroglobulinemia | 1991 |
AL amyloidosis: therapeutic response in two patients with renal involvement.
Topics: Adult; Aged; Amyloidosis; Colchicine; Humans; Kidney; Kidney Function Tests; Male; Melphalan; Nephrotic Syndrome; Prednisone; Proteinuria | 1991 |
Response rates and survival in primary systemic amyloidosis.
Topics: Amyloidosis; Discriminant Analysis; Humans; Melphalan; Multivariate Analysis; Nephrotic Syndrome; Prednisone; Survival Analysis; Time Factors | 1991 |
Weight gain with breast cancer adjuvant treatment.
Topics: Adaptation, Psychological; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Melphalan; Methotrexate; Middle Aged; Prednisone; Recurrence; Regression Analysis; Social Support; Vinblastine; Weight Gain | 1991 |
Lack of correlation between objective response and death rate in multiple myeloma patients treated with oral melphalan and prednisone.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Retrospective Studies; Survival Analysis | 1991 |
Amyloidosis of immunoglobulin origin: useful treatment?
Topics: Aged; Amyloidosis; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis | 1990 |
[A myeloma (IgG-kappa) terminating in acute myelogenous leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Polyploidy; Prednisone | 1990 |
Adult Fanconi syndrome secondary to kappa-light chain myeloma: improvement of tubular functions after treatment for myeloma.
Topics: Aged; Bence Jones Protein; Fanconi Syndrome; Humans; Immunoglobulin kappa-Chains; Kidney Tubules; Male; Melphalan; Multiple Myeloma; Prednisone; Uric Acid | 1990 |
Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carmustine; Cyclophosphamide; Female; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1990 |
Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
Topics: Adult; Aged; Bone Marrow Transplantation; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Transplantation, Autologous; Vincristine | 1990 |
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Humans; Interferon alpha-2; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Recombinant Proteins; Vincristine | 1990 |
Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Evaluation Studies as Topic; Hodgkin Disease; Humans; Male; Melphalan; Prednisone; Premedication; Remission Induction; Vincristine | 1990 |
[Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Evaluation; Humans; Life Tables; Melphalan; Multiple Myeloma; Prednisone; Spain; Survival Rate; Vincristine | 1990 |
Acute leukemia evolving from multiple myeloma and co-expressing myeloid and plasma cell antigens.
Topics: Acute Disease; Antigens, Neoplasm; Antigens, Surface; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Female; Flow Cytometry; Humans; Leukemia, Myeloid; Melphalan; Middle Aged; Multiple Myeloma; Plasma Cells; Prednisone; Time Factors | 1990 |
[Erythropoietin in multiple myeloma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Erythropoiesis; Erythropoietin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Vincristine | 1990 |
[Heterogenicity of the response to chemotherapy in plasmablastic myeloma].
Topics: Adult; Aged; Antigens, Differentiation; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neprilysin; Prednisolone; Prednisone; Prognosis; Vincristine | 1987 |
[Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbo-splenic radiotherapy. The POF 81/12 protocol].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prednisone; Radiation Dosage; Vinblastine; Vincristine | 1989 |
Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients.
Topics: Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Waldenstrom Macroglobulinemia | 1989 |
Advanced prostatic carcinoma: pulmonary manifestations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Fluorouracil; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Male; Melphalan; Methotrexate; Middle Aged; Pleural Effusion; Prednisone; Prostatic Neoplasms; Radiography; Retrospective Studies; Vincristine | 1985 |
Spinal cord compression in myelomatosis: response to chemotherapy alone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Spinal Cord Compression | 1989 |
[Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
Topics: Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Retrospective Studies; Vincristine | 1989 |
A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Peptichemio; Prednisone; Remission Induction; Vincristine | 1989 |
[Complete double remission and prolonged survival of a patient diagnosed with plasma cell leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Remission Induction; Time Factors; Vincristine | 1989 |
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Vincristine | 1989 |
Successful treatment of hemorrhagic syndrome due to an acquired, combined deficiency of factors VII and X in a patient with multiple myeloma and amyloidosis.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Factor VII Deficiency; Factor X Deficiency; Humans; Hypoprothrombinemias; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Shock, Hemorrhagic; Vincristine | 1989 |
Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
Topics: Amyloidosis; Bone Diseases, Metabolic; Bone Marrow; Colchicine; Drug Therapy, Combination; Female; Humans; Liver Diseases; Melphalan; Middle Aged; Prednisone; Remission Induction | 1989 |
Impaired chemiluminescence response by neutrophils in patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Luminescent Measurements; Melphalan; Multiple Myeloma; Myeloma Proteins; Neutrophils; Oxygen Consumption; Paraproteinemias; Peroxidase; Prednisone; Tetradecanoylphorbol Acetate; Vincristine; Zymosan | 1986 |
Successful treatment of peripheral neuropathy with chemotherapy in osteosclerotic myeloma.
Topics: Drug Therapy, Combination; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neural Conduction; Osteosclerosis; Peripheral Nervous System Diseases; Prednisone | 1987 |
Diffuse well-differentiated lymphocytic lymphoma: chemotherapy with BCNU, cyclophosphamide, vincristine, melphalan and prednisone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Middle Aged; Prednisone; Vincristine | 1988 |
IgD multiple myeloma: a cure at 21 years.
Topics: Carcinoma, Bronchogenic; Follow-Up Studies; Humans; Immunoglobulin D; Lung Neoplasms; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Prednisone; Time Factors | 1988 |
Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Humans; Lomustine; Male; Melphalan; Middle Aged; Prednisone; Prognosis; Sarcoma, Ewing; Vincristine; Vindesine | 1988 |
The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Half-Life; Humans; Injections, Intravenous; Male; Melphalan; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Prednisone | 1988 |
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Evaluation; Drug Resistance; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Remission Induction; Vincristine | 1988 |
A comparative pathological study of liver injury after different combination chemotherapies for leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Liver; Melphalan; Prednisolone; Prednisone; Thioguanine | 1988 |
Early plasma cell recruitment in multiple myeloma following chemotherapy.
Topics: Aged; Bone Marrow; Cell Division; DNA; Female; Humans; Kinetics; Male; Melphalan; Middle Aged; Multiple Myeloma; Plasma Cells; Prednisone; Time Factors | 1988 |
[Monoclonal gammapathy of indeterminate origin and myeloma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Drug Therapy, Combination; Humans; Hypergammaglobulinemia; Interferon Type I; Melphalan; Methylprednisolone; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prednisone; Vincristine | 1988 |
M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carmustine; Cyclophosphamide; Drug Resistance; Hemoglobins; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pain; Prednisone; Time Factors; Vincristine | 1988 |
Dose intensity analysis of melphalan and prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Humans; Immunoglobulins; Melphalan; Multiple Myeloma; Prednisone | 1988 |
Multiple myeloma of the serosa coat.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin A; Male; Melphalan; Microscopy, Electron; Multiple Myeloma; Podophyllotoxin; Prednisone; Serous Membrane; Vincristine | 1988 |
[Treatment of plasmacytoma with hyperviscosity syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Plasma Exchange; Plasmacytoma; Prednisone; Syndrome; Vincristine | 1988 |
Multiple myeloma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Invasiveness; Prednisone | 1987 |
[Multiple myeloma. Clinical experience of 15 years in the 10th region].
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone | 1987 |
Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone | 1987 |
An unusual case of POEMS syndrome.
Topics: Drug Therapy, Combination; Female; Hepatomegaly; Humans; Hypergammaglobulinemia; Immunoglobulin G; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Polyneuropathies; Prednisone; Syndrome | 1986 |
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
Topics: Aged; Amyloidosis; Factor X Deficiency; Humans; Hypoprothrombinemias; Liver; Male; Melphalan; Prednisone | 1987 |
Bilateral primary extramedullary orbital plasmacytomas.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Humans; Male; Melphalan; Orbital Neoplasms; Plasmacytoma; Prednisone; Tomography, X-Ray Computed | 1987 |
[Multiple myeloma: therapeutic response to 2 modalities of chemotherapy].
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Prognosis | 1986 |
Complete remission in plasma cell leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Leukemia, Plasma Cell; Melphalan; Middle Aged; Prednisone; Remission Induction; Vincristine | 1987 |
Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergism; Female; Humans; Interferon Type I; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Myocardial Infarction; Prednisone; Sepsis | 1987 |
[Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1986 |
Are the current criteria for response useful in the management of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Humans; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis | 1987 |
Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1987 |
Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
Topics: Amyloidosis; Drug Therapy, Combination; Factor X Deficiency; Humans; Hypoprothrombinemias; Melphalan; Prednisone | 1987 |
[Combined chemotherapy in advanced stages of chronic lymphatic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphoid; Lomustine; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisone | 1987 |
Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation; Female; Heart Diseases; Humans; Interferon Type I; Leukocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Platelet Count; Prednisone | 1986 |
Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
Topics: Aged; Amyloid; Amyloidosis; Colchicine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisone; Prognosis | 1986 |
Prognostic factors for multiple myeloma in the dog.
Topics: Animals; Calcium; Cyclophosphamide; Dog Diseases; Dogs; Kidney; Melphalan; Multiple Myeloma; Prednisone; Prognosis | 1986 |
Orbital plasmacytoma in established myeloma--a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Prednisone; Tomography, X-Ray Computed; Vincristine | 1986 |
Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Carmustine; Cyclophosphamide; Humans; Hypercalcemia; Male; Melphalan; Multiple Myeloma; Paralysis; Plasmapheresis; Prednisone; Seizures; Serum Globulins; Vincristine | 1986 |
[Results with the use of the M-2 protocol in plasmacytoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Evaluation; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Vincristine | 1986 |
Long unmaintained remission in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Time Factors; Vincristine | 1986 |
Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1985 |
[Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Vincristine | 1985 |
[Cytostatic polychemotherapy in the aged].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Fluorouracil; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Procarbazine; Risk; Vincristine | 1985 |
Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Carmustine; Cyclophosphamide; Humans; Immunoglobulins; Leukemia, Monocytic, Acute; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Time Factors; Vincristine | 1985 |
Combination chemotherapy of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Prednisone; Vincristine | 1985 |
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Topics: Amyloidosis; Antithrombin III Deficiency; Biopsy; Blood Coagulation Tests; Colchicine; Factor X Deficiency; Gastrointestinal Hemorrhage; Humans; Hypoprothrombinemias; Kidney; Male; Melphalan; Middle Aged; Nephrotic Syndrome; Prednisone; Splenectomy | 1985 |
[Diagnosis and treatment of Waldenstrom's macroglobulinemia: 4 case reports].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnostic Errors; Female; Humans; Male; Melphalan; Prednisone; Vincristine; Waldenstrom Macroglobulinemia | 1985 |
Monitoring myeloma: light chain isotype suppression. A new parameter.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Immunoelectrophoresis; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Lymphocytes; Male; Melphalan; Middle Aged; Monitoring, Physiologic; Multiple Myeloma; Paraproteins; Prednisone | 1985 |
Vindesine in refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Vincristine; Vindesine | 1986 |
Multiple myeloma masquerading as metastatic breast cancer.
Topics: Agammaglobulinemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Prednisone; Radiography | 1986 |
Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature.
Topics: Adult; Amyloidosis; Female; Humans; Liver Diseases; Male; Melphalan; Middle Aged; Prednisone | 1986 |
Complete remission in plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Leukemia, Plasma Cell; Male; Melphalan; Peptichemio; Prednisone; Time Factors; Vincristine | 1986 |
Controversies in the treatment of plasma cell myeloma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Drug Resistance; Humans; Leukemia; Melphalan; Multiple Myeloma; Pain Management; Prednisone | 1985 |
Follicular hyperkeratosis and cryocrystalglobulinemia syndrome. Occurrence in a patient with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Darier Disease; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Syndrome | 1985 |
Obstructive jaundice from hepatic amyloidosis in a patient with multiple myeloma.
Topics: Amyloidosis; Cholestasis; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1985 |
Weight gain during adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Body Weight; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prognosis; Risk | 1985 |
[Multiple myeloma in stage I. Evaluation of the initial therapy].
Topics: Aged; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Time Factors | 1985 |
Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Leukemia, Lymphoid; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Vincristine | 1985 |
Sideroblastic anemia in multiple myeloma: a preleukemic change.
Topics: Anemia, Sideroblastic; Bone Marrow Examination; Cytarabine; Female; Humans; Immunodiffusion; Immunoelectrophoresis; Immunoglobulins; Iron; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Melphalan; Mercaptopurine; Middle Aged; Multiple Myeloma; Muramidase; Precancerous Conditions; Prednisone; Staining and Labeling; Vincristine | 1973 |
[Cytomorphological, immunochemical and therapeutic aspects of multiple myeloma].
Topics: Adult; Aged; Blood Transfusion; Cyclophosphamide; Epitopes; Female; Humans; Immunoelectrophoresis; Immunoglobulins; Male; Melphalan; Microscopy, Electron; Middle Aged; Multiple Myeloma; Myeloma Proteins; Plasmacytoma; Prednisone | 1973 |
Plasma cell leukemia: detailed studies and response to therapy.
Topics: Acid Phosphatase; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Fluorescent Antibody Technique; Glucuronidase; Histocytochemistry; Humans; Immunoelectrophoresis; Immunoglobulin Fragments; Karyotyping; Leukemia, Plasma Cell; Male; Melphalan; Microscopy, Electron; Microscopy, Fluorescence; Middle Aged; Plasma Cells; Prednisone; Prognosis; Remission, Spontaneous; Staining and Labeling; Vincristine | 1974 |
[Gamma-D-paraproteinemia. Clinical case contribution based on 2 studies].
Topics: Aged; Anemia, Pernicious; Bence Jones Protein; Diagnosis, Differential; Electrophoresis; Female; gamma-Globulins; Humans; Immunoelectrophoresis; Male; Melphalan; Middle Aged; Multiple Myeloma; Paper; Plasmacytoma; Prednisone; Vitamin B 12 | 1967 |
Spontaneous rupture of the spleen on plasma cell leukemia.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Bone Marrow Examination; Diagnosis, Differential; Female; gamma-Globulins; Humans; Infarction; Leukemia, Plasma Cell; Leukocytosis; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Plasma Cells; Prednisone; Spleen; Splenic Neoplasms; Splenic Rupture; Subarachnoid Hemorrhage; Thrombocytopenia | 1969 |
[The treatment of disseminated lupus erythematosus. So-called immunosuppressive drugs].
Topics: Adolescent; Antibodies, Antinuclear; Autoantibodies; Betamethasone; Female; Hepatitis; Humans; Immune Tolerance; Immunosuppressive Agents; Kidney Diseases; Lupus Erythematosus, Systemic; Melphalan; Methotrexate; Neutrophils; Prednisone; Splenectomy | 1970 |
A human IgA-myeloma protein with anti-streptococcal hyaluronidase (ASH) activity.
Topics: Antibodies, Bacterial; Binding Sites, Antibody; Bone Marrow; Bone Marrow Cells; Female; Humans; Hyaluronoglucosaminidase; Immunodiffusion; Immunoelectrophoresis; Immunoglobulin A; Immunoglobulin Fab Fragments; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Saliva | 1973 |
Plasma cell dyscrasia associated with the production of incomplete (?deleted) IgGlambda molecules, gamma heavy chains, and free lambda chains containing carbohydrate: description of the first case.
Topics: Bone Marrow Examination; Carbohydrates; Chromatography, Ion Exchange; Cyclophosphamide; Electrophoresis, Polyacrylamide Gel; Heavy Chain Disease; Humans; Immunodiffusion; Immunoelectrophoresis; Immunoglobulin Fragments; Immunoglobulin G; Male; Melphalan; Middle Aged; Neuraminic Acids; Papain; Plasma Cells; Prednisone; Proteinuria; Pseudomonas Infections; Ultracentrifugation | 1974 |
Immunoglobulin synthesis and tumor kinetics of multiple myeloma.
Topics: Animals; B-Lymphocytes; Clone Cells; Growth Inhibitors; Humans; Immunoglobulins; Kinetics; Melphalan; Mice; Multiple Myeloma; Myeloma Proteins; Prednisone; Radioimmunoassay | 1973 |
Treatment of Sezary syndrome.
Topics: Chlorambucil; Cyclophosphamide; Dermatitis, Exfoliative; Humans; Keratoderma, Palmoplantar; Lymphatic Diseases; Lymphoma; Melphalan; Methotrexate; Nitrogen Mustard Compounds; Prednisone; Pruritus; Remission, Spontaneous; Syndrome; Time Factors; Triethylenemelamine; Vinblastine | 1974 |
Acute leukemias and Burkitt's lymphoma. Present status of therapy.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Choriocarcinoma; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Female; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Mercaptopurine; Methotrexate; Prednisone; Pregnancy; Vincristine; Wilms Tumor | 1968 |
[Diagnostic problems raised by tumors of the skull. A propos 2 cases (author's transl)].
Topics: Aged; Biopsy; Cyclophosphamide; Diagnosis, Differential; Frontal Bone; Humans; Immunoelectrophoresis; Immunoglobulin G; Iodine Radioisotopes; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Parietal Bone; Plasmacytoma; Prednisone; Skull Neoplasms; Thyroid Neoplasms; Thyroidectomy; Vincristine | 1974 |
[Acute leukemia and myeloma].
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Urethane | 1972 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluorouracil; Hodgkin Disease; Humans; Leukemia; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Mechlorethamine; Melphalan; Mice; Mice, Inbred AKR; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Vinblastine; Vincristine | 1974 |
A case of acute myelomonocytic leukaemia associated with myelomatosis.
Topics: Aged; Autopsy; Blood Cell Count; Blood Protein Disorders; Blood Protein Electrophoresis; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Humans; Immunoelectrophoresis; Immunoglobulin G; Leukemia, Myeloid; Male; Melphalan; Multiple Myeloma; Prednisone | 1973 |
Multiple myeloma without initial paraproteins.
Topics: Adult; Bence Jones Protein; Blood Protein Electrophoresis; Bone Marrow Examination; Cyclophosphamide; Female; Fluorides; Humans; Immunodiffusion; Immunoelectrophoresis; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nitrosourea Compounds; Prednisone | 1972 |
Bone healing in multiple myeloma with melphalan chemotherapy.
Topics: Adult; Aged; Blood Urea Nitrogen; Bone Regeneration; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Procarbazine; Radiography; Remission, Spontaneous; Skull; Texas | 1972 |
Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Bence Jones Protein; Cyclophosphamide; Drug Resistance; Female; Humans; Immunoelectrophoresis; Injections, Intravenous; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Ontario; Prednisone; Time Factors | 1972 |
Cutaneous signs of cryoparaproteinemia: control with burst alkeran and prednisone.
Topics: Adult; Blood Protein Disorders; Blood Protein Electrophoresis; Blood Proteins; Cold Temperature; Female; Humans; Immune Sera; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Leg; Melphalan; Multiple Myeloma; Precipitin Tests; Prednisone; Purpura; Skin Manifestations | 1973 |
Persistence of deoxyribonucleic acid polymerase I and its 5'--3' exonuclease activity in PolA mutants of Escherichia coli K12.
Topics: Drug Synergism; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone | 1973 |
[Systemic lupus erythematosus. Etiopathogenesis and immunosuppressive therapy].
Topics: Adolescent; Adult; Antibody Formation; Azathioprine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Melphalan; Methotrexate; Middle Aged; Prednisone | 1973 |
[Prognosis in myelomatosis treated with prednisone and cytostatics].
Topics: Aged; Cyclophosphamide; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Sex Factors; Time Factors | 1973 |
[Rules of current therapy in multiple myeloma].
Topics: Chlorambucil; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Prednisone; Purpura, Hyperglobulinemic; Remission, Spontaneous; Time Factors | 1973 |
Prognosis of myelomatosis on treatment with prednisone and cytostatics.
Topics: Aged; Cyclophosphamide; Drug Therapy, Combination; Electrophoresis, Paper; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Sex Factors; Time Factors | 1973 |
Chemotherapy of multiple myeloma.
Topics: Allopurinol; Cyclophosphamide; Humans; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis | 1973 |
[Malabsorption syndrome and intestinal pseudoobstruction in primary vascular and heart amyloidosis].
Topics: Adult; Amyloidosis; Antibody Formation; Antigen-Antibody Complex; Azathioprine; Chloramphenicol; Cysteine; Heart Diseases; Humans; Intestinal Obstruction; Malabsorption Syndromes; Male; Melphalan; Penicillamine; Prednisone; Time Factors; Vascular Diseases | 1973 |
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
Topics: Adult; Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1974 |
Multiple myeloma. II. The value of melphalan.
Topics: Allopurinol; Bence Jones Protein; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Proteinuria | 1974 |
A urinary cryo-Bence Jones protein gelling at room temperature.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Cellulose; Cold Temperature; Cryoglobulins; Cyclophosphamide; Electrophoresis; Female; Gels; Humans; Immunoelectrophoresis; Melphalan; Middle Aged; Molecular Weight; Multiple Myeloma; Prednisone; Temperature; Ultracentrifugation | 1974 |
[Problem of therapeutic tactics in plasmacytoma].
Topics: Cyclophosphamide; Female; Humans; Male; Melphalan; Plasmacytoma; Prednisone; Procarbazine | 1974 |
Acute renal failure in multiple myeloma.
Topics: Acute Kidney Injury; Aged; Allopurinol; Female; Humans; Male; Melphalan; Multiple Myeloma; Peritoneal Dialysis; Prednisone; Radiography | 1974 |
Successful renal allograft in a patient with pulmonary cryptococcus.
Topics: Adult; Amphotericin B; Azathioprine; Cryptococcosis; Female; Humans; Kidney Transplantation; Lung Diseases, Fungal; Melphalan; Polycystic Kidney Diseases; Prednisone; Transplantation, Homologous | 1969 |
[A case of heart homotransplantation. Analysis of rejection phenomenon].
Topics: Antilymphocyte Serum; Arrhythmias, Cardiac; Azathioprine; Dexamethasone; Electrocardiography; Heart Rate; Heart Transplantation; Hemodynamics; Histocompatibility; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Postoperative Complications; Prednisone; Transplantation Immunology; Transplantation, Homologous | 1970 |
Simultaneous homotransplantation of heart and kidney from the same donor in bilaterally nephrectomized dogs.
Topics: Animals; Antilymphocyte Serum; Azathioprine; Dogs; Electrocardiography; Graft Rejection; Heart Transplantation; Immunosuppression Therapy; Kidney Transplantation; Melphalan; Nephrectomy; Prednisone; Transplantation Immunology; Transplantation, Homologous | 1969 |
[Ulcero-necrotic purpura revealing Kahler's disease, with macroglobulinemia].
Topics: Female; Humans; Leg Ulcer; Melphalan; Middle Aged; Multiple Myeloma; Necrosis; Prednisone; Purpura; Waldenstrom Macroglobulinemia | 1967 |
Ultrastructural aspects of bone marrow and peripheral blood cells in a case of plasma cell leukemia.
Topics: Agammaglobulinemia; Aged; Anti-Bacterial Agents; Bence Jones Protein; Blood Cells; Blood Transfusion; Bone Marrow Cells; Humans; Leukemia, Plasma Cell; Male; Melphalan; Microscopy, Electron; Prednisone | 1971 |
[Intermittent melphalan-predniso(lo)ne massive-dose therapy of plasmacytoma].
Topics: Blood Cell Count; Blood Platelets; Drug Combinations; Humans; Leukocyte Count; Leukopenia; Melphalan; Plasmacytoma; Prednisolone; Prednisone; Thrombocytopenia | 1972 |
Kinetics of tumor growth and regression in IgG multiple myeloma.
Topics: Aged; Computers; Humans; Immunoglobulin G; Kinetics; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Regression, Spontaneous; Prednisone | 1972 |
Cutanous lesions in multiple myeloma.
Topics: Aged; Female; Humans; Melphalan; Multiple Myeloma; Prednisone; Skin Neoplasms | 1972 |
Myeloma of the prostate: a case report.
Topics: Adult; Cobalt Isotopes; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Prostatic Neoplasms; Radioisotope Teletherapy | 1971 |
Alkeran (Melphalan) in the treatment of myelomatosis.
Topics: Adult; Aged; Blood Platelets; Blood Proteins; Creatine; Female; Humans; Hypercalcemia; In Vitro Techniques; Leukocytes; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proteinuria | 1966 |
[Acute renal insufficiency in myelomatosis].
Topics: Acute Kidney Injury; Aged; Bence Jones Protein; Blood Proteins; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Uremia | 1970 |
Melphalan and myeloma. Experience with a low-dose continuous regimen.
Topics: Bone Diseases; Bone Neoplasms; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neurologic Manifestations; Prednisone; Urethane | 1970 |
Retroperitoneal malignant mesenchymoma.
Topics: Adult; Aortography; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans; Male; Melphalan; Mesenchymoma; Middle Aged; Neoplasm Metastasis; Nephrectomy; Prednisone; Radioisotope Teletherapy; Retroperitoneal Neoplasms; Urography | 1971 |
Treatment of multiple myeloma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Blood Cell Count; Blood Platelets; Cyclophosphamide; Humans; Hypercalcemia; Leukocyte Count; Melphalan; Multiple Myeloma; Prednisone | 1968 |
Current management of multiple myeloma.
Topics: Adult; Cyclophosphamide; Female; Humans; Melphalan; Multiple Myeloma; Prednisone | 1968 |
Multiple myeloma. Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases.
Topics: Adult; Aged; Androgens; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immune Sera; Immunoelectrophoresis; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Radiotherapy | 1969 |
Alkeran and multiple myeloma.
Topics: Anemia; Cyclophosphamide; Humans; Leukopenia; Melphalan; Multiple Myeloma; Prednisone; Urethane | 1966 |
Carcinoma of the esophagus simulating multiple myeloma. Report of a case.
Topics: Aged; Diagnosis, Differential; Esophageal Neoplasms; Humans; Male; Melphalan; Multiple Myeloma; Prednisone | 1966 |
[Ganglionar plasmacytoma].
Topics: Aged; Humans; Male; Melphalan; Plasmacytoma; Prednisone | 1966 |
Myeloma proteins, Bence Jones proteins and normal immunoglobulins in multiple myeloma.
Topics: Adult; Aged; Bence Jones Protein; Blood Proteins; Densitometry; Electrophoresis; Female; Humans; Immunoelectrophoresis; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Serum Globulins; Testosterone | 1967 |
Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Prednisone; Procarbazine; Vinblastine; Vincristine; Vindesine | 1983 |
[Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases].
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Time Factors; Vincristine | 1983 |
Kappa light chain nephropathy without evidence of myeloma cells. Response to chemotherapy with cessation of maintenance hemodialysis.
Topics: Aged; Female; Humans; Immune Complex Diseases; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Kidney Failure, Chronic; Kidney Glomerulus; Melphalan; Prednisone; Renal Dialysis; Vincristine | 1982 |
Osteosclerotic myeloma and peripheral neuropathy.
Topics: Adult; Aged; Antibodies, Monoclonal; Bone Neoplasms; Female; Humans; Immunoglobulin kappa-Chains; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteosclerosis; Peripheral Nervous System Diseases; Prednisone | 1983 |
Peripheral neuropathy in osteosclerotic myeloma: clinical and electrodiagnostic improvement with chemotherapy.
Topics: Adult; Drug Therapy, Combination; Electrodiagnosis; Female; Humans; Melphalan; Multiple Myeloma; Osteosclerosis; Peripheral Nervous System Diseases; Prednisone | 1984 |
Chronic granulocytic leukemia after renal transplantation.
Topics: Adult; Allopurinol; Azathioprine; Humans; Hydroxyurea; Kidney Transplantation; Leukemia, Myeloid; Male; Melphalan; Postoperative Complications; Prednisone | 1983 |
Plasma cell leukemia: a report on three patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Time Factors; Vincristine; Whole-Body Irradiation | 1983 |
[Long-term osteoporosis with multiple fractures as the early monosymptomatic stage of multiple myeloma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fractures, Spontaneous; Humans; Male; Melphalan; Multiple Myeloma; Osteoporosis; Prednisone; Vincristine | 1984 |
Long-term survival of patients with multiple myeloma and acute renal failure at presentation.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Procarbazine; Renal Dialysis; Time Factors; Vincristine | 1983 |
Serum-free light chain analysis by crossed immunoelectrophoresis: correlation with plasmapheresis in light chain disease nephropathy.
Topics: Acute Kidney Injury; Aged; Allopurinol; Calcitonin; Carmustine; Counterimmunoelectrophoresis; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Male; Melphalan; Paraproteinemias; Peritoneal Dialysis; Plasmapheresis; Prednisone; Vincristine | 1983 |
[Therapy of malignant gammopathies].
Topics: Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Humans; Hypergammaglobulinemia; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Orthopedic Equipment; Paraproteins; Plasmacytoma; Prednisone; Prognosis; Vincristine; Waldenstrom Macroglobulinemia | 1984 |
[IgM myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Immunoglobulin M; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone | 1983 |
[Systemic light-chain disease as a complication of plasmacytoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Bone Marrow Cells; Carmustine; Cyclophosphamide; Humans; Hypergammaglobulinemia; Hypertension, Renal; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Male; Melphalan; Middle Aged; Nephrotic Syndrome; Plasma Cells; Plasmacytoma; Prednisone; Vincristine | 1984 |
The chemotherapy of granulosa cell tumors of the ovary: experience of the Wisconsin Clinical Cancer Center.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Granulosa Cell Tumor; Humans; Melphalan; Methotrexate; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prednisone; Retrospective Studies; Vincristine | 1984 |
[Evaluation of the prognosis and response to therapy in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis | 1984 |
[Case of plasmacytic leukemia with complete remission and 1-year survival after a combined 5-drug sequence therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Ethamsylate; Female; Humans; Hydroxyurea; Leukemia, Plasma Cell; Melphalan; Prednisone; Time Factors | 1984 |
[Richter's syndrome. Presentation of a rare variant with regression of chronic lymphatic leukemia and review of the literature].
Topics: Blood Transfusion; Female; Hemosiderosis; Humans; Immunoglobulin M; Leukemia, Lymphoid; Lymph Nodes; Lymphatic Diseases; Melphalan; Middle Aged; Paraproteinemias; Prednisone; Syndrome | 1984 |
Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance; Humans; Melphalan; Middle Aged; Multiple Myeloma; Plasma Cells; Prednisone; RNA, Neoplasm; Vincristine | 1984 |
Comparison of M-2 protocol with COP in patients with nodular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cyclophosphamide; Humans; Lymphoma; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; Probability; Time Factors; Vincristine | 1984 |
[Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Creatinine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Vincristine | 1984 |
Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission, Spontaneous; Vincristine | 1984 |
Myeloproliferative disorder with profound hypereosinophilia associated with chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Eosinophilia; Female; Humans; Lymphoma, Non-Hodgkin; Mastectomy; Melphalan; Middle Aged; Myeloproliferative Disorders; Prednisone; Vincristine | 1984 |
[Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1984 |
Multiple myeloma with renal failure. A case for intensive treatment.
Topics: Adult; Aged; Creatinine; Diuretics; Female; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Peritoneal Dialysis; Prednisone; Prognosis; Time Factors; Urea | 1983 |
[Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1983 |
Progress in the treatment of plasma cell myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Prednisone | 1983 |
Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma.
Topics: Adult; Aged; Bone Marrow; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasma Cells; Prednisone; Prognosis; Time Factors | 1983 |
Progress report on vindesine treatment of melphalan-resistant multiple myeloma.
Topics: Antineoplastic Agents; Drug Resistance; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Vinblastine; Vindesine | 1983 |
Clinical staging and therapeutic results in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Procarbazine; Retrospective Studies; Time Factors | 1983 |
Treatment of multiple myeloma with M-2 protocol and without maintenance therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Immunoglobulins; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraproteins; Prednisone; Time Factors; Vincristine | 1983 |
[Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Prognosis; Vincristine | 1983 |
Long-term survival of a patient with multiple myeloma--a cure? A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Protein Electrophoresis; Humans; Immunoglobulin G; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone; Serum Albumin; Time Factors | 1984 |
Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vinblastine; Vindesine | 1984 |
Objective response in amyloidosis treated with intermittent chemotherapy.
Topics: Adult; Amyloidosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver Diseases; Melphalan; Prednisone; Splenic Diseases | 1984 |
Extramedullary plasmacytoma of the gastrointestinal tract in two dogs.
Topics: Animals; Colonic Neoplasms; Cyclophosphamide; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gastric Mucosa; Male; Melphalan; Plasmacytoma; Prednisone; Stomach Neoplasms | 1984 |
[Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; France; Humans; Lomustine; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Vincristine | 1984 |
Treatment of multiple myeloma.
Topics: Alkylating Agents; Antineoplastic Agents; Bone Marrow Examination; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma; Prednisone; Recurrence; Time Factors | 1980 |
Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
Topics: Adult; Aged; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1980 |
Type I cryoglobulinemia: approach to management.
Topics: Aged; Cryoglobulins; Female; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Melphalan; Paraproteinemias; Plasmapheresis; Prednisone | 1981 |
IgE myeloma. Report of a new case and review of the literature.
Topics: Aged; Drug Therapy, Combination; Female; Fructose; Humans; Immunoglobulin E; Indomethacin; Leukemia, Plasma Cell; Melphalan; Multiple Myeloma; Potassium Chloride; Prednisolone; Prednisone | 1981 |
Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin M; Male; Melphalan; Middle Aged; Prednisone; Prognosis; Vincristine; Waldenstrom Macroglobulinemia | 1982 |
Plasma exchange and moderate dose of cytostatics in advanced macro(cryo)globulinemia. A report on three cases.
Topics: Antineoplastic Agents; Cryoglobulinemia; Cyclophosphamide; Dose-Response Relationship, Drug; Humans; Male; Melphalan; Middle Aged; Paraproteinemias; Plasma Exchange; Prednisone; Waldenstrom Macroglobulinemia | 1982 |
[Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Thrombocytopenia; Vincristine | 1983 |
[Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
Topics: Blood Transfusion; Erythrocyte Transfusion; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Myeloproliferative Disorders; Platelet Transfusion; Prednisone; Preleukemia; Time Factors | 1983 |
Cross-resistance to alkylating agents in multiple myeloma.
Topics: Alkylating Agents; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Probability; Recurrence; Time Factors | 1983 |
Prednisone pulse therapy for refractory myeloma.
Topics: Bone Marrow; Doxorubicin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Plasma Cells; Prednisone; Vinblastine; Vincristine; Vindesine | 1983 |
Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukopenia; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Thrombocytopenia; Vincristine | 1982 |
Amyloidosis-a deadly disease.
Topics: Amyloidosis; Attitude to Death; Depression; Drug Therapy, Combination; Humans; Male; Melphalan; Middle Aged; Prednisone | 1980 |
Cyclic oscillation of blood neutrophils in a patient with multiple myeloma.
Topics: Agranulocytosis; Cell Transformation, Neoplastic; Colony-Stimulating Factors; Cyclophosphamide; DNA; Humans; Leukocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Neutrophils; Nitrosourea Compounds; Periodicity; Prednisone | 1980 |
Bullous amyloidosis.
Topics: Aged; Amyloidosis; Humans; Immunoglobulin A; Male; Melphalan; Multiple Myeloma; Prednisone; Skin Diseases, Vesiculobullous | 1980 |
Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.
Topics: Adult; Amyloid; Amyloidosis; Female; Humans; Male; Melphalan; Middle Aged; Nephrotic Syndrome; Prednisone | 1982 |
[Reclassification of multiple myeloma and calculation of the myelomatous mass as prognostic and therapeutic indications].
Topics: Antineoplastic Agents; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis | 1982 |
Vindesine therapy in melphalan-resistant multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Vinblastine; Vindesine | 1981 |
[Results of, and indications for adjuvant chemotherapy in breast cancer].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphatic Metastasis; Melphalan; Menopause; Methotrexate; Middle Aged; Neoplasm Metastasis; Prednisone; Risk; Vincristine | 1981 |
[Therapeutic plasmapheresis in the treatment of plasmacytoma].
Topics: Aged; Blood Viscosity; Creatinine; Humans; Melphalan; Middle Aged; Neoplasm Staging; Plasmacytoma; Plasmapheresis; Prednisone | 1981 |
[Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1980 |
[Therapy results and clinical course in 91 cases of multiple myeloma with regard to their clinical staging (author's transl)].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1980 |
Melphalan-induced pulmonary interstitial fibrosis.
Topics: Female; Humans; Melphalan; Middle Aged; Prednisone; Pulmonary Fibrosis | 1980 |
The growth fraction of human myeloma cells.
Topics: Female; Humans; Kinetics; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Thymidine; Time Factors | 1981 |
[Therapy of plasmacytoma].
Topics: Aged; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis | 1980 |
The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Leucovorin; Lomustine; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melphalan; Methotrexate; Middle Aged; Phosphoramide Mustards; Prednisolone; Prednisone; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Vincristine | 1994 |
Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Pancytopenia; Prednisone; Procarbazine; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Vinblastine; Vincristine | 1994 |
In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD19; Antigens, Differentiation; Antigens, Differentiation, B-Lymphocyte; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Base Sequence; CD56 Antigen; Cell Differentiation; Dexamethasone; DNA, Neoplasm; Doxorubicin; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunophenotyping; Interferons; Interleukin-2; Lymphocyte Count; Melphalan; Membrane Glycoproteins; Molecular Sequence Data; Multiple Myeloma; Myeloma Proteins; Prednisone; Vincristine | 1995 |
Visual hallucinations following treatment with vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Hallucinations; Humans; Lymphoma, T-Cell; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Procarbazine; Salvage Therapy; Serotonin; Structure-Activity Relationship; Vincristine | 1994 |
[IgD-lambda type multiple myeloma associated with IgG-kappa type benign monoclonal gammopathy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunoglobulin D; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Melphalan; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prednisone | 1995 |
[Pneumonia caused by Salmonella in a patient with myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunocompromised Host; Male; Melphalan; Middle Aged; Multiple Myeloma; Pneumonia, Bacterial; Prednisone; Salmonella Infections; Vincristine | 1995 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cell Survival; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Glyoxal; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prednimustine; Prednisolone; Prednisone; Procarbazine; Radiotherapy; Retrospective Studies; Salvage Therapy; Vinblastine; Vincristine | 1995 |
Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Graft Rejection; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma, Follicular; Melphalan; Middle Aged; Pancytopenia; Podophyllotoxin; Prednisone; Prognosis; Teniposide; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Extramedullary plasmacytomas presenting as mediastinal masses: clinicopathologic study of two cases preceding the onset of multiple myeloma.
Topics: Chest Pain; Combined Modality Therapy; Diagnosis, Differential; Dyspnea; Fatal Outcome; Female; Humans; Immunoglobulin lambda-Chains; Male; Mediastinal Neoplasms; Melphalan; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Prednisone | 1995 |
Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Mediastinal Neoplasms; Melphalan; Middle Aged; Prednisone; Procarbazine; Radiotherapy; Radiotherapy Dosage; Survival Rate; Vinblastine; Vincristine | 1993 |
Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follicle Stimulating Hormone; Hodgkin Disease; Humans; Leukemia, Myelomonocytic, Acute; Luteinizing Hormone; Melphalan; Menotropins; Ovulation Induction; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy, Multiple; Primary Ovarian Insufficiency; Remission Induction; Teniposide; Thioguanine; Vincristine | 1993 |
Metastatic extramedullary plasmacytoma of the colon and rectum in a dog.
Topics: Animals; Biopsy, Needle; Blood Protein Electrophoresis; Chemotherapy, Adjuvant; Colonic Neoplasms; Dog Diseases; Dogs; gamma-Globulins; Lymphatic Metastasis; Male; Melphalan; Plasmacytoma; Prednisone; Rectal Neoplasms; Splenic Neoplasms | 1993 |
Who benefits from high-dose therapy for multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Survival Rate | 1995 |
MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Femur; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteoporosis; Pelvic Bones; Prednisone; Spine | 1995 |
Secondary myelodysplastic syndrome in multiple myeloma--a study of nine patients with an attempt to detect myeloma patients at risk.
Topics: Aged; Female; Humans; Israel; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Pancytopenia; Prednisone; Risk Factors | 1994 |
The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival; Vincristine | 1994 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infant, Newborn; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Melphalan; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy Outcome; Procarbazine; Remission Induction; Salvage Therapy; Vincristine | 1994 |
[Primary malignant lymphoma of the urinary bladder achieving complete response by COMPA intraarterial chemotherapy: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Prednisone; Urinary Bladder Neoplasms; Vincristine | 1994 |
Coexisting kappa light chain multiple myeloma and primary hyperparathyroidism.
Topics: Aged; Aged, 80 and over; Female; Humans; Hypercalcemia; Hyperparathyroidism; Immunoglobulin kappa-Chains; Immunoglobulin Light Chains; Melphalan; Multiple Myeloma; Parathyroidectomy; Prednisone | 1994 |
[Skin lesions as a rare initial symptom of Kahler's disease].
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Skin Neoplasms | 1994 |
[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Survival Rate; Vincristine | 1993 |
A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Nucleus; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Interferon-alpha; Male; Melphalan; Microscopy, Electron; Multiple Myeloma; Plasma Cells; Prednisone; Prognosis; Vincristine | 1993 |
Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; HLA-DR Antigens; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin Isotypes; Immunophenotyping; Lomustine; Longitudinal Studies; Male; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Plasma Cells; Prednisone; Prognosis; Regression Analysis; Survival Analysis; Vincristine | 1993 |
Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Interferon-alpha; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Remission Induction; Survival Analysis; Vincristine | 1993 |
[Smoldering myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Combined Modality Therapy; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Prednisone | 1993 |
Paresthesia of the mandibular division, trigeminal nerve.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Female; Humans; Mandibular Neoplasms; Mandibular Nerve; Melphalan; Middle Aged; Multiple Myeloma; Paresthesia; Prednisone; Radiography; Sex Factors | 1993 |
[Recent therapy for refractory myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Podophyllotoxin; Prednisone; Remission Induction; Survival Rate; Vincristine | 1993 |
Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Carmustine; Cholesterol; Cyclophosphamide; Female; Humans; Immunoglobulin G; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphatidylcholines; Phosphatidylethanolamines; Phospholipids; Prednisone; Reference Values; Sphingomyelins; Vincristine | 1995 |
Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 8; Disease Progression; Fatal Outcome; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Melphalan; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Paraproteinemias; Prednisone; Trisomy | 1996 |
[Indications for chemotherapy in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1996 |
Reversible metastatic pulmonary calcification in a patient with multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Calcinosis; Diphosphonates; Female; Humans; Lung Diseases; Melphalan; Middle Aged; Multiple Myeloma; Pamidronate; Prednisone; Tomography, X-Ray Computed | 1996 |
[Long-term fever and light-chain myeloma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Fever of Unknown Origin; Humans; Immunoglobulin lambda-Chains; Interferons; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone | 1995 |
[Sweet's syndrome and multiple myeloma].
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Humans; Immunoglobulin lambda-Chains; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Sweet Syndrome; Time Factors | 1996 |
IgD multiple myeloma. A report of three cases.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Immunoglobulin D; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Retrospective Studies; Time Factors | 1996 |
Kaposi's sarcoma after autologous bone marrow transplantation for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatal Outcome; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Immunocompromised Host; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Sarcoma, Kaposi; Skin Neoplasms; Transplantation, Autologous | 1996 |
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Lymphocyte Count; Male; Melphalan; Mitoxantrone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Vincristine; Whole-Body Irradiation | 1996 |
Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Lymphoma, Follicular; Male; Melphalan; Methotrexate; Podophyllotoxin; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1996 |
Conventional induction treatments do not influence overall survival in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Vincristine | 1997 |
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Male; Melphalan; Methotrexate; Prednisone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Stomach Neoplasms; Transplantation Conditioning; Tumor Lysis Syndrome; Vincristine | 1997 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Leukapheresis; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 1997 |
Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma.
Topics: Alzheimer Disease; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 1997 |
Multifocal plasmacytoma of hand and foot bones.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Fingers; Foot Diseases; Hand Deformities, Acquired; Humans; Melphalan; Metacarpus; Plasmacytoma; Prednisone; Vincristine | 1996 |
[Clinical and evolutive study of plasma cell leukemia. Apropos of 9 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Leukemia, Plasma Cell; Male; Melphalan; Prednisone; Vincristine | 1997 |
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vincristine | 1997 |
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; beta 2-Microglobulin; Female; Hepatocyte Growth Factor; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Regression Analysis; Survival Rate | 1998 |
Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Plasma Cells; Prednisone; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Vault Ribonucleoprotein Particles | 1998 |
[The influence of verapamil on platelet function in patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Platelet Aggregation; Platelet Aggregation Inhibitors; Prednisone; Verapamil; Vincristine | 1997 |
An unusual case of primary systemic amyloidosis.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Colchicine; Female; Gout Suppressants; Humans; Melphalan; Prednisone; Radionuclide Imaging; Skin Diseases; Technetium Tc 99m Dimercaptosuccinic Acid | 1998 |
Primary systemic amyloidosis with delayed progression to multiple myeloma.
Topics: Aged; Amyloidosis; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Survival Rate | 1998 |
[Intensive treatment of T-cell-rich B lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; T-Lymphocyte Subsets; Vincristine | 1998 |
[Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Orbit; Prednisone; Spine | 1998 |
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Transplantation, Autologous; Vincristine | 1998 |
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyps; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Transplantation, Autologous; Vincristine | 1998 |
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Chromosomes, Human, Pair 17; Cyclophosphamide; Dexamethasone; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Interphase; Karyotyping; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
IgG1-kappa biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Fatal Outcome; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Interferon-alpha; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Paraproteins; Prednisone; Sequence Analysis | 1998 |
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
Topics: Antineoplastic Agents; Health Status; Humans; Interferon alpha-2; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Recombinant Proteins; Recurrence; Retrospective Studies; Survival Rate | 1998 |
[The efficacy of polychemotherapy programs in treating multiple myeloma patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Remission Induction; Vincristine | 1998 |
Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Bone Marrow; Cell Division; Female; Follow-Up Studies; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplastic Stem Cells; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Severity of Illness Index; Survival Analysis; Treatment Outcome | 1998 |
Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Humans; Immunophenotyping; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Mitotic Index; Multiple Myeloma; Neoplasm Proteins; Ploidies; Prednisone; Prognosis; Survival Rate; Treatment Outcome | 1999 |
Non-secretory solitary plasmacytoma of the spleen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Humans; Male; Melphalan; Middle Aged; Plasmacytoma; Prednisone; Splenectomy; Splenic Neoplasms; Vincristine | 1998 |
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Plasmacytoma; Prednisone; Salvage Therapy; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 1999 |
Amyloidosis: recognition, confirmation, prognosis, and therapy.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Prednisone; Prognosis; Vincristine | 1999 |
[Multiple myeloma nephropathy as a cause of renal failure--diagnostic difficulties and prospects for treatment].
Topics: Aged; Erythropoietin; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recombinant Proteins; Renal Dialysis; Renal Insufficiency; Treatment Outcome | 1998 |
Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Sex Factors; Survival Rate; Time Factors; Treatment Outcome; Vincristine | 1999 |
Multiple myeloma in the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Doxorubicin; Fatal Outcome; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Melphalan; Middle Aged; Multiple Myeloma; Myasthenia Gravis; Prednisone; Radiography; Vincristine | 1999 |
A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival.
Topics: Adult; Amyloidosis; Antineoplastic Agents; Humans; Immunoglobulin Light Chains; Interferon-alpha; Male; Melphalan; Multiple Myeloma; Nephrotic Syndrome; Prednisone; Remission Induction; Survivors | 1999 |
[Acute and chronic renal failure in patients with myeloma].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hemodiafiltration; Hemofiltration; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Peritoneal Dialysis; Prednisone; Renal Dialysis; Time Factors; Vincristine | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
[Systemic Al-amyloidosis. Clinical course and limits of melphalan therapy].
Topics: Adult; Aged; Amyloidosis; Edema; Female; Humans; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Paresthesia; Prednisone; Prognosis; Proteinuria; Survival Rate | 1999 |
Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Lineage; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clone Cells; Combined Modality Therapy; Diphosphonates; Embryonal Carcinoma Stem Cells; Female; Gene Rearrangement, B-Lymphocyte, Light Chain; Humans; Idarubicin; Immunoglobulin kappa-Chains; Leukemia, Promyelocytic, Acute; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Osteolysis; Pamidronate; Prednisone; Remission Induction; Translocation, Genetic; Tretinoin | 1999 |
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Leukoencephalopathy in multiple myeloma: two case reports.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Female; Humans; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Melphalan; Multiple Myeloma; Polyneuropathies; Prednisone | 1999 |
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Hospital Costs; Hospital Units; Hospitalization; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Netherlands; Parenteral Nutrition; Patient Isolation; Podophyllotoxin; Prednisone; Retrospective Studies; Transplantation, Autologous; Vincristine | 1999 |
Myelomatous effusion with poor response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; Plasma Cells; Pleural Effusion; Prednisone; Tomography, X-Ray Computed; Vincristine | 2000 |
Severe amyloidosis with mild multiple myeloma--an unusual course.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Colchicine; Disease Progression; Fatal Outcome; Female; Heart Failure; Humans; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Prednisone | 2000 |
[Plasmocytic pleural effusion disclosing multiple myeloma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Fatal Outcome; Female; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Melphalan; Middle Aged; Multiple Myeloma; Osteolysis; Plasma Cells; Pleural Effusion; Prednisone; Vincristine | 2000 |
Expression of BAX in plasma cell dyscrasias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Biopsy; Blotting, Western; Bone Marrow; Cell Division; Dexamethasone; Disease-Free Survival; Doxorubicin; Humans; Immunohistochemistry; Melphalan; Multiple Myeloma; Paraproteinemias; Plasma Cells; Prednisone; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recurrence; Time Factors; Vincristine | 2000 |
[Therapy options in systemic AL-amyloidosis with renal involvement].
Topics: Adult; Aged; Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Melphalan; Middle Aged; Prednisone; Risk Factors; Time Factors; Transplantation, Autologous | 2000 |
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Procarbazine; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Vinblastine; Vincristine | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine | 2000 |
[Treatment of AL amyloidosis].
Topics: Amyloidosis; Anti-Inflammatory Agents; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Prednisone; Treatment Outcome | 2001 |
[Acquired C1-esterase inhibitor deficiency with angioedema in lymphoplasmocytic lymphoma].
Topics: Aged; Angioedema; Antineoplastic Combined Chemotherapy Protocols; Complement C1 Inactivator Proteins; Diagnosis, Differential; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Prednisone | 2001 |
Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chymotrypsin; Cohort Studies; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Combinations; Endopeptidases; Female; Humans; Lomustine; Male; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Papain; Prednisone; Proportional Hazards Models; Retrospective Studies; Survival Rate; Trypsin; Vincristine | 2001 |
[High dose therapy with autologous stem cell support--finally a progress in myelomatosis].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Cost-Benefit Analysis; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Transplantation, Autologous | 2001 |
[Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; France; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Randomized Controlled Trials as Topic; Transplantation, Autologous; Vincristine | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease-Free Survival; Doxorubicin; Etoposide; False Negative Reactions; False Positive Reactions; Fibrosis; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Mediastinal Neoplasms; Melphalan; Neoplasm Recurrence, Local; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Tomography, Emission-Computed; Transplantation, Autologous; Vinblastine; Vincristine | 2001 |
Treatment with chemotherapy of scleredema associated with Ig A myeloma.
Topics: Aged; Biopsy, Needle; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Prednisone; Scleroderma, Systemic; Treatment Outcome | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine | 2001 |
Early clinical diagnosis of solitary plasmacytoma of the jaws: a case report with a six year follow-up.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Follow-Up Studies; Humans; Male; Mandibular Neoplasms; Melphalan; Middle Aged; Plasmacytoma; Prednisone; Prognosis; Radiotherapy Dosage; Remission Induction | 2001 |
Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Combined Modality Therapy; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Leukemia, Plasma Cell; Leukemia, Radiation-Induced; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neoplastic Stem Cells; Polymerase Chain Reaction; Prednisone; Radiotherapy; Vincristine | 2002 |
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Chromosomes, Human, Pair 3; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Genes, bcl-2; Humans; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Point Mutation; Prednisolone; Prednisone; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogenes; Transcription Factors; Treatment Outcome; Vincristine | 2002 |
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Life Tables; Male; Melphalan; Mercaptopurine; Middle Aged; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
[Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Plasma Cell; Melphalan; Prednisolone; Prednisone; Vincristine | 2002 |
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Vincristine | 2002 |
Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Procarbazine; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 2002 |
Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone.
Topics: Adult; Anti-Inflammatory Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Histiocytosis; Humans; Melphalan; Necrobiosis Lipoidica; Paraproteinemias; Prednisone | 2002 |
Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate; Time Factors; Transplantation, Autologous; Vincristine | 2002 |
A rare complication of monoclonal gammopathy.
Topics: Amyloidosis; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Fatal Outcome; Female; Humans; Immunoglobulin A; Immunoglobulin Heavy Chains; Immunoglobulin kappa-Chains; Melphalan; Middle Aged; Paraproteinemias; Prednisone | 2002 |
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Survival Rate | 2002 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Transplantation, Autologous; Vincristine | 2003 |
Multiple myeloma associated with systemic lupus erythematosus.
Topics: Aged; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone | 2003 |
[Ascites as the sole clinical manifestation in a patient with nodular regenerative hyperplasia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bronchopneumonia; Combined Modality Therapy; Disease Progression; Fatal Outcome; Focal Nodular Hyperplasia; Humans; Hypertension, Portal; Liver Regeneration; Lumbar Vertebrae; Male; Melphalan; Multiple Myeloma; Plasmacytoma; Prednisone; Spinal Neoplasms | 2003 |
[Pleural effusion as a first sign of Ig D lambda multiple myeloma].
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Dyspnea; Humans; Immunoelectrophoresis; Immunoglobulin D; Immunoglobulin lambda-Chains; Male; Melphalan; Multiple Myeloma; Pleural Effusion; Prednisone; Time Factors | 2003 |
Intraocular extramedullary plasmacytoma in a cat.
Topics: Animals; Antineoplastic Agents; Blindness; Cat Diseases; Cats; Drug Therapy, Combination; Eye Injuries; Eye Neoplasms; Lymphatic Metastasis; Male; Melphalan; Orbit Evisceration; Plasmacytoma; Prednisone | 2003 |
Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients.
Topics: Adult; Aged; Amyloid; Amyloidosis; Cohort Studies; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Prednisone; Retrospective Studies; Risk Assessment; Severity of Illness Index; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2003 |
Testicular plasmacytoma with bone dissemination without medullary plasmacytosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Male; Melphalan; Plasma Cells; Plasmacytoma; Prednisone; Skull Neoplasms; Testicular Neoplasms; Tomography, X-Ray Computed; Vincristine | 2003 |
Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Retrospective Studies; Treatment Outcome | 2003 |
Extramedullary liver plasmacytoma a rare presentation.
Topics: Aged; Antineoplastic Agents; Follow-Up Studies; Humans; Liver Neoplasms; Male; Melphalan; Plasmacytoma; Prednisone; Time Factors; Treatment Outcome | 2003 |
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Treatment Outcome; Vincristine; Waldenstrom Macroglobulinemia | 2003 |
Unusual IgM-secreting multiple myeloma in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Blood Protein Electrophoresis; Bone Marrow; Bone Marrow Cells; Diagnosis, Differential; Dog Diseases; Dogs; Fatal Outcome; Immunoglobulin M; Immunohistochemistry; Lameness, Animal; Male; Melphalan; Multiple Myeloma; Prednisone | 2003 |
CHEMOTHERAPY IN RETICULOSES.
Topics: Chlorambucil; Cyclophosphamide; Genetic Diseases, X-Linked; Hodgkin Disease; Humans; Leukemia, Hairy Cell; Lymphatic Diseases; Melphalan; Nitrogen Mustard Compounds; Peptide Nucleic Acids; Prednisolone; Prednisone; Severe Combined Immunodeficiency; Thiotepa | 1963 |
DRUG THERAPY OF MULTIPLE MYELOMA.
Topics: Humans; Melphalan; Multiple Myeloma; Prednisone; Radiography; Stilbamidines; Urethane | 1964 |
TURNOVER RATE OF PARAPROTEINS IN MYELOMATOSIS. STUDIES ON THE TURNOVER RATE OF SERUM PARAPROTEINS AFTER LABELLING IN VIVO, WITH SPECIAL REFERENCE TO REPEATED TURNOVER-RATE DETERMINATIONS.
Topics: Blood Proteins; Carbon Isotopes; Glycine; Humans; Immunoelectrophoresis; Melphalan; Multiple Myeloma; Paraproteins; Prednisone; Proteins; Urethane | 1964 |
CLINICAL TRIALS IN PROGRESS: LEUKAEMIA AND MULTIPLE MYELOMA.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Drug Therapy; Humans; Infant; Leukemia; Leukemia, Myeloid; Melphalan; Mercaptopurine; Multiple Myeloma; Neoplasms; Phosphorus Isotopes; Prednisone | 1965 |
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Idarubicin; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous; Vincristine | 2004 |
Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Interleukin-18; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prednisone; Prospective Studies; Ribonuclease, Pancreatic; Survival Analysis; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vincristine | 2004 |
Multiple myeloma presenting with widespread osteosclerotic lesions.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Diagnosis, Differential; Female; Humans; Immunoglobulin A; Immunoglobulin Allotypes; Immunoglobulin lambda-Chains; Melphalan; Multiple Myeloma; Osteosclerosis; Prednisone; Radiotherapy; Spinal Cord Compression; Treatment Outcome | 2004 |
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Female; Humans; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Reference Values; Retrospective Studies; Surveys and Questionnaires | 2004 |
Hb H disease and multiple myeloma.
Topics: Aged; alpha-Thalassemia; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Female; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Splenectomy; Thalidomide | 2004 |
Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Paraproteinemias; Prednisone; Prognosis; Tumor Suppressor Protein p53 | 2003 |
Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Bone Resorption; Cyclophosphamide; Dexamethasone; Diphosphonates; Doxorubicin; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Glycoproteins; Humans; Life Tables; Male; Melphalan; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasm Staging; Neovascularization, Pathologic; Osteoprotegerin; Pamidronate; Prednisone; Prognosis; Proteoglycans; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Survival Analysis; Syndecan-1; Syndecans; Vincristine | 2004 |
[Multiple myeloma and HIV infection: report of 3 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; HIV Infections; Humans; Immunoglobulin A; Immunoglobulin G; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Vincristine | 2004 |
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Platelet Transfusion; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Thalidomide | 2004 |
Multiple myeloma associated with CD4+ large granular lymphocytic leukemia: a possible causal relationship.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; CD4 Antigens; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Clone Cells; Combined Modality Therapy; Culture Media, Conditioned; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphoid; Melphalan; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Osteolysis; Paraproteinemias; Prednisone; Vincristine | 2004 |
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
Topics: Aged; Amyloidosis; Drug Therapy, Combination; Factor X Deficiency; Female; Humans; Melphalan; Paraproteinemias; Prednisone; Treatment Outcome | 2004 |
Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Follow-Up Studies; Humans; Italy; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 2005 |
[Primary amyloidosis associated to severe factor X deficiency].
Topics: Amyloidosis; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Factor X Deficiency; Glucocorticoids; Humans; Immunoglobulin lambda-Chains; Kidney; Male; Melphalan; Middle Aged; Nephrotic Syndrome; Prednisone; Treatment Outcome | 2004 |
Radiologic findings in primary pulmonary plasmacytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Cyclophosphamide; Female; Hemoptysis; Humans; Immunoenzyme Techniques; Lung; Lung Neoplasms; Melphalan; Middle Aged; Plasmacytoma; Prednisone; Remission Induction; Tomography, X-Ray Computed | 2005 |
Multiple complications in multiple myeloma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Fractures, Spontaneous; Hip Fractures; Humans; Kidney Failure, Chronic; Kidney Glomerulus; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplastic Cells, Circulating; Prednisone | 2005 |
Plasma cell problems: Case 2. Extramedullary cardiac plasmacytoma presenting with cardiac tamponade.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cyclophosphamide; Female; Heart Neoplasms; Humans; Melphalan; Middle Aged; Plasmacytoma; Prednisolone; Prednisone; Vincristine | 2005 |
Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Drug Therapy, Combination; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide | 2005 |
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2005 |
Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality Therapy; Cyclophosphamide; Female; Hodgkin Disease; Humans; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Procarbazine; Vincristine; Whole-Body Irradiation | 2005 |
Type III hyperlipoproteinemia with xanthomas and multiple myeloma.
Topics: Aged; Antineoplastic Agents, Alkylating; Apolipoprotein E2; Apolipoprotein E3; Apolipoproteins E; Comorbidity; Drug Therapy, Combination; Glucocorticoids; Histiocytes; Humans; Hyperlipoproteinemia Type III; Immunoglobulin A; Lipoproteins, VLDL; Male; Melphalan; Multiple Myeloma; Phenotype; Prednisone; Xanthomatosis | 2005 |
Free plasma amino acids in patients with multiple myeloma.
Topics: Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Humans; Kinetics; Melphalan; Multiple Myeloma; Prednisone; Reference Values | 1989 |
Thyroid hormone and insulin-like growth factor-I in patients with multiple myeloma treated with melphalan and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Euthyroid Sick Syndromes; Female; Humans; Insulin-Like Growth Factor I; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thyroid Hormones | 2006 |
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2005 |
[Haemorrhagic diathesis as an early symptom of systemic amyloidosis].
Topics: Amyloidosis; Death, Sudden, Cardiac; Diagnosis, Differential; Fatal Outcome; Glucocorticoids; Heart Failure; Hemorrhagic Disorders; Humans; Male; Melphalan; Middle Aged; Myocardial Infarction; Paraproteinemias; Prednisone; Spondylitis, Ankylosing | 2006 |
Localized amyloidosis: a survey of 35 French cases.
Topics: Adult; Aged; Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Case-Control Studies; Colchicine; Colon; Data Collection; Endoscopy; Female; Follow-Up Studies; Gout Suppressants; Humans; Immunoglobulin Light Chains; Male; Melphalan; Middle Aged; Phototherapy; Prednisone; Prognosis; Respiratory System | 2005 |
Long-term complete remission in IgD-myeloma.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Humans; Immunoglobulin D; Male; Melphalan; Multiple Myeloma; Prednisone; Remission Induction | 2006 |
Thalidomide for the treatment of leptomeningeal multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunoglobulin G; Melphalan; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Thalidomide; Vindesine | 2006 |
Thalidomide gives food for thought in multiple myeloma.
Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Risk Factors; Survival Analysis; Thalidomide; Venous Thrombosis | 2006 |
Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
Topics: Actuarial Analysis; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Dexamethasone; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Radiation; Doxorubicin; Europe; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; North America; Plasmacytoma; Prednisone; Prognosis; Proportional Hazards Models; Radiotherapy Dosage; Retrospective Studies; Spinal Neoplasms; Treatment Outcome; Vincristine | 2006 |
[Plasmacytoma with multiple hypervascular lesions revealed by angiography in a patient with multiple myeloma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Drug Administration Schedule; Female; Humans; Melphalan; Multiple Myeloma; Neovascularization, Pathologic; Nitrosourea Compounds; Plasmacytoma; Prednisolone; Prednisone; Tomography, X-Ray Computed; Vindesine | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors | 2006 |
Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Transformation, Neoplastic; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Transfusion; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; Rituximab; Time Factors; Vincristine | 2006 |
Advances in the treatment of elderly patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide | 2006 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2006 |
[Four cases of therapy-related leukemia in multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Nitrosourea Compounds; Prednisolone; Prednisone; Vincristine | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[79 year old male with constitutional syndrome and hepatomegaly].
Topics: Abdomen; Aged; Amyloidosis; Anti-Inflammatory Agents; Biopsy; Glucocorticoids; Hepatomegaly; Humans; Liver; Liver Diseases; Male; Melphalan; Myeloablative Agonists; Prednisone; Prognosis; Radiography, Abdominal; Radiography, Thoracic; Tomography, X-Ray Computed; Ultrasonography | 2007 |
Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Graft Survival; Histiocytosis, Langerhans-Cell; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Melphalan; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vinblastine | 2007 |
Amyloidosis: a changing clinical perspective.
Topics: Adult; Aged; Amyloidosis; Antibodies, Monoclonal; Bone Marrow; Bone Marrow Transplantation; Colchicine; Diagnosis, Differential; Disease Management; Female; Humans; Immunotherapy; Lymphoproliferative Disorders; Male; Melphalan; Methylprednisolone; Middle Aged; Plasma Cells; Prednisone; Radioimmunotherapy; South Africa; Survival Rate | 2007 |
[The standard treatments for patients with hematological malignancies in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Rituximab; Survival Rate; Vincristine | 2007 |
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine | 2007 |
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Remission Induction; Rituximab; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Incidence; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prednisone; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis | 2008 |
Making quality-of-life results more meaningful for clinicians.
Topics: Antineoplastic Combined Chemotherapy Protocols; Health Status; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Treatment Outcome | 2008 |
Treatment of myeloma--are we making progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines | 2008 |
Erythrophagocytic multiple myeloma in a cat.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Male; Melphalan; Multiple Myeloma; Prednisone | 2008 |
Non-secretory myeloma: a rare variant of multiple myeloma.
Topics: Adult; Antineoplastic Agents, Alkylating; Glucocorticoids; Humans; Male; Melphalan; Multiple Myeloma; Myeloma Proteins; Prednisone | 2008 |
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation | 2009 |
Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis.
Topics: Amyloidosis; Heart Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Transplantation Conditioning; Treatment Outcome | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
New evidence in oncologic and cardiocirculatory medicine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2009 |
[Papilledema as an indicator of POEMS syndrome].
Topics: Acetazolamide; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Female; Humans; Intracranial Hypertension; Melphalan; Middle Aged; Papilledema; POEMS Syndrome; Prednisone; Rituximab; Visual Fields | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide | 2008 |
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Eruptions; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Salvage Therapy; Vincristine | 2008 |
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglobulin Light Chains; Ischemia; Lenalidomide; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Thalidomide | 2009 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia | 2009 |
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome | 2009 |
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Protein Processing, Post-Translational; STAT3 Transcription Factor; Transplantation, Autologous; Tumor Suppressor Protein p53; Vincristine | 2009 |
Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.
Topics: Aged; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Europe; Female; Humans; Male; Melphalan; Multiple Myeloma; Orphan Drug Production; Prednisone; Survival; Thalidomide | 2009 |
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Combined Modality Therapy; Comorbidity; Creatinine; Dexamethasone; Doxorubicin; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Retrospective Studies; Risk Assessment; Thalidomide; Treatment Outcome; Vincristine | 2009 |
Current treatment of AL amyloidosis.
Topics: Amyloid; Amyloidosis; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Drug Therapy, Combination; Humans; Melphalan; Prednisone; Prognosis; Stem Cell Transplantation; Treatment Outcome | 2009 |
Successful bortezomib-based treatment in POEMS syndrome.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine | 2009 |
Treatment of multiple myeloma in patients with Gaucher disease.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Gaucher Disease; Humans; Immunoglobulins; Leukemia, Myeloid, Acute; Male; Melphalan; Multiple Myeloma; Prednisone; Thrombocytopenia | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Diphosphonates; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Imidazoles; Immunoglobulin A; Immunoglobulin E; Immunoglobulin kappa-Chains; Leukemia, Plasma Cell; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasms, Second Primary; Prednisone; Zoledronic Acid | 2010 |
Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Magnetic Resonance Imaging; Male; Melphalan; Multiple Myeloma; Prednisone; Radiography; Randomized Controlled Trials as Topic | 2009 |
Impedance cardiography in the diagnosis of capillary leak syndrome caused by doxorubicin therapy in a patient with myeloma multiplex.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Cardiography, Impedance; Cyclophosphamide; Doxorubicin; Humans; Lung; Male; Melphalan; Multiple Myeloma; Prednisone; Retreatment; Treatment Outcome; Vincristine | 2010 |
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
Topics: Aged; Consensus; Europe; Guidelines as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Risk Factors; Survival Rate; Thalidomide; Thromboembolism | 2010 |
[Rib fracture with severe cause].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Biopsy, Needle; Bone Marrow; Bone Marrow Neoplasms; Drug Therapy, Combination; Humans; Immunoelectrophoresis; Male; Melphalan; Plasmacytoma; Prednisone; Rib Fractures; Stem Cell Transplantation | 2010 |
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Polyethylene Glycols; Prednisone; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
POEMS syndrome: a rare case of monoclonal plasmaproliferative disorder.
Topics: beta 2-Microglobulin; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Electrophoresis; Female; Glucocorticoids; Humans; Melphalan; Middle Aged; Myeloablative Agonists; POEMS Syndrome; Prednisone | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Infections; Kidney; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Retrospective Studies; Survival Analysis; Vincristine | 2010 |
Optimising bortezomib in newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome | 2010 |
First-line treatment of elderly multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Effect of cobalt-60 (γ radiation) on multidrug-resistant multiple myeloma cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cobalt Radioisotopes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gamma Rays; Humans; Melphalan; Multiple Myeloma; Prednisone; Tetrazolium Salts; Vincristine | 2011 |
De novo AL amyloidosis in the kidney allograft.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis?
Topics: Brain Diseases; Coma; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Myeloablative Agonists; Paraproteinemias; Plasmapheresis; Prednisone; Scleromyxedema; Thalidomide; Treatment Outcome | 2012 |
Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Clinical Trials, Phase I as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Male; Melphalan; Prednisone; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2012 |
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2012 |
Is the low-thalidomide dose MPT regimen beneficial?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2011 |
A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Confidence Intervals; Disease Progression; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Risk; Thalidomide; Time Factors; Treatment Outcome | 2011 |
Drug interaction between lenalidomide and itraconazole.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Intestinal Absorption; Itraconazole; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide | 2012 |
Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 2012 |
[New concept of the treatment in elderly patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunologic Factors; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Transplantation, Autologous | 2011 |
Successful treatment of systemic capillary leak syndrome with intravenous immunoglobulins.
Topics: Anti-Inflammatory Agents; Capillary Leak Syndrome; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Melphalan; Middle Aged; Myeloablative Agonists; Prednisone | 2012 |
Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line.
Topics: ADAM Proteins; ADAM17 Protein; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Matrix; Fibronectins; Gene Expression Regulation, Neoplastic; Humans; Laminin; Melphalan; Multiple Myeloma; Prednisone; Tumor Microenvironment; Up-Regulation; Vincristine | 2012 |
Lenalidomide in myeloma--a high-maintenance friend.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2012 |
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine | 2012 |
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Chromosome Aberrations; Chromosomes, Human, Pair 1; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Gene Amplification; Hemoglobins; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prednisone; Prognosis; Remission Induction; Thalidomide | 2013 |
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Compassionate Use Trials; Crizotinib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphocyte Transfusion; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Molecular Targeted Therapy; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Transplantation, Homologous; Vincristine | 2013 |
Lenalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2012 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; California; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dacarbazine; Databases, Factual; Doxorubicin; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Melphalan; Methotrexate; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Vinblastine; Vincristine | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
Management of tracheobronchial amyloidosis with therapeutic bronchoscopic techniques.
Topics: Airway Obstruction; Amyloidosis; Biopsy; Birefringence; Bone Marrow; Bronchial Diseases; Bronchial Neoplasms; Bronchoscopy; Coloring Agents; Combined Modality Therapy; Congo Red; Diagnosis, Differential; Female; Hemoptysis; Humans; Laser Therapy; Lung; Lung Neoplasms; Male; Melphalan; Middle Aged; Prednisone; Tracheal Diseases | 2013 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid | 2013 |
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2013 |
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult | 2013 |
Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mechlorethamine; Melphalan; Prednisone; Recurrence; Survival Analysis; Vincristine | 2015 |
[Use of intravenous immunoglobulins in a patient with systemic capillary leak syndrome].
Topics: Capillary Leak Syndrome; Combined Modality Therapy; Drug Therapy, Combination; Humans; Hypotension; Immunoglobulins, Intravenous; Immunosuppressive Agents; Intestinal Perforation; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Prednisone; Sepsis; Sympathomimetics; Terbutaline; Theophylline | 2014 |
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.
Topics: Adult; Cost-Benefit Analysis; Female; Humans; Italy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Retrospective Studies; Statistics, Nonparametric; Survival Analysis | 2013 |
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retreatment; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2014 |
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corneal Opacity; Crystallization; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney Failure, Chronic; Lenalidomide; Male; Melphalan; Middle Aged; Paraproteinemias; Paraproteins; Phacoemulsification; Postoperative Complications; Prednisone; Slit Lamp; Thalidomide | 2013 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambucil; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine | 2014 |
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; DNA Copy Number Variations; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prednisone; Pyrazines | 2015 |
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Germany; Glucocorticoids; Hematology; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Pyrazines; Registries | 2014 |
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome; Turkey | 2015 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide | 2015 |
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Plasmacytoma; Prednisone | 2015 |
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis | 2015 |
The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Female; Gene Expression; Humans; Lectins, C-Type; Macrophage Activation; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Receptors, Cell Surface; Solubility; Survival Analysis; Tumor Microenvironment | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antigens, CD34; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone and Bones; Cell Line, Tumor; Drug Carriers; Enzyme-Linked Immunosorbent Assay; Erythrocytes; Humans; Interleukin-6; Melphalan; Metal Nanoparticles; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel; Phenotype; Prednisone; Syndecan-1; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2015 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States | 2016 |
Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Cyclophosphamide; Dexamethasone; Endoglin; Female; Hepatocyte Growth Factor; Humans; Male; Melphalan; Membrane Proteins; Microvessels; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasm Staging; Neovascularization, Pathologic; Prednisone; Receptors, Cell Surface; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |
Clinical Characteristics and Treatment Outcome of Chinese Patients With Systemic Amyloid Light-Chain Amyloidosis: A Retrospective Single-Center Analysis.
Topics: Adult; Aged; Aged, 80 and over; Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prednisone; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2016 |
Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Drug Substitution; Fatal Outcome; Gene Expression; Humans; Immunohistochemistry; Immunophenotyping; Male; Melphalan; Multiple Myeloma; Prednisone | 2016 |
Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Liver Function Tests; Melphalan; Paraproteinemias; Prednisone; Treatment Outcome | 2016 |
Depsidones from Lichens as Natural Product Inhibitors of M-Phase Phosphoprotein 1, a Human Kinesin Required for Cytokinesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cytokinesis; Depsides; Dibenzoxepins; Humans; Kinesins; Lactones; Lichens; Melphalan; Microtubules; Molecular Structure; Prednisone; Procarbazine | 2016 |
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prednisone; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Survival Rate; Thalidomide; Thrombocytopenia; Vincristine | 2016 |
Temporal and Spatial Correlation Between Choroidal Thickness and Visual Function in a Case of POEMS Syndrome.
Topics: Antineoplastic Agents, Alkylating; Choroid; Cord Blood Stem Cell Transplantation; Drug Combinations; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Male; Melphalan; Middle Aged; Organ Size; POEMS Syndrome; Prednisone; Tomography, Optical Coherence; Vision Disorders; Visual Acuity; Visual Fields | 2018 |
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Remission Induction; Retrospective Studies; Thalidomide | 2017 |
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bortezomib; Diarrhea; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neutropenia; Prednisone; Prospective Studies; Republic of Korea; Treatment Outcome | 2017 |
Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015).
Topics: Animals; Antineoplastic Agents, Alkylating; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Lomustine; Male; Melphalan; Plasmacytoma; Prednisone; Skin; Skin Neoplasms | 2017 |
[Extramedullary mediastinal plasmacytoma. Report of one case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mediastinal Neoplasms; Mediastinoscopy; Melphalan; Plasmacytoma; Prednisone; Thalidomide; Tomography; Treatment Outcome | 2017 |
[Diagnostic and evolutionary profile of multiple myeloma in Senegal: monocentric study conducted from 2005 to 2016].
Topics: Aged; Antibodies, Anti-Idiotypic; Antineoplastic Combined Chemotherapy Protocols; Female; Health Services Accessibility; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Retrospective Studies; Senegal; Survival Rate | 2017 |
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2018 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide | 2018 |
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Republic of Korea; Survival Analysis; Treatment Outcome | 2019 |
Extrapolating Survival Data Using Historical Trial-Based a Priori Distributions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Data Interpretation, Statistical; Decision Making; Female; Humans; Interatrial Block; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Quadruplets come of age for newly diagnosed multiple myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
ALCYONE - lighting the way for quadruplet therapy of NDMM.
Topics: Antibodies, Monoclonal; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine | 2020 |
Non-transplant eligible multiple myeloma: deciphering optimal first line regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone | 2020 |
Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Vessels; Carmustine; Cyclophosphamide; Cytarabine; Delayed Diagnosis; Diagnosis, Differential; Doxorubicin; Early Detection of Cancer; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Podophyllotoxin; Prednisone; Rituximab; Skin; Skin Neoplasms; Treatment Outcome; Vincristine | 2020 |
Bortezomib use and outcomes for the treatment of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Queensland; Treatment Outcome | 2020 |
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Case-Control Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Registries; Safety; Stem Cell Transplantation | 2021 |
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Standard of Care; Treatment Outcome | 2021 |
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Cost-Benefit Analysis; Humans; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years | 2021 |
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2021 |
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Czech Republic; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Registries; Thalidomide; Treatment Outcome | 2021 |
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone | 2021 |
Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2022 |
Extramedullary plasmacytoma with colonic involvement: experience in a tertiary hospital.
Topics: Adult; Aged; Bortezomib; Dexamethasone; Diabetes Mellitus, Type 2; Female; Humans; Immunoglobulin G; Male; Melphalan; Multiple Myeloma; Plasmacytoma; Prednisone; Rituximab; Tertiary Care Centers | 2022 |
IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series.
Topics: Bortezomib; Cyclophosphamide; Dexamethasone; Humans; IgA Vasculitis; Immunoglobulin A; Lenalidomide; Melphalan; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Retrospective Studies; Rituximab | 2022 |
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisolone; Prednisone; Prognosis; Treatment Outcome; United Kingdom | 2023 |
Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population.
Topics: Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Melphalan; Multiple Myeloma; Poland; Polymorphism, Single Nucleotide; Prednisone | 2023 |
Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Registries; Retrospective Studies; Treatment Outcome | 2023 |